

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
11 October 2001 (11.10.2001)

PCT

(10) International Publication Number  
**WO 01/74855 A2**

- (51) International Patent Classification<sup>7</sup>: **C07K 14/00**
- (21) International Application Number: PCT/US01/10515
- (22) International Filing Date: 30 March 2001 (30.03.2001)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:  
60/193,504 30 March 2000 (30.03.2000) US
- (71) Applicant: **DENDREON CORPORATION** [US/US];  
3005 1st Avenue, Seattle, WA 98121 (US).
- (72) Inventors: **LAUS, Reiner**; 4733 154th Place S.E., Bellevue, WA (US). **VIDOVIC, Damir**; 14309 S.E. 49th Street, Bellevue, WA 98006 (US). **GRADDIS, Thomas**; 7014 29th Avenue, N.E., Seattle, WA 98115 (US).
- (74) Agents: **THROWER, Larry, W.** et al.; Iota Pi Law Group, P.O. Office Box 60850, Palo Alto, CA 94306-0850 (US).
- (81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW.
- (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
- Published:**  
— *without international search report and to be republished upon receipt of that report*
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

(54) Title: COMPOSITIONS AND METHODS FOR DENDRITIC CELL-BASED IMMUNOTHERAPY

(57) Abstract: Disclosed are immunostimulatory fusion proteins and methods for generating protective DC-induced, T cell-mediated immune responses *in vitro* and *in vivo*. The immunostimulatory fusion proteins comprise a polypeptide antigen component and an immunostimulatory component derived from the intracellular domain of the HER-2 protein. Also disclosed are immunostimulatory compositions comprising dendritic cells pulsed with such an immunostimulatory fusion protein and methods for immunotherapy using the compositions.



**WO 01/74855 A2**

## COMPOSITIONS AND METHODS FOR DENDRITIC CELL-BASED IMMUNOTHERAPY

### 5 Field of the Invention

The present invention relates to an immunostimulatory fusion protein comprising a polypeptide antigen sequence component and a sequence component derived from the intracellular domain of the HER-2 protein which is effective to generate a protective DC-induced, T cell-mediated immune response against the polypeptide antigen; dendritic cells  
10 treated with such a composition and methods for immunotherapy using the fusion protein.

### Background of the Invention

The HER-2/*erbB-2* (also called neu) gene encodes a transmembrane glycoprotein of *Mr* 185,000 (p185) possessing intrinsic tyrosine kinase activity (Akiyama *et al.*, 1986, *Science*  
15 232: 1644) and displaying extensive homology to the epidermal growth factor (EGF) receptor (Coussens *et al.*, 1985, *Science* 230: 1132).

Several lines of evidence suggest a link between the amplification of HER-2 and neoplastic transformation. Amplification and overexpression of the HER-2 proto-oncogene occurred in human breast and ovarian cancers and correlated with both poor prognosis and decreased survival in patients (Slamon *et al.*, 1987, *Science* 235: 177; Slamon *et al.*, 1989,  
20 *Science* 244: 707).

In experimental systems, tumor antigen specific cytotoxic T lymphocytes (CTL) are the most powerful immunological mechanism for the elimination of tumors. (Greenberg, 1991, *Adv. Immunol.* 49: 281). Therefore, tumor specific antigens (Ag) recognized by CTL are  
25 likely to function as tumor rejection Ag, capable of inducing protective immunity *in vivo*.

CTL recognize class I molecules containing peptidic fragments of intracellular proteins that have been transported into endoplasmic reticulum prior to their transfer to the MHC molecule (Germain, 1995, *Ann. NY Acad. Sci.* 754:114; Heemels & Ploegh, 1995, *Annu. Rev. Biochem.* 64:463), while the bulk of class II complexed peptides presented to Th cells are  
30 degradation products of exogenous or cell surface proteins that enter the biosynthetic pathway of class II molecules via endocytosis and a subsequent fusion with lysosomes (Cresswell, 1994, *Annu. Rev. Immunol.* 12: 259). CTL are induced when a protein enters the major histocompatibility complex class I ("MHC I" or "class I") pathway of antigen processing. To enter this pathway the protein must be present in the cytosol of an antigen presenting cell  
35 (APC). There it is degraded into peptides which are then transported into the endoplasmic reticulum, where they associate with HLA class I molecules. These peptides are then displayed together with the class I molecules on the cell surface and can serve as an inducer and target of class I restricted antigen-specific CTL (Rothbard *et al.*, 1987, *Nature* 326: 881).

The priming of an immune response expands and activates "naive" lymphocytes, *i.e.*,  
40 those that have not previously seen a given immunogen such that they become "effector" cells that actively respond. Each naive cell has the potential for seeing one and only one antigenic

epitope, a situation analogous to a key fitting into a lock. Only those cells that recognize their cognate epitope become effector cells.

T-cells can be of the "helper" or "cytotoxic" type. Helper T cells secrete growth factors for lymphoid cells that stimulate the activation and function of B and T cells. The cytotoxic T cells recognize and either directly, or indirectly, kill cells that express a particular antigen. Like B cells, each T cell has receptors specific for one and only one antigenic epitope. T cell receptors recognize fragments of proteins that are displayed on the cell surface by major histocompatibility complexes (MHC). The *in vivo* induction of CTL has typically been accomplished by immunization with live virus or cells (Tanaka, et al., *J. Immunol.*, (1991), 147, 3646-52, Wang, et al., *J. Immunol.*, (1995), 4685-4692). A characteristic of DC, a potent subset of APC, is their ability to trigger *in vivo* responses of naïve CD8<sup>+</sup> cytotoxic T-lymphocytes (CTL), after being pulsed with antigen (Ridge *et al.* 1998 *Nature* 393:474).

Besides their immature (resting or precursor) form, DC exist in two mature states: activated and superactivated. Activated DC can stimulate CD4<sup>+</sup> T helper cells, but not CD8<sup>+</sup> cytotoxic T cells (CTL), while superactivated DC possesses the ability to stimulate CD8<sup>+</sup> CTL.

Although tumor cells may express protein antigens that are recognized as foreign by the subject, and immune surveillance may limit the growth and spread of some types of tumors, the immune system does not always protect the subject from lethal human cancers. Such tumors may overwhelm the immune system due to rapid growth and spread and/or the tumor cells may evade immune destruction. Proposed mechanisms for such evasion include, but are not limited to, (1) down-regulation of Class I MHC antigens on the surface of tumor cells resulting in little or no complexing of processed tumor peptide antigens with Class I MHC as required for recognition by cytotoxic T lymphocytes (CTL), (2) a lack of activation of CTL due to little or no expression of Class II MHC molecules by tumor cells such that they cannot directly activate tumor-specific CD4<sup>+</sup> helper T cells (which produce signals likely to be needed for CTL activity), (3) a lack of co-stimulation cell surface markers that provide secondary signals for activation of CD4<sup>+</sup> helper T cells, and (4) factors produced by tumor cells that suppress anti-tumor responses, such as fas-ligand (Abbas, A.K. *et al.*, Eds., CELLULAR AND MOLECULAR IMMUNOLOGY, 3<sup>rd</sup> edition, W.B. Saunders Co., 394-405, 1997).

It is therefore desirable to provide a means for eliciting CTL responses against tumor-specific proteins. CTL can be induced either *in vivo* with vaccines or can be generated *in vitro* and then be re-infused into the tumor-bearing organism.

### Summary of the Invention

The invention is directed to an immunostimulatory fusion protein which includes a polypeptide or protein antigen sequence component and a sequence component derived from the intracellular domain of the HER-2 protein and is effective to elicit an immune response to the polypeptide or protein antigen sequence component of the fusion protein.

In one aspect, the HER-2 intracellular domain sequence component of the immunostimulatory fusion protein has the sequence presented as SEQ. ID. NO: 25.

In another aspect, the polypeptide or protein component is associated with tumor cells or the causative agent of an infectious disease.

In general, the immunostimulatory fusion protein is produced by translation of a continuous nucleic acid coding sequence. However, the fusion protein may also be produced by chemical coupling.

In one preferred embodiment, the polypeptide or protein component of the fusion protein is the mature HER-2 membrane distal extracellular domain sequence presented as SEQ. ID. NO: 23. Examples of such fusion proteins and the associated amino acid sequences are: HER500 (SEQ ID NO: 1), HER500•hGM-CSF (SEQ ID NO: 2), HER500\* (SEQ ID NO:3) and HER500\*•rGM-CSF (SEQ ID NO: 4).

The invention provides an immunostimulatory fusion protein composition which can mediate a dendritic cell-induced, T cell-mediated immune response.

In one aspect, the immunostimulatory fusion protein composition comprises a polypeptide or protein antigen sequence component and a sequence component derived from the intracellular domain of the HER-2 protein.

In a related aspect, the immunostimulatory fusion protein composition comprises dendritic cells activated by *in vitro* exposure to an immunostimulatory fusion protein of the invention alone, or in combination with the immunostimulatory fusion protein.

The invention also provides a method of producing superactivated DC, by exposing DC to an immunostimulatory fusion protein of the invention, in a manner effective to result in an cellular immune response to the polypeptide or protein antigen sequence component of the fusion protein. In practicing the method, DC may be exposed to immunostimulatory fusion protein *in vitro* or *in vivo*.

The invention provides methods, and compositions, for use immunotherapy of primary or metastatic cancers that are associated with a particular antigen. DC's are obtained from a human donor, exposed to an immunostimulatory fusion protein of the invention in a manner and for a time effective to result in antigen-loaded superactivated DC. The latter are then administered to a subject who has a cancer associated with expression of the polypeptide or protein component of the immunostimulatory fusion protein, resulting in an immunotherapeutic growth inhibiting response against the primary or metastatic cancer or tumor. In such cases, administration of such superactivated DC may be carried out in combination with co-administration of an immunostimulatory fusion protein to the patient.

In another related approach, the invention provides a method of treating cancer where the cancer is associated with the expression of a particular antigen, by administering an immunostimulatory fusion protein of the invention to a patient diagnosed with the cancer in a manner effective to result in an immune response to the polypeptide or protein antigen sequence component of the fusion protein.

In one exemplary embodiment of these aspects of the invention, the cancer is breast carcinoma, ovarian cancer or colon cancer and the polypeptide or protein antigen sequence component of the immunostimulatory fusion protein is the mature HER-2 membrane distal extracellular domain sequence presented as SEQ. ID. NO: 23.

### Brief Description of the Drawings

Figure 1 shows the response of the interleukin-2 (IL-2) secreting mouse MHC class I dependent CD8<sup>+</sup> T cell hybridoma, B3Z [specific for the chicken ovalbumin "OVA" derived immunodominant peptide SIINFEKL (Jameson et al., 1993, *J. Exp. Med.* 177: 1541)], to various antigens (Ag) presented by syngeneic superactivated dendritic cells (DC). CPM refers to counts per minute; cpm refers to a difference between the absolute cpm for a given test group minus the background cpm value obtained in the absence of the soluble Ag (in the experiment shown the latter was 9,581). The composition of the various antigens is indicated in the figure is described below.

Figure 2A shows the results of an experiment directed to the effect of pre-immunization with Ag-pulsed superactivated DC on the survival of mice up to 42 days after challenge with tumor cells, using "None" (open squares), "HER300\*•rGM-CSF" (closed triangles) and HER500\*•rGM-CSF (open circles), as the immunizing antigen.

Figure 2B shows the results of another experiment directed to the effect of pre-immunization with Ag-pulsed superactivated DC on the survival of mice up to 77 days after challenge with tumor cells, using "None" (open circles, 7 mice), "HER500\*" (open squares, 7 mice), HER500\*•rGM-CSF (closed triangles, 8 mice), "HER500" (closed circles, 7 mice), and HER500•hGM-CSF (closed diamonds, 7 mice), as the immunizing antigen.

Figure 3 shows the results of an experiment directed to the effect of post-infection immunization with Ag-pulsed superactivated DC on the survival of mice (10/group) up to 63 days after tumor cell injection, using "None" (closed squares), "HER500\*•rGM-CSF" (closed triangles), HER500 (closed diamonds), and "HER500•hGM-CSF" (open circles) as the immunizing antigen.

### Detailed Description of the Invention

#### I. Definitions

Unless otherwise indicated, the terms below have the following meanings:

As used herein, "presentation of soluble protein antigens in the context of major histocompatibility complex class I molecules (MHC I)" means the soluble protein antigen or fragments thereof, are displayed together with major histocompatibility complex class I molecules on the cell surface and can serve as an inducer and target of class I restricted antigen-specific CTL.

As used herein, the term "pulse" means exposure of APC to antigen for a time sufficient to promote presentation of that antigen on the surface of the APC.

As used herein, the term "modified antigen presenting cells" (modified APC) or "modified dendritic cells" (modified DC) refers to a population of APC or DC, respectively, which have been treated (pulsed) *ex vivo* in manner effective to result in an enhanced ability to present antigen in the context of MHC class I relative to APC or DC which have not been so modified.

The term "more effectively" when used herein relative to the presentation of soluble proteins antigens means at least a 2-fold increase in the magnitude of detectable T cell response following presentation of a soluble protein antigen by APC. For example, this means that at

least a 2-fold increase in the magnitude of T cell response is detected following presentation of a given antigen by a designated number of APC relative to magnitude of T cell response obtained when a different or modified antigen is presented by the same number of APC under the same culture conditions and at an equimolar Ag concentration.

5 As used herein, "antigen presenting cells" (APC) are any cells which, after being pulsed with Ag, can activate T-lymphocytes.

As used herein, "dendritic cells", or "DC", are the most potent subset of APCs that are typically large veiled cells which extend dendrites when cultured *in vitro*.

10 As used herein, "activated DC" are mature DC that can stimulate CD4<sup>+</sup> helper T cells, but not CD8<sup>+</sup> cytotoxic T cells (CTL).

As used herein, "superactivated DC" are mature DC that can stimulate CD8<sup>+</sup> cytotoxic T cells (CTL).

As used herein, the term "allostimulatory" means capable of stimulating allogeneic T cells due to differences in MHC molecules expressed on the cell surface.

15 An "antigen" or "Ag" refers to a substance that reacts alone or in the context of MHC molecules with the products of an immune response (*e.g.*, antibodies, T-cell receptors) which have been stimulated by a specific immunogen. Antigens therefore include the specific immunogens giving rise to the response (*e.g.*, antigenic peptides, proteins or polysaccharides) as well as the entities containing or expressing the specific immunogens (*e.g.*, viruses,  
20 bacteria, etc.).

As used herein, "immunogen" refers to a substance that is able to stimulate or induce a humoral antibody and/or cell-mediated immune response.

"Ag-loaded DC", include DC and various types of PBMC including professional APC and monocytes/macrophages, which have been exposed to an antigen and activated by the Ag.  
25 DC may become Ag-loaded *in vitro*, *e.g.*, by culture *ex vivo* in the presence of a tumor Ag, or *in vivo* by exposure to a tumor antigen.

As used herein, the term "superactivated dendritic cell" refers to DC or DC precursors which have been treated *ex vivo* in such a way that they have an enhanced ability to present antigen in the context of MHC class I relative to the untreated DC.

30 As used herein, the terms "immunostimulatory fusion protein composition" and "antigenic fusion protein composition", may be used interchangeably and refer to a fusion protein of the invention which comprises an antigenic sequence component and a HER-2 intracellular domain sequence component alone and/or DC which have been exposed to such a fusion protein, as further described below.

35 As used herein, "OVA" refers to native ovalbumin; "\*" refers to the immunodominant OVA-derived peptide SIINFEKL; "HER500" refers to the recombinant fusion human HER-2 protein consisting of one half of its extracellular portion fused to the 1/4 of its intracellular part; "HER500\*" refers to the recombinant fusion protein made of HER500 and the immunodominant OVA-derived peptide SIINFEKL inserted between its extracellular and  
40 intracellular components; "HER500\*•rGM-CSF" refers to the recombinant fusion protein composed of HER500\* and rat granulocyte/macrophage colony-stimulating factor (GM-CSF); "HER500•hGM-CSF" refers to the recombinant fusion protein composed of HER500 and

human GM-CSF; and "HER300\*•rGM-CSF" refers to the recombinant fusion human HER-2 protein consisting of one half of its extracellular portion fused to the immunodominant OVA-derived peptide SIINFEKL and rat GM-CSF, as summarized below.

By "protective T cell mediated response" is meant the T cell activity that leads to a slowing or diminution of the growth of cancer cells or a solid tumor, or a reduction in the total number of cancer cells or total tumor burden.

By "cancer or tumor" cell is meant a cell that exhibits a loss of growth control and forms unusually large clones of cells. Tumor or cancer cells generally have lost contact inhibition and may be invasive and/or have the ability to metastasize.

"Tumor antigens" refer to Ag associated with a particular type of cancer or tumor, including tumor-associated Ag and tumor-specific Ag. Examples of tumor antigens are provided below in Section IIA.

As used herein, the term "improved therapeutic outcome" relative to a cancer patient refers to a slowing or diminution of the growth of cancer cells or a solid tumor, or a reduction in the total number of cancer cells or total tumor burden.

As used herein, the term "improved therapeutic outcome" relative to a subject diagnosed as having an infectious disease, refers to a slowing or diminution in the growth of the causative infectious agent within the subject and/or a decrease in, or elimination of, detectable symptoms typically associated with the particular infectious disease.

## II. Immune Response to Soluble Polypeptide Antigens

In experimental systems, tumor antigen specific cytotoxic T lymphocytes (CTL) are the most powerful immunological mechanism for the elimination of tumors. CTL can be induced either *in vivo* with vaccines or can be generated *in vitro* and then be re-infused into the tumor-bearing organism. The *in vivo* induction of CTL is typically accomplished by immunization with live virus or cells (Tanaka, *et al.*, *J. Immunol.*, (1991), 147, 3646-52, Wang, *et al.*, *J. Immunol.*, (1995), 4685-4692).

With the exception of a few special viral proteins such as the SV-40 large T antigen and the Hepatitis B surface antigen, injection of isolated or soluble proteins does not result in induction of CTL (Schirmbeck, *et al.*, *Eur. J. Immunol.*, (1993), 23, 1528-34). CTL are induced when a protein enters the major histocompatibility complex class I ("MHC I" or "class I") pathway of antigen processing. To enter this pathway the protein must be present in the cytosol of an antigen presenting cell (APC). There it is degraded into peptides which are then transported into the endoplasmic reticulum, where they associate with HLA class I molecules. These peptides are then displayed together with the class I molecules on the cell surface and can serve as an inducer and target of class I restricted antigen-specific CTL. Physiologically, only proteins that are endogenously synthesized by the APC enter this pathway.

The priming of an immune response expands and activates "naive" lymphocytes, *i.e.*, those that have not previously seen an immunogen to become "effector" cells that actively respond. Each naive cell has the potential for seeing one and only one antigenic epitope, a situation analogous to a key fitting into a lock. Only those cells that recognize their cognate epitope become effector cells.

T-cells can be of the “helper” or “cytotoxic” (cytotoxic) type. Helper T cells secrete growth factors for lymphoid cells that stimulate the activation and function of B and T cells. The cytotoxic T cells recognize and either directly, or indirectly, kill cells that express a particular antigen. Like B cells, each T cell has receptors specific for one and only one antigenic epitope. T cell receptors recognize fragments of proteins that are displayed on the cell surface by major histocompatibility complexes (MHC).

There are two different types of MHC proteins, Class I and Class II, both of which present proteolytically degraded fragments of proteins to T cells. Class I molecules which are expressed on most cells of the body and present fragments of endogenously synthesized proteins to cytotoxic T cells. Class II molecules which are expressed on specialized antigen presenting cells (APCs) such as macrophages, monocytes, dendritic cells and B cells present protein fragments to T helper cells. (Chen, CH and Wu, TC, *J Biomed Sci.*, 5(4):231-52 1998).

In most cases, Class I molecules present foreign proteins synthesized in a cell. For presentation by Class II, the foreign protein either can be synthesized in the cell or taken up by the cell from the outside (*i.e.*, presented in the form of a free protein or peptide). If an antigen is synthesized in a cell and presented by both Class I and Class II molecules, both antibody producing B cells and cytotoxic T cells are produced. However, if an antigen originated outside of a cell and is expressed only by Class II, the specific immune response is largely limited to T helper cells and antibody production. [THE SCIENTIFIC FUTURE OF DNA FOR IMMUNIZATION, American Academy of Microbiology, Robinson, *et al.*, Eds., 1-29, 1997]

Accordingly, the typical response to soluble protein antigens is a Class II mediated response. The present invention represents compositions and methods which allow soluble protein antigens to enter the Class I presentation pathway.

In addition, some progeny of antigen-stimulated T cells do not develop into effector cells, but become memory cells that are capable of surviving for long periods of time in the absence of additional antigenic challenge. Such memory cells are quiescent and do not produce effector molecules unless they are stimulated by antigen. (See, *e.g.*, Abbas, AK *et al.*, Eds. CELLULAR AND MOLECULAR IMMUNOLOGY, W.B. Saunders Co., pages 116-123; 130-134, 1997).

Naïve T cells (or T cells that have not been previously exposed to a given antigen) require only the correct MHC I-restricting molecule to survive, however to expand, they also must be exposed to antigen. In contrast, memory T cells have a lower functional activation threshold that facilitates secondary responses which are more rapid and stronger than that of naïve T cells.

#### A. Polypeptide Antigens

The present invention is based on the discovery that immunostimulatory compositions comprising a polypeptide antigen component and a sequence component derived from the intracellular domain of the HER-2 protein are effective to generate a protective DC-induced, T cell-mediated immune response against the polypeptide antigen.



Polypeptide antigens of particular interest are those associated with cancer cells, tumors and/or infectious agents.

For example, "tumor-specific antigens" and "tumor-associated antigens" that are characteristic of a particular tissue type, including particular tumor tissues find utility in the immunostimulatory fusion proteins of the invention. Exemplary tumor antigens include, but are not limited to HER-2/neu; prostatic acid phosphate (PAP); MART-1 (associated with melanoma; Coulie, *et al.*, *J. Exp. Med.* 180:35, 1994; Hawakami, *et al.*, *PNAS* 91:3515, 1994; Bakker, *et al.*, *J. Exp. Med.* 179:1005, 1994); the tumor rejection antigen precursors, MAGE, BAGE and GAGE; NY-ESO (cloned from an esophageal cancer); SART-3 (a squamous cell carcinoma antigen), immunoglobulin antigens specific to particular B-cell lymphomas, tumor-associated antigens such as carcinoembryonic antigen (CEA), p53, c-myc, neural cell adhesion molecule (N-CAM) and polymorphic epithelial mucin (PEM), in addition to any of a number of proteins expressed on tumor cells.

Also of interest are antigens specific to particular infectious agents, e.g., viral agents including, but not limited to human immunodeficiency virus (HIV), hepatitis B virus (HBV), influenza, human papilloma virus (HPV), foot and mouth (coxsackieviruses), the rabies virus, herpes simplex virus (HSV), and the causative agents of gastroenteritis, including rotaviruses, adenoviruses, caliciviruses, astroviruses and Norwalk virus; bacterial agents including, but not limited to *E. coli*, *Salmonella thyphimurium*, *Pseudomonas aeruginosa*, *Vibrio cholerae*, *Neisseria gonorrhoeae*, *Helicobacter pylori*, *Hemophilus influenzae*, *Shigella dysenteriae*, *Staphylococcus aureus*, *Mycobacterium tuberculosis* and *Streptococcus pneumoniae*, fungal agents and parasites such as *Giardia*.

#### HER-2, An Exemplary Antigen for use in Immunostimulatory Fusion Proteins

Malignant tumors express a number of proteins including molecules belong to the group of transformation-related molecules such as the oncogene HER-2/Neu/ErbB-2.

Likewise, oncogene product peptide antigens have been identified that are common to specific tumor types. These polypeptides find use as reagents that can generally stimulate T-cell responses effective to react with tumors bearing such antigens. The oncogene product peptide antigen, HER-2/neu (Beckmann *et al.*, *Eur. J. Cancer* 28:322, 1992) is associated with human breast and gynecological cancers.

The association of HER-2 overexpression in cancer cells with malignant phenotypes and chemoresistance is consistent with poor clinical outcome for patients with HER-2-overexpressing tumors. The following is a brief summary of HER-2 overexpression associated with various cancers:

Amplification and overexpression of the HER-2 gene is found in 25-30% of primary breast cancers and is associated with a poor clinical outcome. *In vitro* studies of HER-2 overexpression promoted down-regulation of the estrogen receptor (ER) in estrogen-dependent breast tumor cells (Pietras *et al.*, 1995, *Oncogene* 10: 2435), consistent with clinical data that shows HER-2 overexpression is associated with the ER-negative phenotype (Zeillinger *et al.*, 1989, *Oncogene* 4: 109; Adnane *et al.*, 1989, *Oncogene* 4: 1389), and the failure of tamoxifen therapy in patients with HER-2 overexpression (Wright *et al.*, 1992, *Br. J. Cancer* 65:118).

A study on colorectal cancer patients. demonstrated that the level of HER-2 expression correlated with the progression of colorectal cancer, the relapse-free period and postoperative survival time, and could serve as an independent prognostic factor in HER-2-positive colorectal cancers (Kapitanovic *et al.*, 1997, *Gastroenterology* 112: 1103).

5 The expression of HER-2 protein has also been described as an independent prognostic indicator in ovarian (Slamon *et al.*, 1989, *Science* 244: 707) and endometrial cancers (Saffari *et al.*, 1995, *Cancer Res.* 55: 5693).

Overexpression of HER-2 in NIH/3T3 cells resulted in cellular transformation and tumor growth in athymic mice (Di Fiore *et al.*, 1987, *Science* 237: 178; Hudziak *et al.*, 1987, 10 *Proc. Natl. Acad. Sci. USA* 84: 7159). Cellular and animal experiments have shown that the enhanced HER-2 tyrosine kinase activity increased the expression of malignant phenotypes (Hudziak *et al.*, 1987, *Proc. Natl. Acad. Sci. USA* 84: 7159; Muller *et al.*, 1988, *Cell* 54: 105; Yu & Hung, 1991, *Oncogene* 6:1991; Yu *et al.*, 1993, *Cancer Res.* 53: 891; Zhau *et al.*, 1996, *Prostate* 28: 73). Transgenic mice overexpressing activated c-neu oncogene driven by a 15 mouse mammary tumor promoter, developed synchronously multiple mammary tumors involving the entire glands (Muller *et al.*, 1988, *Cell* 54: 105).

Overexpression of HER-2 was also reported to induce resistance to chemotherapeutic drugs in NSCLC, gastric adenocarcinoma and breast cancers (Tsai *et al.*, 1993, *J. Natl. Cancer Inst.* 85: 897; Tsai *et al.*, 1995, *J. Natl. Cancer Inst.* 87: 682; Paik *et al.*, 1991, *Proc. Am. Assoc. Cancer Res.* 32:291; Wright *et al.*, 1992, *Br. J. Cancer* 65:118). 20

HER-2 peptide and polypeptide antigens can be isolated, synthesized or recombinantly expressed according to methods known in the art. The DNA coding sequence for HER-2/Neu/ErbB-2 may be found at GenBank Accession No. M11730 (human c-erb-B-2 mRNA).

Such isolated HER-2 antigens can be complexed with any of a number of molecules that 25 enhance the immune response to the antigen, as discussed below, either chemically, or as fusion proteins produced recombinantly, according to methods well known in the art.

### III. Immunostimulatory Fusion Proteins

The present invention is based on the discovery that immunostimulatory fusion proteins 30 comprising a polypeptide antigen sequence component and a sequence component derived from the intracellular domain of the HER-2 protein are effective to generate a protective DC-induced, T cell- mediated protective immune response against the antigenic component of the fusion protein.

An exemplary intracellular domain of the HER-2 protein is presented herein, however it 35 will be understood that shorter fragments of the exemplary sequence may also exhibit activity. Most importantly, a sequence component derived from the intracellular domain of the HER-2 protein has been demonstrated to contribute to the immunostimulatory activity of fusion proteins comprising such sequence components.

An immunostimulatory fusion protein construct of the invention may also include one or 40 more sequence components selected from the group consisting of GM-CSF, a reporter sequence such as the immunodominant OVA-derived octapeptide SIINFEKL (OVA<sub>257-264</sub>), one or more

peptide signal sequences and a synthetic purification tag, e.g., an added C-terminal amino acid sequence.

Exemplary immunostimulatory fusion protein constructs described herein have a 32 amino acid PAP signal sequence<sup>1</sup>, a 3 amino acid mature PAP sequence<sup>2</sup>, a 3 amino acid HER-2 signal sequence<sup>3</sup>, and either a C-terminal amino acid purification tag sequence of 9 amino acid residues comprising three consecutive alanines and six consecutive histidines, or a C-terminal amino acid tag sequence of 15 amino acid residues comprising glycine, alanine, 4 consecutive prolines, three consecutive alanines, and six consecutive histidines and the features summarized in Table 1, below.

Table 1. Components Of Exemplary HER-2 Fusion Proteins.

Construct	HER-2 extracellular sequence <sup>4</sup>	SIINFEKL (OVA <sub>257-264</sub> )	HER-2 intracellular sequence <sup>5</sup>	GM-CSF
HER500	+	-	+	-
HER500•hGM-CSF	+	-	+	127 aa (human)
HER500*	+	+	+	-
HER500*•rGM-CSF	+	+	+	127 aa (rat)
HER300*•rGM-CSF	+	+	-	127 aa (rat)

It will be understood that a fusion protein comprising a polypeptide antigen sequence component and a sequence component derived from the intracellular domain of the HER-2 protein are alone effective to generate a protective DC-induced, T cell-mediated protective immune response against the antigenic component of the fusion protein.

Accordingly, the SIINFEKL (OVA<sub>257-264</sub>) sequence, the PAP signal sequence, the mature PAP amino acid sequence, the HER-2 signal sequence, and the C-terminal peptide tag sequence set forth above are not necessary to generate such a response.

The immunostimulatory fusion proteins of the invention may be modified by joining them, either covalently or noncovalently, with a reporter molecule. A wide variety of reporter molecules are known in the art and the selection of the reporter determines the assay format. For example, as detailed in Example 1, the OVA-derived immunodominant octapeptide SIINFEKL (OVA<sub>257-264</sub>) was incorporated into exemplary immunostimulatory HER-2 fusion constructs and antigen presentation of the constructs evaluated. Briefly, the IL-2 secreting mouse T cell hybridoma B3Z, which responds to SIINFEKL (OVA<sub>257-264</sub>), when bound to mouse MHC class I, was stimulated with DC that were pre-pulsed with the HER-2 fusion constructs, and the magnitude of response evaluated by measuring [<sup>3</sup>H]thymidine incorporation in proliferating IL-2 dependent cells, as an indicator of antigen presentation.

<sup>1</sup> 32 amino acids corresponding to amino acids 1 to 32 of Genebank accession No. NM\_001099

<sup>2</sup> 3 amino acids corresponding to amino acids 33 to 35 of Genebank accession No. NM\_001099

<sup>3</sup> 3 amino acids corresponding to amino acids 19 to 21 of Genebank accession No. M11730

<sup>4</sup> 289 amino acids corresponding to amino acids 22 to 310 of Genebank accession No. M11730

<sup>5</sup> 217 amino acids corresponding to amino acids 1038 to 1254 of Genebank accession No. M11730

Additional examples of fusion proteins for use in practicing the invention include, but are not limited to those which include the sequence of a cancer antigen directly fused to the 217 amino acids of membrane distal intracellular HER-2 domain, without additional linker or signal peptide components. Examples of such fusion proteins include, but are not limited to: a fusion protein comprising 180 amino acids of the human autoimmunogenic cancer/testis antigen, NY-ESO-1 (amino acids 1 to 180 of GenBank Accession No. U87459), fused to the 217 amino acids of membrane distal intracellular HER-2 domain (amino acids 1038 to 1254 of GenBank Accession No. M11730), presented herein as SEQ ID NO: 27, the coding sequence for which is presented as SEQ ID NO: 28); a fusion protein comprising 962 amino acids of the squamous cell carcinoma antigen, SART3-IC (amino acids 1 to 962 of GenBank Accession No. AB020880), fused to the 217 amino acids of membrane distal intracellular HER-2 domain (amino acids 1038 to 1254 of GenBank Accession No. M11730), presented herein as SEQ ID NO: 29, the coding sequence for which is presented as SEQ ID NO: 30).

As known in the art, a recombinant polypeptide may also be produced as a fusion with a heterologous polypeptide, such as a signal sequence or other polypeptide having a specific cleavage site at the N-terminus of the mature protein or polypeptide. In general, the signal sequence is specific to the vector/host cell system used to express the recombinant protein.

Recombinant polypeptides or fusion proteins that include a tag sequence placed for example at the amino- or carboxyl-terminus of the polypeptide are also known in the art. The tag sequence enables the polypeptide to be readily detected using an antibody against the tag and facilitates affinity purification of the polypeptide.

Granulocyte-macrophage colony stimulating factor (GM-CSF), has been included in exemplary fusion constructs of the invention. GM-CSF, a glycoprotein with an apparent molecular weight of about 23-33,000 by SDS-PAGE, is a cytokine that has pleiotropic function both in hematopoiesis as well as in immunology. Human and rat GM-CSF have been shown to bind to cells of the monocyte-macrophage, neutrophil and eosinophil cell lineages. Binding of GM-CSF to high affinity receptors results in rapid internalization and degradation of GM-CSF (Metcalf and Nicola in THE HEMOPOIETIC COLONY-STIMULATING FACTORS, Cambridge University Press, NY (1995)). The immunostimulatory effect of a polypeptide complex consisting essentially of GM-CSF and a polypeptide antigen is further described in USSN 08/579,823 (allowed), expressly incorporated by reference herein. Both human and rat GM-CSF are synthesized with a 17-amino acid hydrophobic leader sequence that is proteolytically cleaved during secretion. The mature polypeptides are 127 amino acids in length, and the sequences may be found at GenBank Accession Nos. NM\_000758 and U00620, respectively.

It will be appreciated that the HER-2 extracellular sequence<sup>6</sup> described herein is an example of an antigenic sequence that may be incorporated into an immunostimulatory fusion protein of the invention. It follows that any of a number of antigens associated with tumor cells or an infectious agent, may similarly be incorporated into an immunostimulatory fusion protein of the invention and be effective to generate a protective DC-induced, T cell-mediated

---

<sup>6</sup> 289 amino acids corresponding to amino acids 22 to 310 of Genebank accession No. M11730

protective immune response against the antigenic component of the fusion protein. Exemplary antigens are further described in Section IIA, above.

#### Exemplary HER-2 Antigen Compositions

An immunostimulatory fusion protein of the invention is made by chemical linkage of the antigenic sequence component to the sequence component derived from the intracellular domain of the HER-2 protein, or by expression of a recombinant and continuous nucleic acid coding sequence which is expressed as a fusion protein. Chemical linkage and/or recombinant protein expression may also be used to incorporate additional peptidic sequences into the fusion protein, e.g., a reporter sequence, a signal peptide sequence and/or a purification tag.

Exemplary human HER-2-derived recombinant and continuous nucleic acid coding sequences which have been expressed as fusion proteins are described below.

The exemplary HER500 construct (SEQ ID NO:6) was produced by expression of a coding sequence including in the 5' to 3' direction: the coding sequence for a 32 amino acid PAP signal sequence, the coding sequence for a 3 amino acid sequence of the mature PAP protein, an Ala Arg linker, the coding sequence for a 3 amino acid HER-2 signal sequence, the coding sequence for 289 amino acids of the mature HER-2 membrane distal extracellular domain, the coding sequence for 217 amino acids of the HER-2 membrane distal intracellular domain and the coding sequence for three consecutive alanines, and six consecutive histidines.

The exemplary HER500•hGM-CSF construct (SEQ ID NO:7) was produced by expression of a coding sequence including in the 5' to 3' direction: the coding sequence for a 32 amino acid PAP signal sequence, the coding sequence for a 3 amino acid sequence of the mature PAP protein, an Ala Arg linker, the coding sequence for a 3 amino acid HER-2 signal sequence, the coding sequence for 289 amino acids of mature HER-2 membrane distal extracellular domain, the coding sequence for 217 amino acids of the HER-2 membrane distal intracellular domain, an Ala Ala linker, the coding sequence for mature human GM-CSF (127 residues), and the coding sequence for glycine, alanine, four consecutive prolines, three consecutive alanines, and six consecutive histidines.

The exemplary HER500\* construct (SEQ ID NO:8) was produced by expression of a coding sequence including in the 5' to 3' direction: the coding sequence for a 32 amino acid PAP signal sequence, the coding sequence for a 3 amino acid sequence of the mature PAP protein, an Ala Arg linker, the coding sequence for a 3 amino acid HER-2 signal sequence, the coding sequence for 289 amino acids of mature HER-2 membrane distal extracellular domain, an Ala linker, the coding sequence for the OVA-derived immunodominant octapeptide SIINFELK (OVA<sub>257-264</sub>), the coding sequence for 217 amino acids of the HER-2 membrane distal intracellular domain, three consecutive alanines, and six consecutive histidines.

The exemplary HER500\*•rGM-CSF construct (SEQ ID NO:9) was produced by expression of a coding sequence including in the 5' to 3' direction: the coding sequence for a 32 amino acid PAP signal sequence, the coding sequence for a 3 amino acid sequence of the mature PAP protein, an Ala Arg linker, the coding sequence for a 3 amino acid HER-2 signal sequence, the coding sequence for 289 amino acids of mature HER-2 membrane distal extracellular domain, an Ala linker, the coding sequence for the OVA-derived immunodominant

octapeptide SIINFEKL (OVA<sub>257-264</sub>), the coding sequence for 217 amino acids of the HER-2 membrane distal intracellular domain, an Ala Ala linker, the coding sequence for mature rat GM-CSF (127 residues), and the coding sequence for glycine, alanine, four consecutive prolines, alanine, and six consecutive histidines.

5       The exemplary HER300\*•rGM-CSF construct (SEQ ID NO:10) was produced by expression of a coding sequence including in the 5' to 3' direction: the coding sequence for a 32 amino acid PAP signal sequence, the coding sequence for a 3 amino acid sequence of the mature PAP protein, an Ala Arg linker, the coding sequence for a 3 amino acid HER-2 signal sequence, the coding sequence for 289 amino acids of mature HER-2 membrane distal  
10   extracellular domain, an Ala linker, the coding sequence for the OVA-derived immunodominant octapeptide SIINFEKL (OVA<sub>257-264</sub>), an Ala linker, the coding sequence for mature rat GM-CSF (127 residues), and the coding sequence for glycine, alanine, four consecutive prolines, alanine, and six consecutive histidines.

15       Methods for production of immunostimulatory fusion proteins by chemical linkage of an antigenic sequence to a sequence derived from the intracellular domain of the HER-2 protein include conventional coupling techniques known in the art. In constructs which also include one or more added peptidic sequences, chemical linkage is also accomplished using conventional coupling techniques known in the art. For example, the peptides can be coupled using a dehydrating agent such as dicyclohexyl-carbodiimide (DCCI) to form a peptide bond between the  
20   two peptides. Alternatively, linkages may be formed through sulfhydryl groups, epsilon amino groups, carboxyl groups or other reactive groups present in the polypeptides, using commercially available reagents. (Pierce Co., Rockford, IL).

#### IV. Production of recombinant fusion proteins

25       The invention includes immunostimulatory fusion proteins produced using recombinant techniques. Such an immunostimulatory fusion protein may be produced by any of a number of methods routinely employed by those of skill in the art.

30       Unless otherwise indicated, all terms used herein have the same meaning as they would to one skilled in the relevant art. Practitioners are particularly directed to Sambrook *et al.* (1989) MOLECULAR CLONING: A LABORATORY MANUAL (Second Edition), Cold Spring Harbor Press, Plainview, N.Y. and Ausubel FM *et al.* (1989) CURRENT PROTOCOLS IN MOLECULAR BIOLOGY, John Wiley & Sons, New York, N.Y., for definitions and techniques routinely used by those of skill in the art.

35       The fusion proteins may be produced by culturing recombinant prokaryotic or eukaryotic host cells comprising nucleic acid sequences encoding the fusion protein under conditions promoting expression of the fusion proteins, followed by recovery of the fusion protein from the host cells or the cell culture medium.

40       The nucleic acid encoding sequence an immunostimulatory fusion protein of the invention is inserted into any one of a variety of expression vectors for expressing a polypeptide, as long as it is replicable and viable in the host. In general, the nucleic acid coding sequence is inserted into an appropriate restriction endonuclease site or site(s) using routine techniques. Such procedures and related sub-cloning procedures are deemed to be

within the scope of those skilled in the art. The vector may comprise regulatory sequences, including for example, non-coding sequences, such as introns and control elements, *i.e.*, promoter and terminator elements or 5' and/or 3' untranslated regions, effective for expression of the coding sequence in a suitable host and/or in a vector or host environment in which the immunostimulatory fusion protein coding sequence is not normally expressed, operably linked to the coding sequence. Large numbers of suitable vectors and promoters are known to those of skill in the art, are commercially available, examples of which are described in Sambrook, *et al.*, (*supra*).

The present invention also relates to host cells which have been genetically engineered to contain a vector effective to express an immunostimulatory fusion protein of the invention by recombinant techniques. Host cells are genetically engineered (*i.e.*, transduced, transformed or transfected) with an appropriate vector which may be, for example, a cloning or expression vector. The vector may take the form of a plasmid, a viral particle, a phage, *etc.* The culture conditions, such as temperature, pH and the like, are those routinely used for the host cell selected for expression, and will be apparent to those skilled in the art.

Methods of introducing nucleic acids into cells for expression of heterologous proteins are also known to the ordinarily skilled artisan. Examples include calcium phosphate transfection, DEAE-Dextran mediated transfection, electroporation, nuclear microinjection, bacterial protoplast fusion with intact cells, and the use of polycations, *e.g.*, polybrene or polyornithine. General aspects of transformation involving mammalian cells have been described in U.S. Patent No. 4,399,216, and Keown *et al.*, *Methods in Enzymology*, 185:527-537 (1990), both of which are expressly incorporated by reference herein.

Suitable host cells for cloning or expressing an immunostimulatory fusion protein of the invention include prokaryote, yeast, insect and higher eukaryotic cells. Suitable prokaryotes include but are not limited to eubacteria, such as gram-negative or gram-positive organisms, for example, *E. coli*.

Suitable host cells for the expression of a glycosylated immunostimulatory fusion protein of the invention are derived from multicellular organisms. Examples of invertebrate cells include insect cells such as *Drosophila* S2 and *Spodoptera* Sf9, as well as plant cells. Examples of useful mammalian host cell lines include Chinese hamster ovary (CHO) and COS cells. The selection of the appropriate host cell is deemed to be within the skill in the art.

A process for producing such an immunostimulatory fusion protein comprises culturing host cells under conditions suitable for expression of the fusion protein and recovering the fusion protein from the cell culture. In general, principles, protocols, and practical techniques for maximizing the productivity of cell cultures can be found in MAMMALIAN CELL BIOTECHNOLOGY: A PRACTICAL APPROACH, M. Butler, ed. (IRL Press, 1991) and Sambrook *et al.*, *supra*. More specifically, techniques for expression in the Baculovirus system are described in Engelhard EK *et al. Proc. Nat. Acad. Sci.* 91:3224-3227, 1994, expressly incorporated by reference herein.

Host cells transformed with nucleotide sequences encoding an immunostimulatory fusion protein of the invention may be cultured under conditions suitable for the expression and recovery of the encoded protein from the cell culture. The protein produced by a recombinant

cell may be secreted, membrane-bound, or contained intracellularly depending on the particular sequence and/or the vector used.

As understood by those of skill in the art, an expression vector containing a polynucleotide encoding an immunostimulatory fusion protein of the invention can be designed with signal sequences which direct secretion of the modified immunostimulatory fusion protein through a prokaryotic or eukaryotic cell membrane.

Example 1 details the construction of exemplary immunostimulatory HER-2 fusion proteins, the nucleic acid and deduced amino acid sequences of which are presented in Table 2.

Expression vectors comprising the coding sequence for various HER-2 fusion proteins were used to transfect mammalian 293-EBNA cells and insect SF21 cells. Once constructed, expressed and purified, HER2 fusion proteins containing either rat GM-CSF or human GM-CSF were tested for GM-CSF bioactivities in appropriate assays, routinely employed by those of skill in the art. Both insect and mammalian cell-derived fusion proteins exhibited GM-CSF activity, as evidenced by their ability to support growth of GM-CSF dependent cell lines. Similarly, the presence of HER-2 was verified using HER-2-specific monoclonal antibodies in both Western blot analysis and in an ELISA test, according to methods well-known in the art.

While the foregoing description describes particular embodiments of the present invention, it will be appreciated that persons skilled in the art can substitute the coding sequence for various antigens, and may use different vectors and cell lines for expression, according to known methods and thereby prepare immunostimulatory fusion protein compositions in accordance with the principles described herein.

Whether produced by chemical coupling or by expression of a continuous coding sequence as a recombinant fusion protein, DC may be exposed to an immunostimulatory fusion protein of the invention and be presented by such DC in the context of MHC I, resulting in a cellular immune response to the fusion protein.

## V. Generation Of Activated Dendritic Cells (DC)

### A. Isolation and Characterization of DC Precursors and DC

Human dendritic cell precursors (DC precursors) may be obtained from any of a number of sources including but not limited to peripheral blood, cord blood, bone marrow and lymphoid organs.

DC precursors isolated and enriched by any of a number of methods known in the art will result in a DC precursor population effective for carrying out the methods of the present invention.

In a preferred approach, DC precursors are obtained from peripheral blood. In this approach, peripheral blood mononuclear cells (PBMC) are collected from healthy donors by standard leukapheresis and DC precursors isolated, for example, by either a one-step or a successive two-step buoyant density centrifugation using buoyant density solution BDS 77 or BDS 77 and 65, respectively (Dendreon Corp.), as described in co-owned USSN 60/168,991 (0021).



DC precursors may be obtained from a healthy subject or a subject known to be suffering from a disease associated with the expression of a particular antigen. Such DC precursors may be allogeneic or autologous.

Once DC precursors are obtained, they are cultured under appropriate conditions and for a time sufficient to expand the cell population and maintain the DC's in a state for optimal antigen uptake, processing and presentation.

In one preferred approach to culture of DC precursors, DC are generated from such DC precursors by culture *ex vivo* in serum free or protein-free medium for 40 hours, in the absence of exogenously added cytokines, as detailed in co-owned USSN 60/158,618. Briefly, DC precursors are cultured in teflon bags (American Fluoroseal) at a density of  $1 \times 10^7$  per ml in Aim V medium supplemented with 2mM glutamine in a humidified incubator at 37°C under 5% CO<sub>2</sub> for 40 hours. During the culture period DC precursors are pulsed with Ag.

Preferred aspects of DC isolation and culture include the use of culture medium lacking exogenously supplied cytokines and culture under serum-free conditions in a manner effective to result in the generation of Ag-loaded superactivated DC.

The purity of DC in this fraction may be quantified using, for example, flow cytometry (*i.e.*, FACS) analysis for phenotypic characterization as further described in co-owned USSN 60/158,618, together with functional characterization. Cell surface phenotype analysis is carried out using samples consisting of approximately  $1-3 \times 10^7$  cells, which are incubated in 10% normal mouse serum in PBS for 10 min., washed in PBS and resuspended in 250-750µl PBS. The cell suspension is then dispensed at 30µl/well into round-bottom 96-well plates. FITC-, PE-, and PerCP-conjugated mAb are added at 10µl/well and cells are incubated for 20 min. in the dark on ice. Cells are then washed with 200µl/well of PBS and resuspended in 400µl/well in PBS, then analyzed by FACScan (Becton Dickinson) using cells labeled with isotype-matched control Ab as a negative control. Preferred functional characteristics of mature DCs include the acquisition of allostimulatory and Ag-presenting abilities.

Ag-loaded superactivated DCs have already processed an Ag and have the ability to present the Ag to the immune cells and quickly generate Ag-specific immune responses, e.g., CTL-mediated T cell responses to tumor antigens.

According to another aspect of the invention, DC's can be preserved by cryopreservation either before or after exposure to a HER-2 fusion protein of the invention. Exemplary methods for cryopreservation are further described in co-owned USSN 60,168,991. For small scale cryopreservation, cells can be resuspended at  $20-200 \times 10^6$ /ml in precooled 5% human serum albumin (HAS) (Swiss Red Cross). An equal volume of 20% dimethylsulfoxide (DMSO) in the above HAS solution was then added dropwise. The mixture is aliquoted in cryovials at 1ml/vial and frozen at -80°C in a cryochamber (Nalgene) overnight. The vials are transferred to a liquid nitrogen tank in the morning. For large scale cryopreservation, cells can be resuspended at  $30-600 \times 10^6$ /ml in AIM V. An equal volume of 20% AIM V is then added gradually. The mixture is frozen in freezing containers (Cryocyte, Baxter) at 20 ml/bag using a rate-controlled freezing system (Forma).

## B. Evaluation of Antigenicity of Fusion Proteins

### In Vitro Antigen Presentation

An antigen presentation assay may be used to evaluate the antigen presenting ability of various immunostimulatory fusion proteins. An exemplary assay is described in Example 1, wherein the IL-2 secreting mouse T cell hybridoma B3Z, which responds to the mouse MHC class I (H2-K<sup>b</sup>) bound OVA-derived peptide SIINFEKL (OVA<sub>257-264</sub>; Jameson et al., 1993, *J. Exp. Med.* 177: 1541), is stimulated with various DC that have been pre-pulsed with engineered HER-2 fusion proteins, and the magnitude of response is evaluated by measuring [<sup>3</sup>H]thymidine incorporation in proliferating IL-2 dependent cells.

The assay format described herein may be used to evaluate antigen presentation using a titration of the antigen together with a fixed number of APC.

### B. In vivo assays in animal models

An immunostimulatory fusion protein of the invention may be evaluated *in vivo* in animal models. In such cases, pre-immunization of animals with the immunostimulatory fusion protein composition, or superactivated DC treated *ex vivo* with the composition is effective to suppress *in vivo* growth of tumors or an infectious agent.

In one example of this approach, pre-immunization of mice with activated DC pulsed *ex vivo* with the HER-2 fusion protein composition, HER500\*•rGM-CSF (SEQ ID NO:4), which has an antigenic component consisting of 289 amino acids derived from the extracellular domain of HER2 fused to 217 amino acids derived from the intracellular domain of HER2, suppressed the *in vivo* growth of HER-2-expressing autologous tumors in mice (Example 2). In another approach, animals, *e.g.*, mice, are inoculated with a particular infectious agent or tumor-forming cells, then treated with an immunostimulatory fusion protein of the invention and evaluated for the ability of the antigenic composition to suppress *in vivo* growth of the infectious agent or an established tumor.

Example 3 illustrates this approach, in that post-infection injection of mice with activated DC pulsed *ex vivo* with the HER-2 fusion protein compositions, HER500\*•rGM-CSF (SEQ ID NO:4), HER500•hGM-CSF (SEQ ID NO:2), HER500\* (SEQ ID NO:3), and HER500 (SEQ ID NO:1), increased the survival time for mice previously inoculated with HER-2-expressing autologous tumor cells.

The results of the animal studies confirm that in order to generate an effective anti-tumor response, an immunostimulatory fusion protein of the invention must comprise antigenic sequence component and a sequence component derived from the intracellular domain of HER-2.

## VI. Compositions and Methods for Immunotherapy and Cancer Therapy

The present invention provides immunostimulatory fusion protein compositions that are able to effectively present antigen for the induction of both CD8<sup>+</sup> CTL-mediated as well as CD4<sup>+</sup> Th cell proliferative responses.

As such, the immunostimulatory fusion protein compositions of the present invention are universally useful and can be employed in a wide range of immunotherapeutic,

immunoprophylactic and cancer therapeutic applications involving generation of primary and secondary immune responses.

The invention also provides modified soluble polypeptide or protein antigens presented in the context of MHC Class I.

5 In a preferred embodiment, immunization with a modified soluble protein antigen of the invention results in an MHC Class I-mediated cellular immune response to an antigen which would not elicit a cellular immune response of the same magnitude, if provided in an unmodified form.

10 Immunization with such a modified soluble protein antigen results in an MHC Class I-mediated cellular immune response which is greater in magnitude and accordingly provides greater protection than a cellular immune response to the same antigen if provided in an unmodified form.

15 In one preferred embodiment, the invention provides an immunostimulatory composition comprising DCs exposed *ex vivo* to an immunostimulatory fusion protein comprising a polypeptide antigen sequence component and a sequence component derived from the intracellular domain of the HER-2 protein, as described above, which is able to more effectively induce T-cell responses, than a composition comprising the polypeptide antigen alone.

20 An immunostimulatory composition comprising DCs exposed *ex vivo* to an immunostimulatory fusion protein of the invention alone, or in combination with the immunostimulatory fusion protein finds utility in immunotherapy of a subject and can function as a vaccine.

25 In a related aspect, the invention includes a method of immunizing a subject against a polypeptide antigen associated with a particular type of cancer or infectious disease. The method includes exposing or pulsing DC with an immunostimulatory fusion protein composition, as further described below.

30 In practicing the methods of the invention, the exposing step can be carried out *in vitro* (*ex vivo*), *in vivo* or both *in vitro* and *in vivo*. For example, an immunostimulatory fusion protein of the invention may be directly injected into a subject or DC may be exposed to the immunostimulatory fusion protein *in vitro* in a manner effective to induce cell-surface presentation of the antigenic component of the fusion protein and the pulsed DC returned to the subject.

35 An antigenic composition comprising an immunostimulatory fusion protein alone or in combination with DC stimulated by *in vitro* exposure to the immunostimulatory fusion protein can be used, for example, in direct *in vivo* administration, *ex vivo* somatic therapy, *in vivo* implantable devices or in *ex vivo* extracorporeal devices.

40 It will be understood that any of a number of methods may be used to pulse DC with an immunostimulatory fusion protein of the invention, to make them effective to present antigen in the context of MHC I. The experiments detailed herein demonstrate that activation of DC by exposure to immunostimulatory fusion proteins facilitates processing of the antigenic component of the fusion protein through the "endogenous" class I pathway such that antigens

are presented in association with MHC class I molecules, and accordingly are able to activate CD8<sup>+</sup> CTL.

From the foregoing, it will be appreciated that the invention provides compositions and methods having the unique feature that processing of soluble protein antigens occurs through the MHC class I, as opposed to class II, pathway.

## VII. Therapeutic Applications

### A. Exposing DC *ex vivo* To Immunostimulatory Fusion Protein Compositions

The invention is based on the discovery that DC can be exposed to an immunostimulatory fusion protein composition, either *in vitro* (*ex vivo*), or *in vivo* in a subject, resulting in a protective T cell mediated response against the antigenic component of the fusion protein.

DC are treated *in vitro* (*ex vivo*) with an immunostimulatory fusion protein composition, followed by administration to a subject. The subject may be the same individual from whom the DC were obtained (autologous transplantation) or a different individual (allogeneic transplantation). In allogeneic transplantation, the donor and recipient are matched based on similarity of HLA antigens in order to minimize the immune response of both donor and recipient cells against the other.

A subject may be treated with an immunostimulatory fusion protein composition of the invention alone or in combination with a therapeutic regimen typically used for the condition under treatment, e.g. radiation therapy and/or chemotherapy for the treatment of cancer.

In general, DC precursors are obtained, cultured under serum-free conditions in medium lacking exogenously supplied cytokines, as described above, followed by *in vitro* (*ex vivo*) exposure of the DC to an immunostimulatory fusion protein composition of the invention followed by re-infusion of the activated DC into the subject.

Re-infused *ex vivo* immunostimulatory fusion protein composition-treated DC provide a means for rapid generation of an immune response to the antigenic component of the fusion protein.

### B. *In vivo* Administration of an Immunostimulatory Fusion Protein Composition

In another aspect, the invention is directed to methods of treating a subject by *in vivo* administration of an immunostimulatory fusion protein composition of the invention.

In one embodiment, the subject has a type of cancer which expresses a tumor-specific antigen. In accordance with the present invention, an immunostimulatory fusion protein may be made which comprises a tumor-specific antigen sequence component and a sequence component derived from the intracellular domain of HER-2. In such cases, DC pulsed *ex vivo* with this immunostimulatory fusion protein are administered to a subject, alone or in combination with the fusion protein, resulting in an improved therapeutic outcome for the subject, evidenced by, e.g., a slowing or diminution of the growth of cancer cells or a solid tumor which expresses the tumor-specific antigen, or a reduction in the total number of cancer cells or total tumor burden.

In a related embodiment, the subject has been diagnosed as having a viral, bacterial, fungal or other type of infection, which is associated with the expression of a particular antigen, e.g., a

viral antigen. In accordance with the present invention, an immunostimulatory fusion protein may be made which comprises a sequence component consisting of the antigen, e.g., an HBV-specific antigen, together with a sequence component derived from the intracellular domain of HER-2. In such cases, DC pulsed *ex vivo* with the immunostimulatory fusion protein are administered to a subject, alone or in combination with the fusion protein, resulting in an improved therapeutic outcome for the subject as evidenced by a slowing in the growth of the causative infectious agent within the subject and/or a decrease in, or elimination of, detectable symptoms typically associated with the particular infectious disease.

In either situation, *in vivo* administration of an immunostimulatory fusion protein of the invention to a subject provides a means to generate a protective DC-induced, T cell-mediated immune response to the antigen in the subject, dependent upon (1) the antigenic composition administered, (2) the duration, dose and frequency of administration, and (2) the general condition of the subject.

In one example, the subject has a HER-2-expressing cancer and administration of an immunostimulatory fusion protein composition of the invention which includes HER2 as the antigenic component of the fusion protein provides a means to improve the therapeutic outcome of the subject. In this embodiment, the immunostimulatory HER-2 composition is administered to the subject in a manner effective to result in a cellular immune response to HER-2-expressing cancer cells in the subject.

### C. Treating Patients

Effective delivery of the immunostimulatory fusion protein composition is an important aspect of the invention. In accordance with the invention, such routes of delivery include, but are not limited to, various systemic routes, including parenteral routes, e.g., intravenous (IV), subcutaneous (SC), intraperitoneal (IP), and intramuscular (IM) injection.

It will be appreciated that methods effective to deliver an immunostimulatory fusion protein to dendritic cells or to introduce an immunostimulatory fusion protein or DC composition in close proximity to antigen-expressing cells are also contemplated.

In one preferred embodiment, the immunostimulatory composition is a fusion protein, contained in a pharmaceutically acceptable carrier, and delivered by the intravenous route. In a further aspect of this embodiment, the immunostimulatory fusion protein composition is administered at regular intervals for a short time period, e.g., in bi-weekly intervals for two months or less. However, in some cases the fusion protein composition is administered intermittently over a longer period of time.

Typically, one or more doses of the immunostimulatory fusion protein are administered, generally at bi-weekly intervals for a period of about two months. Preferred doses for administration by the IV, SC or IM route are from about 5 µg/kg per patient to about 5 mg/kg per patient.

In another preferred embodiment, the immunostimulatory composition comprises DC exposed *ex vivo* to an immunostimulatory fusion protein, contained in a pharmaceutically acceptable carrier, and delivered by the IV, SC or IM route.

In one aspect of this embodiment, the immunostimulatory fusion protein composition comprises from  $10^7$  to  $10^{11}$  DC, which have been exposed to from 100 ng/ml to 1 mg/ml of a given immunostimulatory fusion protein, in a manner effective to generate Ag-loaded DC as described in Examples 2 and 3. Doses of about  $10^7$  to  $10^{11}$  DC are then administered to the subject by intravenous or SC or IM injection according to established procedures for a short time period, *e.g.*, at bi-weekly intervals for 2 months or less. However, in some cases the immunostimulatory fusion protein composition is administered intermittently over a longer period of time.

Typically, one or more doses of the immunostimulatory fusion protein composition are administered, generally at regular intervals for a period of about 2 months. In general, the method comprises administering to a subject, in a suitable pharmaceutical carrier, an amount of an immunostimulatory fusion protein or DC composition effective to result in an improved therapeutic outcome for the subject under treatment.

It follows that the immunostimulatory fusion protein or DC composition may be administered in any convenient vehicle, which is physiologically acceptable. Such an immunostimulatory fusion protein or DC composition may include any of a variety of standard physiologically acceptable carrier employed by those of ordinary skill in the art. Examples of such pharmaceutical carriers include, but are not limited to, saline, phosphate buffered saline (PBS), water and Ringer's solution. It will be understood that the choice of suitable physiologically acceptable carrier will vary dependent upon the chosen mode of administration.

Sustained release compositions are also contemplated within the scope of this application. These may include semipermeable polymeric matrices in the form of shaped articles such as films or microcapsules.

In preferred applications of the method, the subject is a human subject. The subject may also be a cancer patient, in particular a patient diagnosed as having a cancer which expresses a particular cancer-specific or cancer-associated antigen, and the patient may or may not be under with chemotherapy and/or radiation therapy.

It will be understood that the effective *in vivo* dose of an immunostimulatory fusion protein or DC composition of the invention will vary according to the frequency and route of administration as well as the condition of the subject under treatment. Accordingly, such *in vivo* therapy will generally require monitoring by tests appropriate to the condition being treated and a corresponding adjustment in the dose or treatment regimen in order to achieve an optimal therapeutic outcome.

#### D. Monitoring Treatment

The efficacy of a given therapeutic regimen involving the methods described herein, may be monitored, *e.g.*, by monitoring the induction of a CTL response, a helper T-cell response, and/or the antibody response to the antigenic component of the fusion protein in peripheral blood using methods well known in the art in addition to monitoring the status of the cancer and the biological condition of the subject, at various time points following such administration.

In cases where the subject has been diagnosed as having a particular type of cancer, the status of the cancer is also monitored using diagnostic techniques appropriate to the type of cancer under treatment. Similarly, in cases where the subject has been diagnosed as having a particular type of infection, the status of the infection is also monitored using diagnostic techniques appropriate to the type of type of infection under treatment.

The immunostimulatory fusion protein or DC composition treatment regimen may be adjusted (dose, frequency, route, etc.), as indicated, based on the condition of the subject under treatment and the results of the assays described above.

## VIII. Utility

The present invention provides immunostimulatory fusion protein compositions that are able to effectively present antigen for the induction of both CD8<sup>+</sup> CTL-mediated as well as CD4<sup>+</sup> Th cell proliferative responses.

As such, the immunostimulatory fusion protein compositions of the invention are universally useful and can be employed in a wide range of immunotherapeutic, immunoprophylactic and cancer therapeutic applications involving generation of primary and secondary immune responses.

The immunostimulatory fusion protein compositions of the invention find utility in immunotherapy of cancers which are associated with expression of a particular antigen. For example, the HER-2 fusion protein compositions described herein find utility in immunotherapy of HER-2 expressing tumors, such as, breast carcinoma, ovarian cancer and colon cancer.

The advantages of the present invention include induction of enhanced cellular immunity to isolated or soluble polypeptide or protein antigens by presenting an immunostimulatory fusion protein of the invention to a dendritic cell (DC), resulting in DC activation. As discussed above, such induction is not generally observed using soluble, polypeptide or protein antigens as induction materials. The generation of such activated DC, may be accomplished *in vitro* (*ex vivo*) using autologous or allogeneic DC or may take place *in vivo* following administration of an immunostimulatory fusion protein of the invention to a subject.

All patent and literature references cited in the present specification are hereby expressly incorporated by reference in their entirety.

The following examples illustrate but are not intended in any way to limit the invention.

### Example 1

#### Production Of Exemplary HER-2 Fusion Proteins

In one example, human HER-2 was cloned from a SK-BR3 cell line according to methods known in the art. The stop codon at the 3' end of the sequence was mutated away, and a Not I site inserted in its place, to fuse the HER-2 cDNA to C-terminal tag peptide, rat GM-CSF, or human GM-CSF DNA. GM-CSF DNA was cloned from a PBMC library according to standard methods. A Not I site was inserted at the 5' end of the DNA, and an Xba I cloning site was inserted at the 3' end, along with an in-frame stop codon. PCR-generated cDNA's were

digested with appropriate restriction enzymes and cloned into restriction vectors for transfection into specific mammalian or insect cell lines.

Expression vectors comprising the coding sequence for various HER2 fusion proteins were used to transfect mammalian 293-EBNA cells (Invitrogen) (transient expression) and insect SF21 cells (Clontech, Palo Alto, CA). Fusion protein products were recovered from the tissue culture supernatants, and affinity purified by passage over a metal affinity column, (NTA resin, Qiagen). For HER500\*•rGM-CSF, analysis by SDS-PAGE revealed protein bands migrating at 120 kDa and 110 kDa as products from mammalian and insect cells, respectively. The predicted size of the 690 polypeptide backbone is 74877 Da.

Human HER-2-derived proteins were produced as recombinant proteins using the following coding sequences.

The HER500\*•rGM-CSF construct (SEQ ID NO: 4) was produced by expression of a coding sequence which included, in the 5' to 3' direction: a 32 amino acid PAP signal peptide, a 3 amino acid sequence of the mature PAP protein, an Ala Arg linker, a 3 amino acid HER-2 signal sequence, 289 amino acids of the mature HER-2 membrane distal extracellular domain, an Ala linker, the OVA-derived immunodominant octapeptide SIINFEKL (OVA<sub>257-264</sub>), 217 amino acids of the HER-2 membrane distal intracellular domain, an Ala Ala linker, a 127 amino acid mature rat GM-CSF sequence, and Gly Ala Pro Pro Pro Pro Ala His His His His His His.

The HER300\*•rGM-CSF construct (SEQ ID NO: 5) was produced by expression of a coding sequence which included, in the 5' to 3' direction: a 32 amino acid PAP signal sequence, a 3 amino acid sequence of the mature PAP protein, an Ala Arg linker, a 3 amino acid HER-2 signal sequence, 289 amino acids of the mature HER-2 membrane distal extracellular domain, an Ala linker, the OVA-derived immunodominant octapeptide SIINFEKL (OVA<sub>257-264</sub>), an Ala linker, a 127 amino acid mature rat GM-CSF sequence, and Gly Ala Pro Pro Pro Pro Ala His His His His His His.

BP8 baculovirus expression vectors (Clontech) comprising the coding sequence for the HER500\*•rGM-CSF (SEQ ID NO: 9) or HER300\*•rGM-CSF (SEQ ID NO: 10) fusion proteins were used to transfect SF21 cells. Fusion protein products were recovered from tissue culture supernatants, and affinity purified by metal affinity chromatography. Analysis by SDS-PAGE revealed protein bands migrating at 105 kDa for HER500\*•rGM-CSF and 60 kDa for HER300\*•rGM-CSF.

Once constructed, expressed and purified, HER-2 fusion molecules containing rat GM-CSF or human GM-CSF were tested for GM-CSF bioactivity appropriate assays and the presence of HER-2 was verified using HER-2-specific monoclonal antibodies in both Western blot analysis and in an ELISA test, according to methods well-known in the art.

#### Evaluation of *in vitro* presentation of HER-2 fusion proteins

The IL-2 secreting mouse T cell hybridoma B3Z, which responds to the mouse MHC class I (H2-K<sup>b</sup>) bound OVA-derived peptide SIINFEKL (OVA<sub>257-264</sub>; Jameson et al., 1993, *J. Exp. Med.* 177: 1541), was used to evaluate the antigen presenting ability of HER-2 fusion proteins containing the OVA-derived immunodominant peptide SIINFEKL.



Tissue cultures were maintained in IMDM medium supplemented with 10% FCS, 2 mM L-glutamine, 0.1 mg/ml kanamycin sulfate and  $3 \times 10^{-5}$  M 2-ME (Gibco, Grand Island, NY) at 37°C in a humidified atmosphere containing 5% CO<sub>2</sub> (tissue culture incubator).

Enriched preparations of activated DC were obtained by incubating autologous C57BL/6 spleen cells in tissue culture flasks for 2 h at 37°C, removing non-adherent cells, and culturing the remaining adherent cells for 2 days with 1 µM ionomycin.

An IL-2 secretion assay was performed as described previously [Kruisbeek, 1998, in Coligan *et al.* (eds.) *Current Protocols in Immunology*, Wiley, New York, NY, 1:3.14]. More specifically, 10<sup>5</sup> hybridoma cells were cultured in 0.2-ml microwells in the presence of  $3 \times 10^4$  activated DC and various concentrations of HER-2 antigens. One day later, culture supernatants were harvested and tested at 50% concentration for their ability to support the proliferation of 10<sup>4</sup> HT-2 cells (an IL-2 dependent cell line) for 24 h, as measured by [<sup>3</sup>H]thymidine incorporation during the final 6 h culture period.

The response of B3Z cells to the HER300\*•rGM-CSF and HER500\*•rGM-CSF fusion proteins relative to OVA (Grade VII, 99% pure chicken ovalbumin purchased from Sigma, St. Louis, MO), was evaluated *in vitro*. The cell proliferation response indicated as CPM based on 3H thymidine uptake (Fig. 1) indicate that HER300\*•rGM-CSF and HER500\*•rGM-CSF fusion proteins are more efficient in stimulating B3Z than native OVA itself (about, 10-fold, and >100-fold, respectively). The 10-fold superiority of HER500\*•rGM-CSF over HER300\*•rGM-CSF indicates that the enhanced presentation of Ag is correlated with the inclusion of the additional intracellular HER-2 domain derived 217 amino acids in the fusion protein (which are present in HER500\*•rGM-CSF but absent in HER300\*•rGM-CSF).

### Example 2

#### Prevention of *in vivo* tumor growth by pre-immunization with Ag-pulsed DC

The effect of pre-immunization with HER-2-pulsed activated DC on suppression of *in vivo* growth of HER-2-expressing autologous tumors was evaluated in a murine model.

The mouse tumor cell line E.HER-2 was generated by transfecting EL-4 cells (C57BL/6 mouse strain derived thymoma; ATCC, Rockville, MD) with the full length human HER-2 cDNA according to standard methods.

Human HER-2-derived proteins were produced as recombinant proteins as previously described in Example 1, using the following coding sequences.

The HER500 construct (SEQ ID NO: 1) was produced by expression of a coding sequence which included, in the 5' to 3' direction: a 32 amino acid PAP signal sequence, a 3 amino acid sequence of the mature PAP protein, an Ala Arg linker, 3 amino acids of HER-2 signal sequence, 289 amino acids of mature HER-2 membrane distal extracellular domain, 217 amino acids of the HER-2 membrane distal intracellular domain and a C-terminal tag consisting of Ala Ala Ala His His His His His.

The HER500•hGM-CSF construct (SEQ ID NO: 2) was produced by expression of a coding sequence which included, in the 5' to 3' direction: a 32 amino acid PAP signal sequence, a 3 amino acid sequence of the mature PAP protein, an Ala Arg linker, 3 amino acids of HER-2 signal sequence, 289 amino acids of the mature HER-2 membrane distal

extracellular domain, 217 amino acids of the HER-2 membrane distal intracellular domain, an Ala Ala linker, a 127 amino acid mature human GM-CSF sequence and a C-terminal tag consisting of Gly Ala Pro Pro Pro Pro Ala Ala His His His His His His.

5 The HER500\* construct (SEQ ID NO: 3) was produced by expression of a coding sequence which included, in the 5' to 3' direction: the coding sequence for: a 32 amino acid PAP signal sequence, a 3 amino acid sequence of the mature PAP protein, an Ala Arg linker, 3 amino acids of HER-2 signal sequence, 289 amino acids of the mature HER-2 membrane distal extracellular domain, a Ala linker, the OVA-derived immunodominant octapeptide SIINFEKL (OVA<sub>257-264</sub>), 217 amino acids of the HER2 membrane distal intracellular domain and a C-  
10 terminal tag consisting of Ala Ala Ala His His His His His His His.

The HER500\*rGM-CSF construct (SEQ ID NO: 4) was produced by expression of a coding sequence which included, in the 5' to 3' direction: a 32 amino acid PAP signal sequence, a 3 amino acid sequence of the mature PAP protein, an Ala Arg linker, 3 amino acids of HER-2 signal sequence, 289 amino acids of the mature HER-2 membrane distal  
15 extracellular domain, an Ala linker, the OVA-derived immunodominant octapeptide SIINFEKL (OVA<sub>257-264</sub>), 217 amino acids of the HER2 membrane distal intracellular domain, an Ala Ala linker, a 127 amino acid mature rat GM-CSF sequence and a C-terminal tag consisting of Gly Ala Pro Pro Pro Pro Pro Pro Ala His His His His His His.

The HER300\*rGM-CSF construct (SEQ ID NO: 5) was produced by expression of a  
20 coding sequence which included, in the 5' to 3' direction: a 32 amino acid PAP signal sequence, a 3 amino acid sequence of the mature PAP protein, an Ala Arg linker, 3 amino acids of HER-2 signal sequence, 289 amino acids of the mature HER-2 membrane distal extracellular domain, an Ala linker, the OVA-derived immunodominant octapeptide SIINFEKL (OVA<sub>257-264</sub>), an Ala linker, a 127 amino acid mature rat GM-CSF sequence and a C-terminal  
25 tag consisting of Gly Ala Pro Pro Pro Pro Pro Pro Ala His His His His His His.

Eight-week old randomized female C57BL/6 mice were given 3 IP injections of  $2.5 \times 10^5$  Ag-pulsed activated DC in 0.1 ml PBS at 2-weeks intervals. Enriched preparations of activated DC were obtained by incubating female C57BL/6 spleen cells in tissue culture flasks for 2h at 37°C, removing non-adherent cells, and subsequently culturing the remaining  
30 adherent cells for 2 days in the presence of 1  $\mu$ M ionomycin (Sigma, St. Louis, MO; Czerniecki *et al.*, 1997, *J. Immunol.* 159: 3823; Ridge *et al.*, 1998, *Nature* 393: 474). The DC obtained in this manner were pulsed by 16h co-culture with each of the indicated HER-2 fusion proteins at 1  $\mu$ M, washed two times and injected into mice. Two weeks after the last *in vivo* immunization, mice were challenged with an IP injection of  $5 \times 10^5$  E.HER-2 cells in 0.1  
35 ml PBS. Mice were monitored daily and their survival recorded. The results of two independent experiments are shown in Figs. 2A and 2B, respectively.

While immunization with HER500\*•rGM-CSF-pulsed DC prevented the tumor growth, treatment with HER300\*•rGM-CSF had no effect (Fig. 2A). These results are consistent with the results obtained *in vitro* in that they confirm the importance of the  
40 intracellular HER-2 domain derived segment in attaining a strong level of Ag presentation in order to generate an effective anti-tumor response. Experimental results shown in Fig. 2B demonstrate that a significant level of *in vivo* protection against a HER-2 expressing tumor can

also be generated (a) when HER500-containing immunogens are either fused to the human GM-CSF (HER500•hGM-CSF), (b) in the absence of any GM-CSF when both an intracellular and extracellular portion of the HER-2 antigen is resnet in the construct (HER500 and HER500\*), and (c) in the absence of the OVA-derived peptide SIINFEKL (HER500 and HER500•hGM-CSF).

### Example 3

#### In vivo suppression of an established tumor by immunization with Ag-pulsed activated DC

The efficacy of immunotherapy with different HER-2 fusion proteins was further evaluated by administration of the HER-2 fusion proteins to tumor-bearing laboratory mice (*i.e.*, animals that were pre-injected with HER-2 expressing tumor cells). Twelve-week old IP injection of  $5 \times 10^5$  E.HER-2 cells in 0.1 ml PBS on day 0, followed by 2 IP injections of  $2.5 \times 10^5$  Ag-pulsed activated DC in 0.1 ml PBS (prepared as described in Example 2) one and 12 days later, respectively. Mice were monitored daily and their survival recorded. As shown in Fig. 3, treatment with DC pulsed with the HER500-containing antigenic constructs (HER500•rGM-CSF, HER500, and HER500•hGM-CSF), exhibited a notable therapeutic effect, considerably prolonging the survival of tumor-bearing mice.

Description	SEQ ID NO
HER500 amino acid sequence: MRAAPLLLARAASLSLGFLLFFWLDRSVLAKELARGAASTQVCTGTDMLRLPASPETHLDMRLHLYQG CQVVQGNLELTYPNTASLSFLQDIQEVQGYVLIHNNQVRQVPLQRLRIVRGTLFEDNYALAVLDNGDPLN NTTPVTGASPGGLRELQLRSLTEILKGGVLIQRNPQLCYQDTILWKDIFHKNNQLALTLIDTNRSRACHPCSPM CKGSRGWGESSEDCQSLTRTVCAAGGCARCKGPLPTDCHEQCAAGCTGPKHSDCLACLFHNSGICELHCPA LVTYNTDTFESMPNPEGRTYFGASCVTACPYNYLSTDVSGAGGMVHHRHRSSTRSGGGDLTLGLEPSEEE APRSPLAPSEGAGSDVFDGDLGMGAAGLQSLPTHDPSPQLQRYSEDPTVPLPSETDGYVAPLTCSPQPEYVNQ PDVRPQPPSPREGPLPAARPAGATLERAKTLPKGNGVVKDVFAFGGAVENPEYLTPOGGAAPQPHPPAFSP AFDNLYYWDQDPPERGAPPSTFKGTPTAENPEYLGDLVPAAAHHHHHH	1
HER500•hGM-CSF amino acid sequence: MRAAPLLLARAASLSLGFLLFFWLDRSVLAKELARGAASTQVCTGTDMLRLPASPETHLDMRLHLYQG CQVVQGNLELTYPNTASLSFLQDIQEVQGYVLIHNNQVRQVPLQRLRIVRGTLFEDNYALAVLDNGDPLN NTTPVTGASPGGLRELQLRSLTEILKGGVLIQRNPQLCYQDTILWKDIFHKNNQLALTLIDTNRSRACHPCSPM CKGSRGWGESSEDCQSLTRTVCAAGGCARCKGPLPTDCHEQCAAGCTGPKHSDCLACLFHNSGICELHCPA LVTYNTDTFESMPNPEGRTYFGASCVTACPYNYLSTDVSGAGGMVHHRHRSSTRSGGGDLTLGLEPSEEE APRSPLAPSEGAGSDVFDGDLGMGAAGLQSLPTHDPSPQLQRYSEDPTVPLPSETDGYVAPLTCSPQPEYVNQ PDVRPQPPSPREGPLPAARPAGATLERAKTLPKGNGVVKDVFAFGGAVENPEYLTPOGGAAPQPHPPAFSP AFDNLYYWDQDPPERGAPPSTFKGTPTAENPEYLGDLVPAAPARSPSPSTQPEHVNIAIQEARLLNLSRDT AAEMNETVEISEMFDLQEPCLQTRLELYKQGLRGSCLKKGPLTMMASHYKQHCPTPETSCATQITFESF KENLKDFLLVIPFDCWEPVQEGAPPPAAHHHHHH	2
HER500* amino acid sequence: MRAAPLLLARAASLSLGFLLFFWLDRSVLAKELARGAASTQVCTGTDMLRLPASPETHLDMRLHLYQG CQVVQGNLELTYPNTASLSFLQDIQEVQGYVLIHNNQVRQVPLQRLRIVRGTLFEDNYALAVLDNGDPLN NTTPVTGASPGGLRELQLRSLTEILKGGVLIQRNPQLCYQDTILWKDIFHKNNQLALTLIDTNRSRACHPCSPM CKGSRGWGESSEDCQSLTRTVCAAGGCARCKGPLPTDCHEQCAAGCTGPKHSDCLACLFHNSGICELHCPA LVTYNTDTFESMPNPEGRTYFGASCVTACPYNYLSTDVSGASIIINFEKL GAGGMVHHRHRSSTRSGGGDLTL GLEPSEEEAPRSPLAPSEGAGSDVFDGDLGMGAAGLQSLPTHDPSPQLQRYSEDPTVPLPSETDGYVAPLTCSP QPEYVNQPDVRPQPPSPREGPLPAARPAGATLERAKTLPKGNGVVKDVFAFGGAVENPEYLTPOGGAAPQPH PPPAFSPAFDNLYYWDQDPPERGAPPSTFKGTPTAENPEYLGDLVPAAAHHHHHH	3

<p>HER500*•rGM-CSF amino acid sequence:</p> <p>MRAAPLLLLARAASLSLGFLLFFWLDRSVLAKELARGAASTQVCTGTDMLRLPASPETHLDMLRHL YQG  CQVVQGNLELT YLPTNASLSFLQDIQEVQGYVLI AHNQVRQVPLQRLRIVRG TQLFEDNYALAVLDNGDPLN  NTTPVTGASPGGLRELQLRSLTEILKGGVLIQRNPQLCYQDTILWKDIFHKNNQLAL TLIDTNRSRACHPCSPM  CKGSRCWGESSEDCQSLTRTV CAGGCARCKGPLPTDCCHEQCAAGCTGPKHSDCLACLFHNSGICELHCPA  LVTYNTDTFESMPNPEG RYTFGASCVTACPYNYLSTDVGSASINFEKLGAGGMVHHRHRSSTRSGGGDLTL  GLEPSEEEAPRSPLAPSEGAGSDVFDGDLGMGAAGLQSLPTHDPSP LQRYSEDPTVPLPSETDGYVAPLTCSP  QPEYVNQPDVVRPQPPSPREGPLPAARPAGATLERAKT LSPGKNGVVKDVF AFGGAVENPEY LTPQGGAAPQP  HPPPAFSPAFDNLYYWDQDPPERGAPPSTFKGTPTAENPEY LGLDVPAAAPTRSPNPVTRPWKHVDAIKEALS  LLNDMRALENEKNEDVDIISNEFSIQRPCTCVQTRLKLYKQGLRG NLTCLNGALTMIA SHYQTNCPPPTETDCEI  EVTTFEDFIK NLKGFLFDIPDCWKPVQKGAPPPAHHHHHH</p>	4
<p>HER300*•rGM-CSF amino acid sequence:</p> <p>MRAAPLLLLARAASLSLGFLLFFWLDRSVLAKELARGAASTQVCTGTDMLRLPASPETHLDMLRHL YQG  CQVVQGNLELT YLPTNASLSFLQDIQEVQGYVLI AHNQVRQVPLQRLRIVRG TQLFEDNYALAVLDNGDPLN  NTTPVTGASPGGLRELQLRSLTEILKGGVLIQRNPQLCYQDTILWKDIFHKNNQLAL TLIDTNRSRACHPCSPM  CKGSRCWGESSEDCQSLTRTV CAGGCARCKGPLPTDCCHEQCAAGCTGPKHSDCLACLFHNSGICELHCPA  LVTYNTDTFESMPNPEG RYTFGASCVTACPYNYLSTDVGSASINFEKLAAPTRSPNPVTRPWKHVDAIKEALS  LLNDMRALENEKNEDVDIISNEFSIQRPCTCVQTRLKLYKQGLRG NLTCLNGALTMIA SHYQTNCPPPTETDCEI  EVTTFEDFIK NLKGFLFDIPDCWKPVQKGAPPPAHHHHHH</p>	5
<p>HER500 nucleotide coding sequence:</p> <p>ATGAGAGCTGCACCCCTCCTCCTGGCCAGGGCAGCAAGCCTTAGCCTTGGCTTCTTGTTC TGCTTTT  CTGGCTAGACCGAAGTGTACTAGCCAAGGAGTTGGCGCGCGGGGCCGCTCGACCCAAGTGTGCACCGG  CACAGACATGAAGCTGCGGCTCCCTGCCAGTCCCAGACCCACCTGGACATGCTCCGCCACCTCTACCA  GGGCTGCCAGGTGGTGCAGGGAACCTGGAACACCTACCTGCCCCACCAATGCCAGCCTGTCTTCTCTG  CAGGATATCCAGGAGGTGCAGGGCTACGTGCTCATCGCTCACAAACCAAGTGAGGCAGGTCCCACTCAG  AGGCTGCGGATTGTGCGAGGCACCCAGCTCTTTGAGGACAACTATGCCCTGGCCGTGTAGACAATGGA  GACCCGCTGAACAATACCAACCCCTGTACAGGGGCTCCCCAGGAGGCCTGCGGGAGCTGCAGCTTCGA  AGCCTCACAGAGATCTTGAAAGGAGGGGTCTTGATCCAGCGGAACCCCCAGCTCTGCTACCAGGACACG  ATTTTGTGGAAGGACATCTTCCACAAGAACAACAGCTGGCTCTCAGCTGATAGACACCAACCGCTCTC  GGGCCTGCCACCCCTGTTCTCCGATGTGTAAAGGGCTCCCGCTGCTGGGGAGAGAGTTCTGAGGATTGTCA  GAGCCTGACGCGCACTGTCTGTGCGGCTGGCTGTGCCCGCTGCAAGGGGGCCACTGCCCCTGACTGTCTGC  CATGAGCAGTGTGCTGCGGCTGCACGGGCCCCAAGCACTCTGACTGCCTGGCCTGCCTCCACTTCAACC  ACAGTGGCATCTGTGAGCTGCACTGCCCAGCCCTGGTCACTACAACACAGACACGTTTGAGTCCATGCC  CAATCCCGAGGGCCGGTATACATTGCGCGCCAGCTGTGTGACTGCCTGTCCCTACAACCTACCTTTCTACG  GACGTGGGATCGGGCGCTGGGGGCATGGTCCACCACAGGCACCGCAGCTCATCTACCAGGAGTGGCGGT  GGGGACCTGACACTAGGGCTGGAGCCCTCTGAAGAGGAGGGCCCCAGGTCTCCACTGGCACCCCTCCGAA  GGGGCTGGCTCCGATGTATTTGATGGTGACCTGGGAATGGGGGCAGCCAAGGGGCTGCAAGGCCTCCCC  ACACATGACCCCAGCCCTCTACAGCGGTACAGTGAGGACCCCCACAGTACCCCTGCCCTCTGAGACTGAT  GGCTACGTTGCCCCCTGACCTGCAGCCCCAGCCTGAATATGTGAACCAGCCAGATGTTTCGGCCCCAGC  CCCCCTCGCCCCGAGAGGGCCCTCTGCCTGCTGCCCGACCTGCTGGTGCCACTCTGGAAGGGCCAAGAC  TCTCTCCCCAGGGAAGAATGGGGTCGTCAAAGACGTTTTTGCCTTTGGGGGTGCCGTGGAGAACCCCGAG  TACTTGACACCCCAGGAGGAGCTGCCCTCAGCCCCACCCCTCTCTGCTTCAGCCCAGCCTTCGACA  ACCTCTATTACTGGGACAGGACCCACCAGAGCGGGGGGCTCCACCCAGCACCTTCAAAGGGACACCTA  CGGCAGAGAACCCAGAGTACCTGGGTCTGGACGTGCCAGCGGCCGCACATCACCATCACCATCAC</p>	6

<p>HER500•hGM-CSF nucleotide coding sequence:</p> <p>ATGAGAGCTGCACCCCTCCTCTGGCCAGGGCAGCAAGCCTTAGCCTTGGCTTCTTGTTTCTGCTTTTTTT  CTGGCTAGACCGAAGTGTACTAGCCAAGGAGTTGGCGCGCGGGGCCGCTCGACCCAAGTGTGACCGG  CACAGACATGAAGCTGCGGCTCCCTGCCAGTCCCGAGACCCACCTGGACATGCTCCGCCACCTCTACCA  GGGCTGCCAGGTGGTGCAGGGAAACCTGGAACCTACCTACCTGCCCACCAATGCCAGCCTGTCCTTCCTG  CAGGATATCCAGGAGGTGCAGGGCTACGTGCTCATCGCTCACAACCAAGTGAGGCAGGTCCCAGTGCAG  AGGCTGCGGATTGTGCGAGGCACCCAGCTCTTTGAGGACAACCTATGCCCTGGCCGTGCTAGACAATGGA  GACCCGCTGAACAATACCACCCCTGTACAGGGGCCTCCCCAGGAGGCCTGCGGGAGCTGCAGCTTCGA  AGCCTCACAGAGATCTTGAAGGAGGGGTCTTGATCCAGCGGAACCCCAAGCTCTGCTACCAGGACACG  ATTTTGTGGAAGGACATCTTCCACAAGAACAACCAGCTGGCTCTCACACTGATAGACACCAACCGCTCTC  GGGCTGCCACCCCTGTTCTCCGATGTGTAAGGGCTCCCGCTGCTGGGGAGAGAGTTCTGAGGATTGTCA  GAGCCTGACGCGCACTGTCTGTGCCGGTGGCTGTGCCCGCTGCAAGGGGCCACTGCCCACTGACTGCTGC  CATGAGCAGTGTGCTGCCGGTGCACGGGCCCCAAGCACTCTGACTGCCTGGCCTGCCTCCACTTCAACC  ACAGTGGCATCTGTGAGCTGCACTGCCCAGCCCTGGTCACTACAACACAGACACGTTTGAGTCCATGCC  CAATCCCGAGGGCCGGTATACATTCGGCGCCAGCTGTGTGACTGCCTGTCCCTACAACCTACCTTTCTACG  GACGTGGGATCGGGCGCTGGGGCATGGTCCACCACAGGCACCGCAGCTCATCTACCAGGAGTGGCGGT  GGGACCTGACATAGGGCTGGAGCCCTCTGAAGAGGAGGCCCCCAAGTCTCCACTGGCACCCTCCGAA  GGGGCTGGCTCCGATGTATTTGATGGTGACCTGGGAATGGGGGCAGCCAAGGGGCTGCAAAGCCTCCCC  ACACATGACCCCAAGCCCTCTACAGCGGTACAGTGAGGACCCACAGTACCCCTGCCCTCTGAGACTGAT  GGCTACGTTGCCCCCTGACCTGCAGCCCCCAGCCTGAATATGTGAACCAGCCAGATGTTGGGCCCCAGC  CCCCCTCGCCCCGAGAGGGCCCTCTGCCTGCTGCCCGACCTGCTGGTGCCACTCTGGAAAGGGCCAAGAC  TCTCTCCCCAGGGAAGAATGGGGTCGTCAAAGACGTTTTTGCCCTTTGGGGGTGCCGTGGAGAACCCCGAG  TACTTGACACCCAGGGAGGAGCTGCCCTCAGCCCCACCCTCCTCCTGCCTTCAGCCCAGCCTTCGACA  ACCTCTATTACTGGGACCAGGACCCACAGAGCGGGGGCTCCACCAGCACCTTCAAAGGGACACCTA  CGGCAGAGAAACCCAGAGTACCTGGGTCTGGACGTGCCAGCGGCCGACCCGCCCGCTCGCCCCAGCCCCA  GCACACAGCCCTGGGAGCATGTGAATGCCATCCAGGAGGCCCGGCGTCTCCTGAACCTGAGTAGAGACA  CTGCTGCTGAGATGAATGAAACAGTAGAAGTCATCTCAGAAATGTTTGACCTCCAGGAGCCGACCTGCCT  ACAGACCCGCTGGAGCTGTACAAGCAGGGCCTGCGGGGCAGCCTCACCAAGCTCAAGGGCCCCCTTGAC  CATGATGGCCAGCCACTACAAACAGCACTGCCCTCCAACCCCGAAACTTCCTGTGCAACCCAGATTATC  ACCTTTGAAAGTTTCAAAGAGAACCTGAAGGACTTTCTGCTTGTCTATCCCTTTGACTGTGGGAGCCAG  TCCAGGAGGGCGCGCCACCCCGCGGCGCCGCACATCACCATCACCATCAC</p>	7
<p>HER500* nucleotide coding sequence:</p> <p>ATGAGAGCTGCACCCCTCCTCTGGCCAGGGCAGCAAGCCTTAGCCTTGGCTTCTTGTTTCTGCTTTTTTT  CTGGCTAGACCGAAGTGTACTAGCCAAGGAGTTGGCGCGCGGGGCCGCTCGACCCAAGTGTGACCGG  CACAGACATGAAGCTGCGGCTCCCTGCCAGTCCCGAGACCCACCTGGACATGCTCCGCCACCTCTACCA  GGGCTGCCAGGTGGTGCAGGGAAACCTGGAACCTACCTACCTGCCCACCAATGCCAGCCTGTCCTTCCTG  CAGGATATCCAGGAGGTGCAGGGCTACGTGCTCATCGCTCACAACCAAGTGAGGCAGGTCCCAGTGCAG  AGGCTGCGGATTGTGCGAGGCACCCAGCTCTTTGAGGACAACCTATGCCCTGGCCGTGCTAGACAATGGA  GACCCGCTGAACAATACCACCCCTGTACAGGGGCCTCCCCAGGAGGCCTGCGGGAGCTGCAGCTTCGA  AGCCTCACAGAGATCTTGAAGGAGGGGTCTTGATCCAGCGGAACCCCAAGCTCTGCTACCAGGACACG  ATTTTGTGGAAGGACATCTTCCACAAGAACAACCAGCTGGCTCTCACACTGATAGACACCAACCGCTCTC  GGGCTGCCACCCCTGTTCTCCGATGTGTAAGGGCTCCCGCTGCTGGGGAGAGAGTTCTGAGGATTGTCA  GAGCCTGACGCGCACTGTCTGTGCCGGTGGCTGTGCCCGCTGCAAGGGGCCACTGCCCACTGACTGCTGC  CATGAGCAGTGTGCTGCCGGTGCACGGGCCCCAAGCACTCTGACTGCCTGGCCTGCCTCCACTTCAACC  ACAGTGGCATCTGTGAGCTGCACTGCCCAGCCCTGGTCACTACAACACAGACACGTTTGAGTCCATGCC  CAATCCCGAGGGCCGGTATACATTCGGCGCCAGCTGTGTGACTGCCTGTCCCTACAACCTACCTTTCTACG  GACGTGGGATCCGCTAGCATCATTAATTTGAGAAGTTGGGCGCTGGGGGCATGGTCCACCACAGGCAC  CGCAGCTCATCTACCAGGAGTGGCGGTGGGGACCTGACACTAGGGCTGGAGCCCTCTGAAGAGGAGGCC  CCCAGGTCTCCACTGGCACCCCTCCGAAGGGGCTGGCTCCGATGTATTTGATGGTGACCTGGGAATGGGG  CAGCCAAGGGGCTGCAAAGCCTCCCCACACATGACCCAGCCCTCTACAGCGGTACAGTGAGGACCCCA  CAGTACCCCTGCCCTCTGAGACTGATGGCTACGTTGCCCCCTGACCTGCAGCCCCCAGCCTGAATATGT  GAACCAAGCAGATGTTCCGGCCCCAGCCCCCTTCCGCCCGAGAGGGCCCTCTGCCTGCTGCCCGACCTGCT  GGTGCCACTCTGGAAAGGGCCAAGACTCTCTCCCCAGGGAAGAATGGGGTCGTCAAAGACGTTTTTGCC  TTGGGGGTGCCGTGGAGAACCCGAGTACTTGACACCCAGGGAGGAGCTGCCCTCAGCCCCACCCT  CCTCCTGCCTTACAGCCAGCCTTCGACAACCTCTATTACTGGGACCAGGACCCACAGAGCGGGGGGCTC  CACCCAGCACCTTCAAAGGGACACCTACGGCAGAGAACCAGAGTACCTGGGTCTGGACGTGCCAGCGG  CCGCACATCACCATCACCATCAC</p>	8

<p>HER500*<i>r</i>GM-CSF nucleotide coding sequence:</p> <p>ATGAGAGCTGCACCCCTCCTCTGGCCAGGGCAGCAAGCCTTAGCCTTGGCTTCTTGTCTTCTGCTTTT  TTTCTGGCTAGACCGAAGTGTACTAGCCAAGGAGTTGGCGCGCGGGGCCGCGTCGACCCAAGTGTGC  ACCGGCACAGACATGAAGCTGCGGCTCCCTGCCAGTCCCGAGACCCACCTGGACATGCTCCGCCACC  TCTACCAGGGCTGCCAGGTGGTGCAGGGAAACCTGGAACACCTACCTGCCCACCAATGCCAGCCT  GTCCTTCTGCAGGATATCCAGGAGGTGCAGGGCTACGTGCTCATCGCTCACAACCAAGTGAGGCAG  GTCCCACTGCAGAGGCTGCGGATTGTGCGAGGCACCCAGCTCTTTGAGGACAACCTATGCCCTGGCCG  TGCTAGACAATGGAGACCCGCTGAACAATACCACCCCTGTACAGGGGCCTCCCCAGGAGGCCTGCG  GGAGCTGCAGCTTCGAAGCCTCACAGAGATCTTGAAAGGAGGGGTCTTGATCCAGCGGAACCCCCAG  CTCTGCTACCAGGACACGATTTTGTGGAAGGACATCTTCCACAAGAACAACAGCTGGCTCTCACAC  TGATAGACACCAACCGCTCTCGGGCCTGCCACCCCTGTTCTCCGATGTGTAAAGGGCTCCCGTCTGCTGG  GGAGAGAGTTCTGAGGATTGTGAGAGCTGACGCGCACTGTCTGTGCCGGTGGCTGTGCCCGCTGCA  AGGGGCCACTGCCCACTGACTGCTGCCATGAGCAGTGTGCTGCCGGCTGCACGGGCCCCAAGCACTC  TGACTGCCTGGCCTGCCTCACTTCAACCACAGTGGCATCTGTGAGCTGCACTGCCAGCCCTGGTCA  CCTACAACACAGACACGTTTGAGTCCATGCCCAATCCCGAGGGCCGGTATACATTGCGCGCCAGCTG  TGTGACTGCCTGTCCCTACAACCTACCTTTCTACGGACGTGGGATCCGCTAGCATCATTAAATTCGAGA  AGTTGGGCGCTGGGGGCATGGTCCACCACAGGCACCGCAGCTCATCTACCAGGAGTGGCGGTGGGA  CCTGACACTAGGGCTGGAGCCCTCTGAAGAGGAGGGCCCCAGGTCTCCACTGGCACCCCTCCGAAGGG  GCTGGCTCCGATGTATTGATGGTGACCTGGGAATGGGGGAGCCAAGGGGCTGCAAAGCCTCCCCA  CACATGACCCAGCCCTCTACAGCGGTACAGTGAGGACCCACAGTACCCCTGCCCTCTGAGACTGA  TGGCTACGTTGCCCCCTGACCTGCAGCCCCCAGCCTGAATATGTGAACCAGCCAGATGTTGCGCCC  CAGCCCCCTTCGCCCCGAGAGGGCCCTCTGCCTGTGCCCGACCTGCTGGTGCCACTCTGAAAGGG  CCAAGACTCTCTCCCCAGGGAAGAATGGGGTCTGTAAGACGTTTTTGCCTTTGGGGGTGCCGTGGA  GAACCCCGAGTACTTGACACCCAGGGAGGAGCTGCCCCCTAGCCCCACCCCTCCTGCCTTCAGC  CCAGCCTTCGACAACCTCTATTACTGGGACCAGGACCCACAGAGCGGGGGGCTCCACCCAGCACT  TCAAAGGGACACCTACGGCAGAGAACCAGAGTACCTGGGTCTGGACGTGCCAGCGGCCGCCCCCA  CCCGCTCACCCCAACCCCTGTACCCGCGCCCTGGAAGCATGTAGATGCCATCAAAGAAGCTCTGAGCCT  CCTAAATGACATGCGTGCTCTGGAGAACGAAAAGAACGAAGACGTAGACATCATCTCTAATGAGTTC  TCCATCCAGAGGCCGACATGTGTGCAGACCCGCTGAAGCTATACAAGCAGGGTCTACGGGGCAACC  TCACCAAACCTCAATGGCGCCTTGACCATGATAGCCAGCCACTACCAGACGAACCTGCCCTCCAACCC  GGAAACTGACTGTGAAATAGAAGTCACCACCTTTGAGGATTTATAAAGAACCTTAAAGGCTTTCTG  TTTGATATCCCTTTTGACTGCTGGAAGCCGGTCCAGAAAGGCGCGCCACCCCGCCGGCGCATCACC  ATCACCATCAC</p>	9
<p>HER300*<i>r</i>GM-CSF nucleotide coding sequence:</p> <p>ATGAGAGCTGCACCCCTCCTCTGGCCAGGGCAGCAAGCCTTAGCCTTGGCTTCTTGTCTTCTGCTTTT  TTTCTGGCTAGACCGAAGTGTACTAGCCAAGGAGTTGGCGCGCGGGGCCGCGTCGACCCAAGTGTGC  ACCGGCACAGACATGAAGCTGCGGCTCCCTGCCAGTCCCGAGACCCACCTGGACATGCTCCGCCACC  TCTACCAGGGCTGCCAGGTGGTGCAGGGAAACCTGGAACACCTACCTGCCCACCAATGCCAGCCT  GTCCTTCTGCAGGATATCCAGGAGGTGCAGGGCTACGTGCTCATCGCTCACAACCAAGTGAGGCAG  GTCCCACTGCAGAGGCTGCGGATTGTGCGAGGCACCCAGCTCTTTGAGGACAACCTATGCCCTGGCCG  TGCTAGACAATGGAGACCCGCTGAACAATACCACCCCTGTACAGGGGCCTCCCCAGGAGGCCTGCG  GGAGCTGCAGCTTCGAAGCCTCACAGAGATCTTGAAAGGAGGGGTCTTGATCCAGCGGAACCCCCAG  CTCTGCTACCAGGACACGATTTTGTGGAAGGACATCTTCCACAAGAACAACAGCTGGCTCTCACAC  TGATAGACACCAACCGCTCTCGGGCCTGCCACCCCTGTTCTCCGATGTGTAAAGGGCTCCCGTCTGCTGG  GGAGAGAGTTCTGAGGATTGTGAGAGCCTGACGCGCACTGTCTGTGCCGGTGGCTGTGCCCGCTGCA  AGGGGCCACTGCCCACTGACTGCTGCCATGAGCAGTGTGCTGCCGGCTGCACGGGCCCCAAGCACTC  TGACTGCCTGGCCTGCCTCACTTCAACCACAGTGGCATCTGTGAGCTGCACTGCCAGCCCTGGTCA  CCTACAACACAGACACGTTTGAGTCCATGCCCAATCCCGAGGGCCGGTATACATTGCGCGCCAGCTG  TGTGACTGCCTGTCCCTACAACCTACCTTTCTACGGACGTGGGATCCGCTAGCATCATTAAATTCGAGA  AGTTGGCGGCCCCACCCGCTCACCAACCCCTGTACCCGCGCCCTGGAAGCATGTAGATGCCATCAA  AGAAGCTCTGAGCCTCTAAATGACATGCGTGTCTGAGAGAACGAAAAGAACGAAGACGTAGACAT  CATCTCTAATGAGTTCTCCATCCAGAGGCCGACATGTGTGCAGACCCGCTGAAGCTATACAAGCAG  GGTCTACGGGGCAACCTCACCAAACCTCAATGGCGCCTTGACCATGATAGCCAGCCACTACCAGACGA  ACTGCCCTCCAACCCCGAAACTGACTGTGAAATAGAAGTCACCACCTTTGAGGATTTATAAAGAA  CCTTAAAGGCTTTCTGTTTGATATCCCTTTTGACTGCTGGAAGCCGGTCCAGAAAGGCGCGCCACCC  CGCCGGCGCATCACCATCACCATCAC</p>	10

32 amino acid PAP signal sequence: (corresponding to amino acids 1 to 32 of GenBank Accession No. NM_001099) MRAAPLLLARAASLSLGLFLFFWLD RSVLA	11
3 amino acid mature PAP amino acid: (corresponding to amino acids 33 to 35 of GenBank Accession No. NM_001099) KEL	12
3 amino acid HER-2 signal sequence: (corresponding to amino acids 19 to 21 GenBank Accession No. M11730) GAA	13
2 amino acid linker sequence between mature PAP and HER-2 signal sequence: Ala Arg	14
C-terminal 9 amino acid sequence found on HER500 and HER500* constructs: Ala Ala Ala His His His His His His	15
C-terminal 15 amino acid sequence found in HER500-hGM-CSF: Gly Ala Pro Pro Pro Pro Ala Ala His His His His His His	16
C-terminal 13 amino acid sequence found in HER500* and HER300* rat GM-CSF constructs: Gly Ala Pro Pro Pro Pro Ala His His His His His His His	17
Mature human GM-CSF amino acid sequence: (corresponding to amino acids 18 to 144 GenBank Accession No. NM_000758) APARSPSPSTQPWEHVNAIQEARRLLNLSRDTAAEMNETVEVISEMFDLQEP TCLQTRLELYKQGLRGS LT KLKGPLTMMASHYKQHCPPTPETSCATQITFESFKENLKDFLLVIPFDCWEPVQE	18
Mature human GM-CSF nucleotide sequence: (corresponding to nucleotides 60 to 440 GenBank Accession No. NM_000758) GCACCCGCCCCGCTCGCCCCAGCCCCAGCACGCAGCCCTGGGAGCATGTGAATGCCATCCAGGAGGCCCC GGCGTCTCCTGAACCTGAGTAGAGACACTGCTGCTGAGATGAATGAAACAGTAGAAGTCATCTCAGA AATGTTTGACCTCCAGGAGCCGACCTGCCTACAGACCCGCTGGAGCTGTACAAGCAGGGCCTGCGG GGCAGCCTACCAAGCTCAAGGGCCCCCTTGACCATGATGGCCAGCCACTACAAGCAGCACTGCCCTC CAACCCCGGAAACTTCTGTGCAACCCAGACTATCACCTTTGAAAGTTTCAAAGAGAACCTGAAGGA CTTTCTGCTTGTCATCCCCCTTTGACTGCTGGGAGCCAGTCCAGGAG	19
Mature rat GM-CSF amino acid sequence: (corresponding to amino acids 1 to 127 GenBank Accession No. U00620) APTRSPNPVTRPWKHVDAIKEALSLLNDMRALENEKNEDVDIISNEFSIQRP TCVQTRLKLYKQGLRGNLT KLNGALTMIA SHYQTNCPPTPETDCEIEVTTTFEDFIKLNKGLFLDIPFDCWKPVQK	20
Mature rat GM-CSF nucleotide sequence: (corresponding to nucleotide 1 to 381 GenBank Accession No. U00620) GCACCCACCCGCTCACCCAACCCTGTCAACCCGGCCCTGGAAGCATGTAGATGCCATCAAAGAAGCTC TGAGCCTCTAAATGACATGCGTGCTCTGGAGAACGAAAAGAACGAAGACGTAGACATCATCTCTAA TGAGTTCTCCATCCAGAGGCCGACATGTGTGCAGACCCGCTGAAAGCTATACAAGCAGGGTCTACGG GGCAACCTCACAAACTCAATGGCGCCTTGACCATGATAGCCAGCCACTACCAGACGAACTGCCCTC CAACCCCGGAAACTGACTGTGAAATAGAAGTCACCACCTTTGAGGATTTTATAAAGAACCTTAAAGG CTTTCTGTTTGATATCCCTTTTGACTGCTGGAAGCCGGTCCAGAAA	21
Reporter peptide in constructs HER500* and HER500*ratGM-CSF: (OVA-derived immunodominant octapeptide SIINF EKL (OVA <sub>257-264</sub> ))	22
289 amino acids of mature HER-2 membrane distal extracellular domain: (amino acids 22 to 310 of GenBank Accession No. M11730) STQVCTGTDMLRLPASPETHLDMLRHLYQGCQVVGQNLLELTLYLPTNASLSFLQDIQEVQGYVLIH NQ VRQVPLQRLRIVRG TQLFEDNYALAVLDNGDPLNNTTPVTGASPGGLRELQLRSLTEILKGGVLIQRNPQL CYQDTILWKDIFHKNNQLALTLIDTNRSRACHPCSPMCKGSRCWGESSEDCQSLTRTV CAGGCARCKGPL PTDCCHEQCAAGCTGPKHSDCLACLFHNHSGICELHCPALVTYNTDTFESMPNPEGRTYTFGASCVTACPY NYLSTDVGS	23

coding sequence for 289 amino acids of mature HER-2 membrane distal extracellular domain: (nucleotides 214 to 1080 of GenBank Accession No. M11730) AGCACCCAAGTGTGCACCGGCACAGACATGAAGCTGCGGCTCCCTGCCAGTCCCGAGACCCACCTGG ACATGCTCCGCCACCTCTACCAGGGCTGCCAGGTGGTGCAGGGAAACCTGGAACCTCACCTACCTGCC CACCAATGCCAGCCTGTCCTTCCTGCAGGATATCCAGGAGGTGCAGGGCTACGTGCTCATCGCTCAC AACCAAGTGAGGCAGGTCCCACTGCAGAGGCTGCGGATTGTGCGAGGCACCCAGCTCTTTGAGGACA ACTATGCCCTGGCCGTGCTAGACAATGGAGACCCGCTGAACAATACCACCCCTGTCACAGGGGCTC CCCAGGAGGCTGCGGGAGCTGCAGCTTCGAAGCCTCACAGAGATCTTGAAAGGAGGGGTCTTGATC CAGCGGAACCCCCAGCTCTGCTACCAGGACACGATTTTGTGGAAGGACATCTTCCACAAGAACAACC AGCTGGCTCTCAGACTGATAGACACCAACCGCTCTCGGGCTGCCACCCCTGTTCTCCGATGTGTAAAG GGTCCCCGCTGCTGGGGAGAGAGTTCTGAGGATTGTGAGAGCCTGACGCGCACTGTCTGTGCCGGTG GCTGTGCCCCTGCAAGGGGCCACTGCCCACTGACTGCTGCCATGAGCAGTGTGCTGCCGGCTGCAC GGGCCCCAAGCACTCTGACTGCCTGGCTGCCTCCACTTCAACCACAGTGGCATCTGTGAGCTGCAC TGCCAGCCCTGGTCACCTACAACACAGACACGTTTGTAGTCCATGCCCAATCCCGAGGGCCGGTATA CATTCGGCGCCAGCTGTGTGACTGCCTGTCCCTACAACTACCTTTCTACGGACGTGGGATCC	24
217 amino acids of the membrane distal intracellular HER-2 domain: (amino acids 1038 to 1254 of GenBank Accession No. M11730) GAGGMVHHRHSSTRSGGGDLTLGLEPSEEEAPRSPLAPSEGAGSDVFDGLGMGAAGKGLQSLPHDPS PLQRYSEDPTVPLPSETDGYVAPLTCSPQPEYVNQPDVRPQPPSPREGPLPAARFAGATLERAKTLSPGKN GVVKDVFAGGAVENPEYLTPOGGAAPQHPPPAFSPAFDNLYYWDQDPPERGAPPSTFKGTPTAENPEY LGLDVP	25
coding sequence for 217 amino acids of the membrane distal intracellular HER-2 domain: (nucleotides 3262 to 3912 of GenBank Accession No. M11730) GGCGCTGGGGGCATGGTCCACCACAGGCACCGCAGCTCATCTACCAGGAGTGGCGGTGGGGACCTGA CACTAGGGCTGGAGCCCTCTGAAGAGGAGGCCCCCAGGTCTCCACTGGCACCCCTCCGAAGGGGTGG CTCCGATGTATTTGATGGTGACCTGGGAATGGGGGCAGCCAAGGGGTGCAAAGCCTCCCCACACAT GACCCAGCCCTCTACAGCGGTACAGTGAGGACCCACAGTACCCCTGCCCTCTGAGACTGATGGCTA CGTTGCCCCCTGACCTGCAGCCCCAGCCTGAATATGTGAACCAGCCAGATGTTCCGGCCCCAGCCCC CTTCGCCCCGAGAGGGCCCTCTGCCTGCTGCCCGACCTGCTGGTGCCACTCTGGAAGGGCCAAGACT CTCTCCCCAGGGAAGAATGGGGTCGTCAAAGACGTTTTTGCCTTTGGGGGTGCCGTGGAGAACCCCGA GTACTTGACACCCAGGGAGGAGCTGCCCTCAGCCCCACCCTCCTCCTGCCTTCAGCCCAGCCTTCG ACAACCTCTATTACTGGGACCAGGACCCACCAGAGCGGGGGGCTCCACCCAGCACCTTCAAAGGGAC ACCTACGGCAGAGAACCCAGAGTACCTGGGTCTGGACGTGCCA	26
NY-ESO-IC Amino Acid Sequence: amino acids 1 to 180 of GenBank Accession No. U87459 fused to the 217 amino acids of membrane distal intracellular HER-2 domain (amino acids 1038 to 1254 of GenBank Accession No. M11730)	27
NY-ESO-IC DNA Sequence: nucleotides 54 to 593 of GenBank Accession No. U87459 fused to the coding sequence for the 217 amino acids of the membrane distal intracellular HER-2 domain (nucleotides 3262 to 3912 of GenBank Accession No. M11730):	28
SART3-IC Amino Acid Sequence: amino acids 1 to 962 of GenBank Accession No. AB020880 fused to the 217 amino acids of membrane distal intracellular HER-2 domain (amino acids 1038 to 1254 of GenBank Accession No. M11730)	29
SART3-IC DNA Sequence: nucleotides 20 to 2905 of GenBank Accession No. AB020880 fused to the coding sequence for the 217 amino acids of the membrane distal intracellular HER-2 domain (nucleotides 3262 to 3912 of GenBank Accession No. M11730)	30



## IT IS CLAIMED

1. An immunostimulatory fusion protein, comprising  
a polypeptide or protein antigen sequence component and a sequence component derived  
5 from the intracellular domain of the HER-2 protein where said immunostimulatory fusion protein  
is effective to elicit a cellular immune response to the polypeptide or protein antigen sequence  
component of the fusion protein.

2. The immunostimulatory fusion protein of claim 1, wherein the HER-2 intracellular  
10 domain sequence component has the sequence presented as SEQ. ID. NO: 25.

3. The immunostimulatory fusion protein of claim 1, wherein the polypeptide or protein  
component is associated with tumor cells.

4. The immunostimulatory fusion protein of claim 1, wherein said fusion protein is  
15 produced by translation of a continuous nucleic acid coding sequence.

5. The immunostimulatory fusion protein of claim 1, wherein the fusion protein is  
20 produced by chemical coupling.

6. The immunostimulatory fusion protein of claim 1, wherein the polypeptide or protein  
component is the mature HER-2 membrane distal extracellular domain sequence presented as  
SEQ. ID. NO: 23.

7. The immunostimulatory HER2 fusion protein of claim 6, where the HER-2 fusion  
25 protein is selected from the group consisting of HER500 (SEQ ID NO: 1), HER500•hGM-CSF  
(SEQ ID NO: 2), HER500\* (SEQ ID NO:3) and HER500\*•rGM-CSF (SEQ ID NO: 4).

8. The immunostimulatory HER2 fusion protein of claim 7, where the fusion protein is  
30 HER500•hGM-CSF (SEQ ID NO: 2).


9. The immunostimulatory HER2 fusion protein of claim 1, where the cellular immune  
response is a dendritic cell-induced, T cell-mediated immune response.

10. An immunostimulatory fusion protein composition, comprising  
35 dendritic cells superactivated by *in vitro* exposure to an immunostimulatory fusion protein  
of claim 1.


11. An immunostimulatory fusion protein composition according to claim 10, further  
40 comprising the immunostimulatory fusion protein of claim 1.

12. A method of producing superactivated DC, by exposure to an immunostimulatory fusion protein, comprising  
exposing a dendritic cell (DC) or dendritic cell precursor (DCP) to an immunostimulatory fusion protein comprising a polypeptide or protein antigen sequence component and a sequence  
5 component derived from the intracellular domain of the HER-2 protein, in a manner effective to result in a cellular immune response to the polypeptide or protein antigen sequence component of the fusion protein.
13. The method of claim 12, where said exposing takes place *in vitro*.
- 10 14. The method of claim 12, where said exposing takes place *in vivo*.
- 15 15. Use of an immunostimulatory HER2 fusion protein according to any one of claims 1 to 9 in treating cancer where the cancer is associated with a particular antigen.
16. Use of superactivated DC according to any one of claims 12 to 14 in treating cancer where the cancer is associated with a particular antigen.
- 20 17. The use of an immunostimulatory HER2 fusion protein according to any one of claims 1 to 9 in the manufacture of a medicament for treating cancer where the cancer is associated with a particular antigen.
- 25 18. The use of superactivated DC according to any one of claims 12 to 14 in the manufacture of a medicament for treating cancer where the cancer is associated with a particular antigen.


1 / 4

**Fig. 1**

2 / 4

**Fig. 2A**

3 / 4

**Fig. 2B**




Fig. 3

## SEQUENCE LISTING

<110> Dendreon Corporation

# <120> Compositions and Methods for Dendritic Cell-Based Immunotherapy

<130> 7636-0022.41

<140> Not Yet Assigned

<141> Filed Herewith

<150> US 60/193,504

<151> 2000-03-30

<160> 30

<170> FastSEQ for Windows Version 4.0

 $\langle 210 \rangle$  1

<211> 555

&lt;212&gt; PRT

<213> Artificial Sequence

 $\langle 220 \rangle$ 

<223> HER500 construct

<400> 1

Met 1	Arg	Ala	Ala	Pro 5	Leu	Leu	Leu	Ala	Arg 10	Ala	Ala	Ser	Leu	Ser 15	Leu
Gly	Phe	Leu	Phe 20	Leu	Leu	Phe	Phe	Trp 25	Leu	Asp	Arg	Ser	Val 30	Leu	Ala
Lys	Glu	Leu 35	Ala	Arg	Gly	Ala	Ala 40	Ser	Thr	Gln	Val	Cys 45	Thr	Gly	Thr
Asp	Met 50	Lys	Leu	Arg	Leu	Pro 55	Ala	Ser	Pro	Glu	Thr 60	His	Leu	Asp	Met
Leu 65	Arg	His	Leu	Tyr	Gln 70	Gly	Cys	Gln	Val	Val 75	Gln	Gly	Asn	Leu	Glu 80
Leu	Thr	Tyr	Leu	Pro 85	Thr	Asn	Ala	Ser	Leu 90	Ser	Phe	Leu	Gln 95	Asp	Ile
Gln	Glu	Val	Gln 100	Gly	Tyr	Val	Leu	Ile 105	Ala	His	Asn	Gln 110	Val	Arg	Gln
Val	Pro	Leu 115	Gln	Arg	Leu	Arg	Ile 120	Val	Arg	Gly	Thr	Gln 125	Leu	Phe	Glu
Asp	Asn 130	Tyr	Ala	Leu	Ala	Val 135	Leu	Asp	Asn	Gly	Asp 140	Pro	Leu	Asn	Asn
Thr 145	Thr	Pro	Val	Thr	Gly 150	Ala	Ser	Pro	Gly	Gly 155	Leu	Arg	Glu	Leu	Gln 160
Leu	Arg	Ser	Leu	Thr 165	Glu	Ile	Leu	Lys	Gly 170	Gly	Val	Leu	Ile	Gln 175	Arg
Asn	Pro	Gln	Leu 180	Cys	Tyr	Gln	Asp	Thr 185	Ile	Leu	Trp	Lys	Asp 190	Ile	Phe
His	Lys 195	Asn	Asn	Gln	Leu	Ala	Leu 200	Thr	Leu	Ile	Asp	Thr 205	Asn	Arg	Ser
Arg	Ala 210	Cys	His	Pro	Cys	Ser	Pro 215	Met	Cys	Lys	Gly	Ser	Arg	Cys	Trp
Gly 225	Glu	Ser	Ser	Glu	Asp 230	Cys	Gln	Ser	Leu	Thr 235	Arg	Thr	Val	Cys	Ala 240
Gly	Gly	Cys	Ala	Arg 245	Cys	Lys	Gly	Pro	Leu 250	Pro	Thr	Asp	Cys	Cys 255	His

Glu Gln Cys Ala Ala Gly Cys Thr Gly Pro Lys His Ser Asp Cys Leu  
 260 265 270  
 Ala Cys Leu His Phe Asn His Ser Gly Ile Cys Glu Leu His Cys Pro  
 275 280 285  
 Ala Leu Val Thr Tyr Asn Thr Asp Thr Phe Glu Ser Met Pro Asn Pro  
 290 295 300  
 Glu Gly Arg Tyr Thr Phe Gly Ala Ser Cys Val Thr Ala Cys Pro Tyr  
 305 310 315 320  
 Asn Tyr Leu Ser Thr Asp Val Gly Ser Gly Ala Gly Gly Met Val His  
 325 330 335  
 His Arg His Arg Ser Ser Ser Thr Arg Ser Gly Gly Gly Asp Leu Thr  
 340 345 350  
 Leu Gly Leu Glu Pro Ser Glu Glu Glu Ala Pro Arg Ser Pro Leu Ala  
 355 360 365  
 Pro Ser Glu Gly Ala Gly Ser Asp Val Phe Asp Gly Asp Leu Gly Met  
 370 375 380  
 Gly Ala Ala Lys Gly Leu Gln Ser Leu Pro Thr His Asp Pro Ser Pro  
 385 390 395 400  
 Leu Gln Arg Tyr Ser Glu Asp Pro Thr Val Pro Leu Pro Ser Glu Thr  
 405 410 415  
 Asp Gly Tyr Val Ala Pro Leu Thr Cys Ser Pro Gln Pro Glu Tyr Val  
 420 425 430  
 Asn Gln Pro Asp Val Arg Pro Gln Pro Pro Ser Pro Arg Glu Gly Pro  
 435 440 445  
 Leu Pro Ala Ala Arg Pro Ala Gly Ala Thr Leu Glu Arg Ala Lys Thr  
 450 455 460  
 Leu Ser Pro Gly Lys Asn Gly Val Val Lys Asp Val Phe Ala Phe Gly  
 465 470 475 480  
 Gly Ala Val Glu Asn Pro Glu Tyr Leu Thr Pro Gln Gly Gly Ala Ala  
 485 490 495  
 Pro Gln Pro His Pro Pro Pro Ala Phe Ser Pro Ala Phe Asp Asn Leu  
 500 505 510  
 Tyr Tyr Trp Asp Gln Asp Pro Pro Glu Arg Gly Ala Pro Pro Ser Thr  
 515 520 525  
 Phe Lys Gly Thr Pro Thr Ala Glu Asn Pro Glu Tyr Leu Gly Leu Asp  
 530 535 540  
 Val Pro Ala Ala Ala His His His His His  
 545 550 555

<210> 2

<211> 690

<212> PRT

<213> Artificial Sequence

<220>

<223> HER500-hGM-CSF construct

<400> 2

Met Arg Ala Ala Pro Leu Leu Leu Ala Arg Ala Ala Ser Leu Ser Leu  
 1 5 10 15  
 Gly Phe Leu Phe Leu Leu Phe Phe Trp Leu Asp Arg Ser Val Leu Ala  
 20 25 30  
 Lys Glu Leu Ala Arg Gly Ala Ala Ser Thr Gln Val Cys Thr Gly Thr  
 35 40 45  
 Asp Met Lys Leu Arg Leu Pro Ala Ser Pro Glu Thr His Leu Asp Met  
 50 55 60  
 Leu Arg His Leu Tyr Gln Gly Cys Gln Val Val Gln Gly Asn Leu Glu  
 65 70 75 80  
 Leu Thr Tyr Leu Pro Thr Asn Ala Ser Leu Ser Phe Leu Gln Asp Ile  
 85 90 95  
 Gln Glu Val Gln Gly Tyr Val Leu Ile Ala His Asn Gln Val Arg Gln  
 100 105 110



Val	Pro	Leu	Gln	Arg	Leu	Arg	Ile	Val	Arg	Gly	Thr	Gln	Leu	Phe	Glu		
		115					120					125					
Asp	Asn	Tyr	Ala	Leu	Ala	Val	Leu	Asp	Asn	Gly	Asp	Pro	Leu	Asn	Asn		
	130					135					140						
Thr	Thr	Pro	Val	Thr	Gly	Ala	Ser	Pro	Gly	Gly	Leu	Arg	Glu	Leu	Gln		
145					150					155					160		
Leu	Arg	Ser	Leu	Thr	Glu	Ile	Leu	Lys	Gly	Gly	Val	Leu	Ile	Gln	Arg		
				165					170					175			
Asn	Pro	Gln	Leu	Cys	Tyr	Gln	Asp	Thr	Ile	Leu	Trp	Lys	Asp	Ile	Phe		
		180					185						190				
His	Lys	Asn	Asn	Gln	Leu	Ala	Leu	Thr	Leu	Ile	Asp	Thr	Asn	Arg	Ser		
	195						200					205					
Arg	Ala	Cys	His	Pro	Cys	Ser	Pro	Met	Cys	Lys	Gly	Ser	Arg	Cys	Trp		
	210					215					220						
Gly	Glu	Ser	Ser	Glu	Asp	Cys	Gln	Ser	Leu	Thr	Arg	Thr	Val	Cys	Ala		
225					230					235					240		
Gly	Gly	Cys	Ala	Arg	Cys	Lys	Gly	Pro	Leu	Pro	Thr	Asp	Cys	Cys	His		
				245					250					255			
Glu	Gln	Cys	Ala	Ala	Gly	Cys	Thr	Gly	Pro	Lys	His	Ser	Asp	Cys	Leu		
		260					265						270				
Ala	Cys	Leu	His	Phe	Asn	His	Ser	Gly	Ile	Cys	Glu	Leu	His	Cys	Pro		
	275					280						285					
Ala	Leu	Val	Thr	Tyr	Asn	Thr	Asp	Thr	Phe	Glu	Ser	Met	Pro	Asn	Pro		
	290				295					300							
Glu	Gly	Arg	Tyr	Thr	Phe	Gly	Ala	Ser	Cys	Val	Thr	Ala	Cys	Pro	Tyr		
305					310					315					320		
Asn	Tyr	Leu	Ser	Thr	Asp	Val	Gly	Ser	Gly	Ala	Gly	Gly	Met	Val	His		
				325					330					335			
His	Arg	His	Arg	Ser	Ser	Ser	Thr	Arg	Ser	Gly	Gly	Gly	Asp	Leu	Thr		
		340					345						350				
Leu	Gly	Leu	Glu	Pro	Ser	Glu	Glu	Glu	Ala	Pro	Arg	Ser	Pro	Leu	Ala		
		355				360						365					
Pro	Ser	Glu	Gly	Ala	Gly	Ser	Asp	Val	Phe	Asp	Gly	Asp	Leu	Gly	Met		
	370				375					380							
Gly	Ala	Ala	Lys	Gly	Leu	Gln	Ser	Leu	Pro	Thr	His	Asp	Pro	Ser	Pro		
385					390					395					400		
Leu	Gln	Arg	Tyr	Ser	Glu	Asp	Pro	Thr	Val	Pro	Leu	Pro	Ser	Glu	Thr		
				405					410					415			
Asp	Gly	Tyr	Val	Ala	Pro	Leu	Thr	Cys	Ser	Pro	Gln	Pro	Glu	Tyr	Val		
			420				425						430				
Asn	Gln	Pro	Asp	Val	Arg	Pro	Gln	Pro	Pro	Ser	Pro	Arg	Glu	Gly	Pro		
		435					440					445					
Leu	Pro	Ala	Ala	Arg	Pro	Ala	Gly	Ala	Thr	Leu	Glu	Arg	Ala	Lys	Thr		
	450					455					460						
Leu	Ser	Pro	Gly	Lys	Asn	Gly	Val	Val	Lys	Asp	Val	Phe	Ala	Phe	Gly		
465					470					475					480		
Gly	Ala	Val	Glu	Asn	Pro	Glu	Tyr	Leu	Thr	Pro	Gln	Gly	Gly	Ala	Ala		
				485					490					495			
Pro	Gln	Pro	His	Pro	Pro	Pro	Ala	Phe	Ser	Pro	Ala	Phe	Asp	Asn	Leu		
		500					505					510					
Tyr	Tyr	Trp	Asp	Gln	Asp	Pro	Pro	Glu	Arg	Gly	Ala	Pro	Pro	Ser	Thr		
		515					520					525					
Phe	Lys	Gly	Thr	Pro	Thr	Ala	Glu	Asn	Pro	Glu	Tyr	Leu	Gly	Leu	Asp		
	530					535				540							
Val	Pro	Ala	Ala	Ala	Pro	Ala	Arg	Ser	Pro	Ser	Pro	Ser	Thr	Gln	Pro		
545					550					555					560		
Trp	Glu	His	Val	Asn	Ala	Ile	Gln	Glu	Ala	Arg	Arg	Leu	Leu	Asn	Leu		
				565					570					575			
Ser	Arg	Asp	Thr	Ala	Ala	Glu	Met	Asn	Glu	Thr	Val	Glu	Val	Ile	Ser		
			580					585				590					
Glu	Met	Phe	Asp	Leu	Gln	Glu	Pro	Thr	Cys	Leu	Gln	Thr	Arg	Leu	Glu		
		595					600					605					

Leu Tyr Lys Gln Gly Leu Arg Gly Ser Leu Thr Lys Leu Lys Gly Pro  
 610 615 620  
 Leu Thr Met Met Ala Ser His Tyr Lys Gln His Cys Pro Pro Thr Pro  
 625 630 635 640  
 Glu Thr Ser Cys Ala Thr Gln Ile Ile Thr Phe Glu Ser Phe Lys Glu  
 645 650 655  
 Asn Leu Lys Asp Phe Leu Leu Val Ile Pro Phe Asp Cys Trp Glu Pro  
 660 665 670  
 Val Gln Glu Gly Ala Pro Pro Pro Pro Ala Ala Ala His His His His  
 675 680 685  
 His His  
 690

<210> 3  
 <211> 564  
 <212> PRT  
 <213> Artificial Sequence

<220>  
 <223> HER500\* construct

<400> 3  
 Met Arg Ala Ala Pro Leu Leu Leu Ala Arg Ala Ala Ser Leu Ser Leu  
 1 5 10 15  
 Gly Phe Leu Phe Leu Leu Phe Phe Trp Leu Asp Arg Ser Val Leu Ala  
 20 25 30  
 Lys Glu Leu Ala Arg Gly Ala Ala Ser Thr Gln Val Cys Thr Gly Thr  
 35 40 45  
 Asp Met Lys Leu Arg Leu Pro Ala Ser Pro Glu Thr His Leu Asp Met  
 50 55 60  
 Leu Arg His Leu Tyr Gln Gly Cys Gln Val Val Gln Gly Asn Leu Glu  
 65 70 75 80  
 Leu Thr Tyr Leu Pro Thr Asn Ala Ser Leu Ser Phe Leu Gln Asp Ile  
 85 90 95  
 Gln Glu Val Gln Gly Tyr Val Leu Ile Ala His Asn Gln Val Arg Gln  
 100 105 110  
 Val Pro Leu Gln Arg Leu Arg Ile Val Arg Gly Thr Gln Leu Phe Glu  
 115 120 125  
 Asp Asn Tyr Ala Leu Ala Val Leu Asp Asn Gly Asp Pro Leu Asn Asn  
 130 135 140  
 Thr Thr Pro Val Thr Gly Ala Ser Pro Gly Gly Leu Arg Glu Leu Gln  
 145 150 155 160  
 Leu Arg Ser Leu Thr Glu Ile Leu Lys Gly Gly Val Leu Ile Gln Arg  
 165 170 175  
 Asn Pro Gln Leu Cys Tyr Gln Asp Thr Ile Leu Trp Lys Asp Ile Phe  
 180 185 190  
 His Lys Asn Asn Gln Leu Ala Leu Thr Leu Ile Asp Thr Asn Arg Ser  
 195 200 205  
 Arg Ala Cys His Pro Cys Ser Pro Met Cys Lys Gly Ser Arg Cys Trp  
 210 215 220  
 Gly Glu Ser Ser Glu Asp Cys Gln Ser Leu Thr Arg Thr Val Cys Ala  
 225 230 235 240  
 Gly Gly Cys Ala Arg Cys Lys Gly Pro Leu Pro Thr Asp Cys Cys His  
 245 250 255  
 Glu Gln Cys Ala Ala Gly Cys Thr Gly Pro Lys His Ser Asp Cys Leu  
 260 265 270  
 Ala Cys Leu His Phe Asn His Ser Gly Ile Cys Glu Leu His Cys Pro  
 275 280 285  
 Ala Leu Val Thr Tyr Asn Thr Asp Thr Phe Glu Ser Met Pro Asn Pro  
 290 295 300  
 Glu Gly Arg Tyr Thr Phe Gly Ala Ser Cys Val Thr Ala Cys Pro Tyr  
 305 310 315 320

```

Asn Tyr Leu Ser Thr Asp Val Gly Ser Ala Ser Ile Ile Asn Phe Glu
      325      330      335
Lys Leu Gly Ala Gly Gly Met Val His His Arg His Arg Ser Ser Ser
      340      345      350
Thr Arg Ser Gly Gly Gly Asp Leu Thr Leu Gly Leu Glu Pro Ser Glu
      355      360      365
Glu Glu Ala Pro Arg Ser Pro Leu Ala Pro Ser Glu Gly Ala Gly Ser
      370      375      380
Asp Val Phe Asp Gly Asp Leu Gly Met Gly Ala Ala Lys Gly Leu Gln
385      390      395      400
Ser Leu Pro Thr His Asp Pro Ser Pro Leu Gln Arg Tyr Ser Glu Asp
      405      410      415
Pro Thr Val Pro Leu Pro Ser Glu Thr Asp Gly Tyr Val Ala Pro Leu
      420      425      430
Thr Cys Ser Pro Gln Pro Glu Tyr Val Asn Gln Pro Asp Val Arg Pro
      435      440      445
Gln Pro Pro Ser Pro Arg Glu Gly Pro Leu Pro Ala Ala Arg Pro Ala
      450      455      460
Gly Ala Thr Leu Glu Arg Ala Lys Thr Leu Ser Pro Gly Lys Asn Gly
465      470      475      480
Val Val Lys Asp Val Phe Ala Phe Gly Gly Ala Val Glu Asn Pro Glu
      485      490      495
Tyr Leu Thr Pro Gln Gly Gly Ala Ala Pro Gln Pro His Pro Pro Pro
      500      505      510
Ala Phe Ser Pro Ala Phe Asp Asn Leu Tyr Tyr Trp Asp Gln Asp Pro
      515      520      525
Pro Glu Arg Gly Ala Pro Pro Ser Thr Phe Lys Gly Thr Pro Thr Ala
      530      535      540
Glu Asn Pro Glu Tyr Leu Gly Leu Asp Val Pro Ala Ala Ala His His
545      550      555      560
His His His His

```

&lt;210&gt; 4

&lt;211&gt; 697

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; HER500\*-rGM-CSF construct

&lt;400&gt; 4

```

Met Arg Ala Ala Pro Leu Leu Leu Ala Arg Ala Ala Ser Leu Ser Leu
1      5      10      15
Gly Phe Leu Phe Leu Leu Phe Phe Trp Leu Asp Arg Ser Val Leu Ala
      20      25      30
Lys Glu Leu Ala Arg Gly Ala Ala Ser Thr Gln Val Cys Thr Gly Thr
      35      40      45
Asp Met Lys Leu Arg Leu Pro Ala Ser Pro Glu Thr His Leu Asp Met
      50      55      60
Leu Arg His Leu Tyr Gln Gly Cys Gln Val Val Gln Gly Asn Leu Glu
65      70      75      80
Leu Thr Tyr Leu Pro Thr Asn Ala Ser Leu Ser Phe Leu Gln Asp Ile
      85      90      95
Gln Glu Val Gln Gly Tyr Val Leu Ile Ala His Asn Gln Val Arg Gln
      100      105      110
Val Pro Leu Gln Arg Leu Arg Ile Val Arg Gly Thr Gln Leu Phe Glu
      115      120      125
Asp Asn Tyr Ala Leu Ala Val Leu Asp Asn Gly Asp Pro Leu Asn Asn
      130      135      140
Thr Thr Pro Val Thr Gly Ala Ser Pro Gly Gly Leu Arg Glu Leu Gln
145      150      155      160

```

Leu Arg Ser Leu Thr Glu Ile Leu Lys Gly Gly Val Leu Ile Gln Arg  
 165 170 175  
 Asn Pro Gln Leu Cys Tyr Gln Asp Thr Ile Leu Trp Lys Asp Ile Phe  
 180 185 190  
 His Lys Asn Asn Gln Leu Ala Leu Thr Leu Ile Asp Thr Asn Arg Ser  
 195 200 205  
 Arg Ala Cys His Pro Cys Ser Pro Met Cys Lys Gly Ser Arg Cys Trp  
 210 215 220  
 Gly Glu Ser Ser Glu Asp Cys Gln Ser Leu Thr Arg Thr Val Cys Ala  
 225 230 235 240  
 Gly Gly Cys Ala Arg Cys Lys Gly Pro Leu Pro Thr Asp Cys Cys His  
 245 250 255  
 Glu Gln Cys Ala Ala Gly Cys Thr Gly Pro Lys His Ser Asp Cys Leu  
 260 265 270  
 Ala Cys Leu His Phe Asn His Ser Gly Ile Cys Glu Leu His Cys Pro  
 275 280 285  
 Ala Leu Val Thr Tyr Asn Thr Asp Thr Phe Glu Ser Met Pro Asn Pro  
 290 295 300  
 Glu Gly Arg Tyr Thr Phe Gly Ala Ser Cys Val Thr Ala Cys Pro Tyr  
 305 310 315 320  
 Asn Tyr Leu Ser Thr Asp Val Gly Ser Ala Ser Ile Ile Asn Phe Glu  
 325 330 335  
 Lys Leu Gly Ala Gly Gly Met Val His His Arg His Arg Ser Ser Ser  
 340 345 350  
 Thr Arg Ser Gly Gly Gly Asp Leu Thr Leu Gly Leu Glu Pro Ser Glu  
 355 360 365  
 Glu Glu Ala Pro Arg Ser Pro Leu Ala Pro Ser Glu Gly Ala Gly Ser  
 370 375 380  
 Asp Val Phe Asp Gly Asp Leu Gly Met Gly Ala Ala Lys Gly Leu Gln  
 385 390 395 400  
 Ser Leu Pro Thr His Asp Pro Ser Pro Leu Gln Arg Tyr Ser Glu Asp  
 405 410 415  
 Pro Thr Val Pro Leu Pro Ser Glu Thr Asp Gly Tyr Val Ala Pro Leu  
 420 425 430  
 Thr Cys Ser Pro Gln Pro Glu Tyr Val Asn Gln Pro Asp Val Arg Pro  
 435 440 445  
 Gln Pro Pro Ser Pro Arg Glu Gly Pro Leu Pro Ala Ala Arg Pro Ala  
 450 455 460  
 Gly Ala Thr Leu Glu Arg Ala Lys Thr Leu Ser Pro Gly Lys Asn Gly  
 465 470 475 480  
 Val Val Lys Asp Val Phe Ala Phe Gly Gly Ala Val Glu Asn Pro Glu  
 485 490 495  
 Tyr Leu Thr Pro Gln Gly Gly Ala Ala Pro Gln Pro His Pro Pro Pro  
 500 505 510  
 Ala Phe Ser Pro Ala Phe Asp Asn Leu Tyr Tyr Trp Asp Gln Asp Pro  
 515 520 525  
 Pro Glu Arg Gly Ala Pro Pro Ser Thr Phe Lys Gly Thr Pro Thr Ala  
 530 535 540  
 Glu Asn Pro Glu Tyr Leu Gly Leu Asp Val Pro Ala Ala Ala Pro Thr  
 545 550 555 560  
 Arg Ser Pro Asn Pro Val Thr Arg Pro Trp Lys His Val Asp Ala Ile  
 565 570 575  
 Lys Glu Ala Leu Ser Leu Leu Asn Asp Met Arg Ala Leu Glu Asn Glu  
 580 585 590  
 Lys Asn Glu Asp Val Asp Ile Ile Ser Asn Glu Phe Ser Ile Gln Arg  
 595 600 605  
 Pro Thr Cys Val Gln Thr Arg Leu Lys Leu Tyr Lys Gln Gly Leu Arg  
 610 615 620  
 Gly Asn Leu Thr Lys Leu Asn Gly Ala Leu Thr Met Ile Ala Ser His  
 625 630 635 640  
 Tyr Gln Thr Asn Cys Pro Pro Thr Pro Glu Thr Asp Cys Glu Ile Glu  
 645 650 655

Val	Thr	Thr	Phe	Glu	Asp	Phe	Ile	Lys	Asn	Leu	Lys	Gly	Phe	Leu	Phe
			660					665					670		
Asp	Ile	Pro	Phe	Asp	Cys	Trp	Lys	Pro	Val	Gln	Lys	Gly	Ala	Pro	Pro
		675					680					685			
Pro	Pro	Ala	His	His	His	His	His	His							
		690					695								

&lt;210&gt; 5

&lt;211&gt; 479

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; HER300\*-rGM-CSF construct

&lt;400&gt; 5

Met	Arg	Ala	Ala	Pro	Leu	Leu	Leu	Ala	Arg	Ala	Ala	Ser	Leu	Ser	Leu
1				5					10				15		
Gly	Phe	Leu	Phe	Leu	Leu	Phe	Phe	Trp	Leu	Asp	Arg	Ser	Val	Leu	Ala
			20					25					30		
Lys	Glu	Leu	Ala	Arg	Gly	Ala	Ala	Ser	Thr	Gln	Val	Cys	Thr	Gly	Thr
			35				40					45			
Asp	Met	Lys	Leu	Arg	Leu	Pro	Ala	Ser	Pro	Glu	Thr	His	Leu	Asp	Met
	50					55					60				
Leu	Arg	His	Leu	Tyr	Gln	Gly	Cys	Gln	Val	Val	Gln	Gly	Asn	Leu	Glu
	65				70					75					80
Leu	Thr	Tyr	Leu	Pro	Thr	Asn	Ala	Ser	Leu	Ser	Phe	Leu	Gln	Asp	Ile
				85					90					95	
Gln	Glu	Val	Gln	Gly	Tyr	Val	Leu	Ile	Ala	His	Asn	Gln	Val	Arg	Gln
			100					105					110		
Val	Pro	Leu	Gln	Arg	Leu	Arg	Ile	Val	Arg	Gly	Thr	Gln	Leu	Phe	Glu
			115				120					125			
Asp	Asn	Tyr	Ala	Leu	Ala	Val	Leu	Asp	Asn	Gly	Asp	Pro	Leu	Asn	Asn
	130					135					140				
Thr	Thr	Pro	Val	Thr	Gly	Ala	Ser	Pro	Gly	Gly	Leu	Arg	Glu	Leu	Gln
	145				150					155					160
Leu	Arg	Ser	Leu	Thr	Glu	Ile	Leu	Lys	Gly	Gly	Val	Leu	Ile	Gln	Arg
				165					170					175	
Asn	Pro	Gln	Leu	Cys	Tyr	Gln	Asp	Thr	Ile	Leu	Trp	Lys	Asp	Ile	Phe
			180					185					190		
His	Lys	Asn	Asn	Gln	Leu	Ala	Leu	Thr	Leu	Ile	Asp	Thr	Asn	Arg	Ser
	195						200					205			
Arg	Ala	Cys	His	Pro	Cys	Ser	Pro	Met	Cys	Lys	Gly	Ser	Arg	Cys	Trp
	210					215					220				
Gly	Glu	Ser	Ser	Glu	Asp	Cys	Gln	Ser	Leu	Thr	Arg	Thr	Val	Cys	Ala
	225				230					235					240
Gly	Gly	Cys	Ala	Arg	Cys	Lys	Gly	Pro	Leu	Pro	Thr	Asp	Cys	Cys	His
			245						250					255	
Glu	Gln	Cys	Ala	Ala	Gly	Cys	Thr	Gly	Pro	Lys	His	Ser	Asp	Cys	Leu
			260					265					270		
Ala	Cys	Leu	His	Phe	Asn	His	Ser	Gly	Ile	Cys	Glu	Leu	His	Cys	Pro
	275						280					285			
Ala	Leu	Val	Thr	Tyr	Asn	Thr	Asp	Thr	Phe	Glu	Ser	Met	Pro	Asn	Pro
	290					295					300				
Glu	Gly	Arg	Tyr	Thr	Phe	Gly	Ala	Ser	Cys	Val	Thr	Ala	Cys	Pro	Tyr
	305				310					315					320
Asn	Tyr	Leu	Ser	Thr	Asp	Val	Gly	Ser	Ala	Ser	Ile	Ile	Asn	Phe	Glu
				325					330					335	
Lys	Leu	Ala	Ala	Pro	Thr	Arg	Ser	Pro	Asn	Pro	Val	Thr	Arg	Pro	Trp
			340					345					350		
Lys	His	Val	Asp	Ala	Ile	Lys	Glu	Ala	Leu	Ser	Leu	Leu	Asn	Asp	Met
		355					360					365			

```

Arg Ala Leu Glu Asn Glu Lys Asn Glu Asp Val Asp Ile Ile Ser Asn
  370                      375                      380
Glu Phe Ser Ile Gln Arg Pro Thr Cys Val Gln Thr Arg Leu Lys Leu
 385                      390                      395                      400
Tyr Lys Gln Gly Leu Arg Gly Asn Leu Thr Lys Leu Asn Gly Ala Leu
                      405                      410                      415
Thr Met Ile Ala Ser His Tyr Gln Thr Asn Cys Pro Pro Thr Pro Glu
                      420                      425                      430
Thr Asp Cys Glu Ile Glu Val Thr Thr Phe Glu Asp Phe Ile Lys Asn
                      435                      440                      445
Leu Lys Gly Phe Leu Phe Asp Ile Pro Phe Asp Cys Trp Lys Pro Val
                      450                      455                      460
Gln Lys Gly Ala Pro Pro Pro Pro Ala His His His His His His
 465                      470                      475

```

&lt;210&gt; 6

&lt;211&gt; 1665

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; HER500 construct

&lt;400&gt; 6

```

atgagagctg caccctcct cctggccagg gcagcaagcc ttagccttgg cttcttgttt      60
ctgctttttt tctggctaga ccgaagtgt ctagccaagg agttggcgcg cggggccgcg      120
tcgacccaag tgtgcaccgg cacagacatg aagctgcggc tccctgccag tcccagagacc      180
cacctggaca tgctccgcca cctctaccag ggctgccagg tgggtgcagg aaacctggaa      240
ctcacctacc tgccaccaa tgccagcctg tccttctctg aggatatcca ggaggtgcag      300
ggctacgtgc tcatcgctca caaccaagtg aggcaggtcc cactgcagag gctgcggatt      360
gtgcgaggca cccagctott tgaggacaac tatgccctgg ccgtgctaga caatggagac      420
ccgtgaaca ataccacccc tgtcacaggg gcctccccag gaggcctgcg ggagctgcag      480
cttcgaagcc tcacagagat cttgaaagga ggggtcttga tccagcgga cccccagctc      540
tgctaccagg acacgatttt gtggaaggac atcttccaca agaacaacca gctggctctc      600
acactgatag acaccaaccg ctctcggggc tgccaccctt gttctccgat gtgtaagggc      660
tcccgtgct ggggagagag ttctgaggat tgtcagagcc tgacgcgcac tgtctgtgcc      720
ggtggctgtg cccgtgcaa ggggccactg cccactgact gctgccatga gcagtgtgct      780
gccggctgca cgggccccaa gcactctgac tgcttgccct gcctccactt caaccacagt      840
ggcatctgtg agctgcactg cccagccctg gtcacctaca acacagacac gtttgagtcc      900
atgcccaatc ccgagggccg gtatacatc ggcgccagct gtgtgactgc ctgtccctac      960
aactaccttt ctacggacgt gggatcgggc gctgggggca tgggtccacca caggcaccgc      1020
agctcatcta ccaggagtgg cggtggggac ctgacactag ggctggagcc ctctgaagag      1080
gaggccccca ggtctccact ggcaccctcc gaaggggctg gctccgatgt atttgatggt      1140
gacctgggaa tgggggcagc caaggggctg caaagcctcc ccacacatga cccagccct      1200
ctacagcgg acagtgagga cccacagta cccctgccct ctgagactga tggctacgtt      1260
gccccctga cctgcagccc ccagcctgaa tatgtgaacc agccagatgt tcggccccag      1320
cccccttcgc cccgagaggg ccctctgect gctgcccagc ctgctggtgc cactctggaa      1380
agggccaaga ctctctcccc agggaagaat ggggtcgtca aagacgtttt tgcctttggg      1440
ggtgccgtgg agaaccccga gtacttgaca ccccaggag gagctgcccc tcagccccac      1500
ctctctctg ccttcagccc agccttcgac aacctctatt actgggacca ggacccacca      1560
gagcgggggg ctccaccag caccttcaaa gggacaccta cggcagagaa cccagagtac      1620
ctgggtctgg acgtgccagc ggccgcacat caccatcacc atcac      1665

```

&lt;210&gt; 7

&lt;211&gt; 2070

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; HER500-hGM-CSF construct

&lt;400&gt; 7

atgagagctg	cacccctcct	cctggccagg	gcagcaagcc	ttagccttgg	cttcttgttt	60
ctgctttttt	tctggctaga	ccgaagtgt	ctagccaagg	agttggcgcg	cggggcccgcg	120
tcgacccaag	tgtgcaccgg	cacagacatg	aagctgcggc	tccctgccag	tcccgagacc	180
cacctggaca	tgtccgcca	cctctaccag	ggctgccagg	tgggtgcagg	aaacctggaa	240
ctcacctacc	tgcccaccaa	tgccagcctg	tccttcctgc	aggatatcca	ggaggtgcag	300
ggctacgtgc	tcacgtctca	caaccaagt	aggcaggctc	cactgcagag	gctgcggtat	360
gtgcgaggca	cccagctctt	tgaggacaac	tatgccctgg	ccgtgctaga	caatggagac	420
ccgtgaaca	ataccacccc	tgtcacagg	gcctccccag	gaggcctgcg	ggagctgcag	480
cttcgaagcc	tcacagagat	cttgaaagga	gggtcttga	tccagcgaa	ccccagctc	540
tgctaccagg	acacgatttt	gtggaaggac	atcttcacaca	agaacaacca	gctggctctc	600
acactgatag	acaccaaccg	ctctcggggc	tgccacccct	gttctccgat	gtgtaagggc	660
tcccgctgct	ggggagagag	ttctgaggat	tgtcagagcc	tgacgcgcac	tgtctgtgcc	720
ggtggctgtg	cccgtgcaa	ggggccactg	cccactgact	gctgccatga	gcagtgtgct	780
gccggctgca	cgggccccaa	gcactctgac	tgccctggcct	gcctccactt	caaccacagt	840
ggcatctgtg	agctgcactg	cccagccctg	gtcacctaca	acacagacac	gtttgagtc	900
atgcccattc	ccgaggggccg	gtatacatte	ggcgccagct	gtgtgactgc	ctgtccctac	960
aactaccttt	ctacggacgt	gggatccggc	gctgggggca	tggtccacca	caggcaccgc	1020
agctcatcta	ccaggagtgg	cggtagggag	ctgacactag	ggctggagcc	ctctgaagag	1080
gaggcccca	ggtctccact	ggcaccctcc	gaaggggctg	gctccgatgt	atttgatggt	1140
gacctgggaa	tgggggcgagc	caaggggctg	caaagcctcc	ccacacatga	ccccagccct	1200
ctacagcggg	acagtgagga	ccccacagta	ccctgccct	ctgagactga	tggtacgtt	1260
gccccctga	cctgcagccc	ccagcctgaa	tatgtgaacc	agccagatgt	tggccccag	1320
cccccttcgc	cccgagaggg	ccctctgcct	gctgcccgac	ctgctgggtg	cactctggaa	1380
agggccaaga	ctctctcccc	agggaagaat	gggtcgtca	aagacgtttt	tgcccttggg	1440
ggtgccgtgg	agaaccccga	gtacttgaca	ccccaggag	gagctgcccc	tcagccccac	1500
cctcctcctg	ccttcagccc	agccttcgac	aacctctatt	actgggacca	ggaccacca	1560
gagcgggggg	ctccaccag	caccttcaaa	gggacaccta	cggcagagaa	cccagagtac	1620
ctgggtctgg	acgtgccagc	ggccgcaccc	cccgcctgc	ccagccccag	cacacagccc	1680
tgggagcatg	tgaatgccat	ccaggaggcc	cggcgtctcc	tgaacctgag	tagagacact	1740
gctgctgaga	tgaatgaaac	agtagaagtc	atctcagaaa	tgtttgacct	ccaggagccg	1800
acctgcctac	agaccgcct	ggagctgtac	aagcagggcc	tgccggggcag	cctcaccaag	1860
ctcaagggcc	ccttgaccat	gatggccagc	cactacaaac	agcactgccc	tccaaacccg	1920
gaaacttcct	gtgcaaccca	gattatcacc	tttgaaagtt	tcaaagagaa	cctgaaggac	1980
tttctgcttg	tcacccctt	tgactgctgg	gagccagtcc	aggagggcgc	gccacccccg	2040
ccggcgccgc	cacatcacca	tcaccatcac				2070

&lt;210&gt; 8

&lt;211&gt; 1692

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; HER500\* construct

&lt;400&gt; 8

atgagagctg	cacccctcct	cctggccagg	gcagcaagcc	ttagccttgg	cttcttgttt	60
ctgctttttt	tctggctaga	ccgaagtgt	ctagccaagg	agttggcgcg	cggggcccgcg	120
tcgacccaag	tgtgcaccgg	cacagacatg	aagctgcggc	tccctgccag	tcccgagacc	180
cacctggaca	tgtccgcca	cctctaccag	ggctgccagg	tgggtgcagg	aaacctggaa	240
ctcacctacc	tgcccaccaa	tgccagcctg	tccttcctgc	aggatatcca	ggaggtgcag	300
ggctacgtgc	tcacgtctca	caaccaagt	aggcaggctc	cactgcagag	gctgcggtat	360
gtgcgaggca	cccagctctt	tgaggacaac	tatgccctgg	ccgtgctaga	caatggagac	420
ccgtgaaca	ataccacccc	tgtcacagg	gcctccccag	gaggcctgcg	ggagctgcag	480
cttcgaagcc	tcacagagat	cttgaaagga	gggtcttga	tccagcgaa	ccccagctc	540
tgctaccagg	acacgatttt	gtggaaggac	atcttcacaca	agaacaacca	gctggctctc	600
acactgatag	acaccaaccg	ctctcggggc	tgccacccct	gttctccgat	gtgtaagggc	660
tcccgctgct	ggggagagag	ttctgaggat	tgtcagagcc	tgacgcgcac	tgtctgtgcc	720
ggtggctgtg	cccgtgcaa	ggggccactg	cccactgact	gctgccatga	gcagtgtgct	780
gccggctgca	cgggccccaa	gcactctgac	tgccctggcct	gcctccactt	caaccacagt	840
ggcatctgtg	agctgcactg	cccagccctg	gtcacctaca	acacagacac	gtttgagtc	900
atgcccattc	ccgaggggccg	gtatacatte	ggcgccagct	gtgtgactgc	ctgtccctac	960
aactaccttt	ctacggacgt	gggatccgct	agcatcatta	atttcgagaa	gttggggcgt	1020

gggggcatgg	tccaccacag	gcaccgcagc	tcattctacca	ggagtggcgg	tggggacctg	1080
acactagggc	tggagccctc	tgaagaggag	gccccaggt	ctccactggc	accctccgaa	1140
ggggctggct	ccgatgtatt	tgatggtgac	ctgggaatgg	gggcagccaa	ggggctgcaa	1200
agcctcccca	cacatgaccc	cagccctcta	cagcgggtaca	gtgaggaccc	cacagtaccc	1260
ctgccctctg	agactgatgg	ctacgtttgcc	cccttgacct	gcagccccc	gcctgaatat	1320
gtgaaccagc	cagatgttcg	gccccagccc	ccttcgcccc	gagagggccc	tctgcctgct	1380
gcccagacctg	ctgggtgccac	tctggaaagg	gccaagactc	tctccccagg	gaagaatggg	1440
gtcgtcaaaag	acgttttttg	ctttgggggt	gccgtggaga	accccagata	cttgacaccc	1500
cagggaggag	ctgcccctca	gccccaccct	cctcctgcct	tcagcccagc	cttcgacaac	1560
ctctattact	gggaccagga	cccaccagag	cggggggctc	caccagcac	cttcaaagg	1620
acacctacgg	cagagaaccc	agagtacctg	ggtctggacg	tgccagcggc	cgcacatcac	1680
catcaccatc	ac					1692

&lt;210&gt; 9

&lt;211&gt; 2091

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; HER500\*-rGM-CSF construct

&lt;400&gt; 9

atgagagctg	cacccctcct	cctggccagg	gcagcaagcc	ttagccttgg	cttcttgttt	60
ctgctttttt	tctggctaga	ccgaagtgtg	ctagccaagg	agttggcgcg	cggggccgcg	120
tcgacccaag	tgtgcaccgg	cacagacatg	aagctgcggc	tccctgccag	tcccagagac	180
cacctggaca	tgctccgcca	cctctaccag	ggctgccagg	tggtgcagg	aaacctggaa	240
ctcacctacc	tgcccaccaa	tgccagcctg	tccctcctgc	aggatatcca	ggaggtgcag	300
ggctacgtgc	tcctcgtcca	caaccaagtg	aggcaggtcc	actgcagag	gctgcggatt	360
gtgcgaggca	cccagctctt	tgaggacaac	tatgccctgg	ccgtgctaga	caatggagac	420
ccgctgaaca	ataccacccc	tgccacagg	gcctccccag	gaggcctgcg	ggagctgcag	480
cttcgaagcc	tcacagagat	cttgaaagga	ggggtcttga	tccagcggaa	ccccagctc	540
tgctaccagg	acacgatttt	gtggaaggac	atcttccaca	agaacaacca	gctggctctc	600
acactgatag	acaccaaccg	ctctcgggcc	tgccaccctt	gttctccgat	gtgtaagggc	660
tcccgcctgct	ggggagagag	ttctgaggat	tgctcagagc	tgacgcgcac	tgtctgtgcc	720
ggtggctgtg	cccgcctgca	ggggccactg	cccactgact	gctgccatga	gcagtgtgct	780
gccggctgca	cgggccccaa	gcactctgac	tgccctggcct	gcctccactt	caaccacagt	840
ggcatctgtg	agctgcactg	cccagccctg	gtcacctaca	acacagacac	gtttgagttc	900
atgcccaate	ccgagggcgg	gtatacattc	ggcgccagct	gtgtgactgc	ctgtccctac	960
aactaccttt	ctacggacgt	gggatccgct	agcatcatta	atttcgagaa	gttggggcgt	1020
gggggcatgg	tccaccacag	gcaccgcagc	tcattctacca	ggagtggcgg	tggggacctg	1080
acactagggc	tggagccctc	tgaagaggag	gccccaggt	ctccactggc	accctccgaa	1140
ggggctggct	ccgatgtatt	tgatggtgac	ctgggaatgg	gggcagccaa	ggggctgcaa	1200
agcctcccca	cacatgaccc	cagccctcta	cagcgggtaca	gtgaggaccc	cacagtaccc	1260
ctgccctctg	agactgatgg	ctacgtttgcc	cccttgacct	gcagccccc	gcctgaatat	1320
gtgaaccagc	cagatgttcg	gccccagccc	ccttcgcccc	gagagggccc	tctgcctgct	1380
gcccagacctg	ctgggtgccac	tctggaaagg	gccaagactc	tctccccagg	gaagaatggg	1440
gtcgtcaaaag	acgttttttg	ctttgggggt	gccgtggaga	accccagata	cttgacaccc	1500
cagggaggag	ctgcccctca	gccccaccct	cctcctgcct	tcagcccagc	cttcgacaac	1560
ctctattact	gggaccagga	cccaccagag	cggggggctc	caccagcac	cttcaaagg	1620
acacctacgg	cagagaaccc	agagtacctg	ggtctggacg	tgccagcggc	cgccccacc	1680
cgctcaccga	accctgtcac	ccggccctgg	aagcatgtag	atgccatcaa	agaagctctg	1740
agcctcctaa	atgacatgcg	tgctctggag	aacgaaaaga	acgaagacgt	agacatcatc	1800
tctaattgag	tctccatcca	gaggccgaca	tgtgtgcaga	ccgcctgaa	gctatacaag	1860
cagggctctac	ggggcaacct	caccaaactc	aatggcgctt	tgaccatgat	agccagccac	1920
taccagacga	actgccctcc	aaccccgcaa	actgactgtg	aaatagaagt	caccaccttt	1980
gaggatttca	taaagaacct	taaaggcttt	ctgtttgata	tcccttttga	ctgctggaag	2040
ccggtccaga	aaggcgcgcc	acccccgcgg	gcgcatcacc	atcaccatca	c	2091

&lt;210&gt; 10

&lt;211&gt; 1437

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence



&lt;220&gt;

&lt;223&gt; HER300\*rGM-CSF construct

&lt;400&gt; 10

```

atgagagctg caccctctct cctggccagg gcagcaagcc ttagccttgg cttcttggtt 60
ctgctttttt tctggctaga ccgaagtgtg ctagccaagg agttggcgcg cggggccgcg 120
tcgacccaag tgtgcaccgg cacagacatg aagctgcggc tccctgccag tcccagacc 180
cacctggaca tgctccgcca cctctaccag ggctgccagg tggatgcagg aaacctggaa 240
ctcacctacc tgcccaccaa tgccagcctg tccttcctgc aggatatcca ggaggtgcag 300
ggctacgtgc tcatcgctca caaccaagtg aggcaggctc cactgcagag gctgcggatt 360
gtgcgaggca cccagctctt tgaggacaac tatgccctgg ccgtgctaga caatggagac 420
ccgctgaaca ataccacccc tgtcacaggg gcctccccag gaggcctgcg ggagctgcag 480
cttcgaagcc tcacagagat cttgaaagga ggggtcttga tccagcgga cccccagctc 540
tgctaccagg acacgatttt gtggaaggac atcttcaca agaacaacca gctggctctc 600
acactgatag acaccaaccg ctctcgggcc tgccaccctt gttctccgat gtgtaagggc 660
tcccgtgctg ggggagagag ttctgaggat tgtcagagcc tgacgcgcac tgtctgtgcc 720
ggtggctgtg cccgctgcaa gggggccactg cccactgact gctgccatga gcagtgtgct 780
gccggtgca cgggccccaa gcactctgac tgctggcctt gcctccactt caaccacagt 840
ggcatctgtg agctgcactg cccagccctg gtcacctaca acacagacac gtttgagtcc 900
atgcccaatc ccgagggccg gtatacatc ggcgccagct gtgtgactgc ctgtccctac 960
aactaccttt ctacggacgt gggatccgct agcatcatta atttcgagaa gttggccgcc 1020
cccaccgct caccacaacc tgtcaccggg ccctggaagc atgtagatgc catcaaagaa 1080
gctctgagcc tcctaaatga catgcgtgct ctggagaacg aaaagaacga agacgtagac 1140
atcatctcta atgagttctc catccagagg ccgacatgtg tgcagaccgg cctgaagcta 1200
tacaagcagg gtctacgggg caacctcacc aaactcaatg gcgccttgac catgatagcc 1260
agccactacc agacgaactg cctccaacc ccggaaactg actgtgaaat agaagtcacc 1320
acctttgagg atttcataaa gaaccttaaa ggctttctgt ttgatatccc ttttgactgc 1380
tggaagccgg tccagaaagg cgcgccaccc ccgcccggcg atcaccatca ccacacac 1437

```

&lt;210&gt; 11

&lt;211&gt; 32

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 11

```

Met Arg Ala Ala Pro Leu Leu Leu Ala Arg Ala Ala Ser Leu Ser Leu
 1             5             10             15
Gly Phe Leu Phe Leu Leu Phe Phe Trp Leu Asp Arg Ser Val Leu Ala
          20             25             30

```

&lt;210&gt; 12

&lt;211&gt; 3

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 12

```

Lys Glu Leu
 1

```

&lt;210&gt; 13

&lt;211&gt; 3

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 13

```

Gly Ala Ala
 1

```

&lt;210&gt; 14

&lt;211&gt; 2

&lt;212&gt; PRT

<213> Artificial Sequence

<220>

<223> linker

<400> 14

Ala Arg

1

<210> 15

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> C-terminal sequence of HER500 and HER500\* constructs

<400> 15

Ala Ala Ala His His His His His His

1

5

<210> 16

<211> 15

<212> PRT

<213> Artificial Sequence

<220>

<223> C-terminal sequence of HER500-hGM-CSF construct

<400> 16

Gly Ala Pro Pro Pro Pro Ala Ala Ala His His His His His His

1

5

10

15

<210> 17

<211> 13

<212> PRT

<213> Artificial Sequence

<220>

<223> C-terminal sequence of HER500\* and HER300\* rat GM-CSF constructs

<400> 17

Gly Ala Pro Pro Pro Pro Ala His His His His His His

1

5

10

<210> 18

<211> 127

<212> PRT

<213> Homo sapiens

<400> 18

Ala Pro Ala Arg Ser Pro Ser Pro Ser Thr Gln Pro Trp Glu His Val

1

5

10

15

Asn Ala Ile Gln Glu Ala Arg Arg Leu Asn Leu Ser Arg Asp Thr

20

25

30

Ala Ala Glu Met Asn Glu Thr Val Glu Val Ile Ser Glu Met Phe Asp

35

40

45

Leu Gln Glu Pro Thr Cys Leu Gln Thr Arg Leu Glu Leu Tyr Lys Gln

50

55

60

Gly Leu Arg Gly Ser Leu Thr Lys Leu Lys Gly Pro Leu Thr Met Met

65					70					75					80
Ala	Ser	His	Tyr	Lys	Gln	His	Cys	Pro	Pro	Thr	Pro	Glu	Thr	Ser	Cys
				85					90					95	
Ala	Thr	Gln	Ile	Ile	Thr	Phe	Glu	Ser	Phe	Lys	Glu	Asn	Leu	Lys	Asp
			100					105					110		
Phe	Leu	Leu	Val	Ile	Pro	Phe	Asp	Cys	Trp	Glu	Pro	Val	Gln	Glu	
		115					120					125			

<210> 19  
 <211> 381  
 <212> DNA  
 <213> Homo sapiens

<400> 19  
 gcacccgccc gctcgcccag cccagcagcag cagccctggg agcatgtgaa tgccatccag 60  
 gagggcccggc gtctcctgaa cctgagtaga gacactgctg ctgagatgaa tgaaacagta 120  
 gaagtcattct cagaaatggt tgacctccag gagccgacct gcctacagac ccgcctggag 180  
 ctgtacaagc agggcctgcg gggcagcctc accaagctca agggcccctt gacctgatg 240  
 gccagccact acaagcagca ctgccctcca accccggaaa cttcctgtgc aaccagact 300  
 atcacctttg aaagtttcaa agagaacctg aaggactttc tgcttgtcat cccctttgac 360  
 tgctgggagc cagtcaggag g 381

<210> 20  
 <211> 127  
 <212> PRT  
 <213> Rattus norvegicus

<400> 20  
 Ala Pro Thr Arg Ser Pro Asn Pro Val Thr Arg Pro Trp Lys His Val  
 1 5 10 15  
 Asp Ala Ile Lys Glu Ala Leu Ser Leu Leu Asn Asp Met Arg Ala Leu  
 20 25 30  
 Glu Asn Glu Lys Asn Glu Asp Val Asp Ile Ile Ser Asn Glu Phe Ser  
 35 40 45  
 Ile Gln Arg Pro Thr Cys Val Gln Thr Arg Leu Lys Leu Tyr Lys Gln  
 50 55 60  
 Gly Leu Arg Gly Asn Leu Thr Lys Leu Asn Gly Ala Leu Thr Met Ile  
 65 70 75 80  
 Ala Ser His Tyr Gln Thr Asn Cys Pro Pro Thr Pro Glu Thr Asp Cys  
 85 90 95  
 Glu Ile Glu Val Thr Thr Phe Glu Asp Phe Ile Lys Asn Leu Lys Gly  
 100 105 110  
 Phe Leu Phe Asp Ile Pro Phe Asp Cys Trp Lys Pro Val Gln Lys  
 115 120 125

<210> 21  
 <211> 381  
 <212> DNA  
 <213> Rattus norvegicus

<400> 21  
 gcacccaccc gctcacccaa ccctgtcacc cggccctgga agcatgtaga tgccatcaaa 60  
 gaagctctga gcctcctaaa tgacatgcgt gctctggaga acgaaaagaa cgaagacgta 120  
 gacatcatct ctaatgagtt ctccatccag aggccgacat gtgtgcagac ccgcctgaag 180  
 ctatacaagc aggggtctacg gggcaacctc accaaactca atggcgcctt gacctgata 240  
 gccagccact accagacgaa ctgccctcca accccggaaa ctgactgtga aatagaagtc 300  
 accacctttg aggatttcat aaagaacctt aaaggctttc tgtttgatat cccttttgac 360  
 tgctggaagc cggtcaggaa a 381

<210> 22  
 <211> 8  
 <212> PRT

<213> Artificial Sequence

<220>

<223> OVA-derived immunodominant octapeptide

<400> 22

Ser Ile Ile Asn Phe Glu Lys Leu  
1 5

<210> 23

<211> 289

<212> PRT

<213> Homo sapiens

<400> 23

Ser Thr Gln Val Cys Thr Gly Thr Asp Met Lys Leu Arg Leu Pro Ala  
1 5 10 15  
Ser Pro Glu Thr His Leu Asp Met Leu Arg His Leu Tyr Gln Gly Cys  
20 25 30  
Gln Val Val Gln Gly Asn Leu Glu Leu Thr Tyr Leu Pro Thr Asn Ala  
35 40 45  
Ser Leu Ser Phe Leu Gln Asp Ile Gln Glu Val Gln Gly Tyr Val Leu  
50 55 60  
Ile Ala His Asn Gln Val Arg Gln Val Pro Leu Gln Arg Leu Arg Ile  
65 70 75 80  
Val Arg Gly Thr Gln Leu Phe Glu Asp Asn Tyr Ala Leu Ala Val Leu  
85 90 95  
Asp Asn Gly Asp Pro Leu Asn Asn Thr Thr Pro Val Thr Gly Ala Ser  
100 105 110  
Pro Gly Gly Leu Arg Glu Leu Gln Leu Arg Ser Leu Thr Glu Ile Leu  
115 120 125  
Lys Gly Gly Val Leu Ile Gln Arg Asn Pro Gln Leu Cys Tyr Gln Asp  
130 135 140  
Thr Ile Leu Trp Lys Asp Ile Phe His Lys Asn Asn Gln Leu Ala Leu  
145 150 155 160  
Thr Leu Ile Asp Thr Asn Arg Ser Arg Ala Cys His Pro Cys Ser Pro  
165 170 175  
Met Cys Lys Gly Ser Arg Cys Trp Gly Glu Ser Ser Glu Asp Cys Gln  
180 185 190  
Ser Leu Thr Arg Thr Val Cys Ala Gly Gly Cys Ala Arg Cys Lys Gly  
195 200 205  
Pro Leu Pro Thr Asp Cys Cys His Glu Gln Cys Ala Ala Gly Cys Thr  
210 215 220  
Gly Pro Lys His Ser Asp Cys Leu Ala Cys Leu His Phe Asn His Ser  
225 230 235 240  
Gly Ile Cys Glu Leu His Cys Pro Ala Leu Val Thr Tyr Asn Thr Asp  
245 250 255  
Thr Phe Glu Ser Met Pro Asn Pro Glu Gly Arg Tyr Thr Phe Gly Ala  
260 265 270  
Ser Cys Val Thr Ala Cys Pro Tyr Asn Tyr Leu Ser Thr Asp Val Gly  
275 280 285  
Ser

<210> 24

<211> 867

<212> DNA

<213> Homo sapiens

<400> 24

agcaccacaag tgtgcaccgg cacagacatg aagctgcggc tccctgccag tcccagagacc 60  
cacctggaca tgctccgcca cctctaccag ggctgccagg tgggtgcaggg aaacctggaa 120

```

ctcacctacc tgcccaccaa tgccagcctg tccttcctgc aggatatcca ggaggtgcag 180
ggctacgtgc tcatcgctca caaccaagtg aggcaggtcc cactgcagag gctgcggatt 240
gtgcgaggca cccagctctt tgaggacaac tatgccctgg ccgtgctaga caatggagac 300
ccgctgaaca ataccacccc tgtcacaggg gcctccccag gaggcctgcg ggagctgcag 360
cttcgaagcc tcacagagat cttgaaagga ggggtcttga tccagcggaa cccccagctc 420
tgctaccagg acacgatttt gtggaaggac atcttccaca agaacaacca gctggctctc 480
aactgatag acaccaaccg ctctcgggcc tgccaccctt gttctccgat gtgtaagggc 540
tcccgcgtgct ggggagagag ttctgaggat tgtcagagcc tgacgcgcac tgtctgtgcc 600
ggtggctgtg cccgcgtgcaa ggggccactg cccactgact gctgccatga gcagtgtgct 660
gccggctgca cgggccccaa gcactctgac tgcctggcct gcctccactt caaccacagt 720
ggcatctgtg agctgcactg cccagccctg gtcacctaca acacagacac gtttgagtcc 780
atgcccaatc ccgagggccg gtatacatte ggcgccagct gtgtgactgc ctgtccctac 840
aactaccttt ctacggacgt gggatcc 867

```

&lt;210&gt; 25

&lt;211&gt; 217

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 25

```

Gly Ala Gly Gly Met Val His His Arg His Arg Ser Ser Ser Thr Arg
 1          5          10          15
Ser Gly Gly Gly Asp Leu Thr Leu Gly Leu Glu Pro Ser Glu Glu Glu
          20          25          30
Ala Pro Arg Ser Pro Leu Ala Pro Ser Glu Gly Ala Gly Ser Asp Val
          35          40          45
Phe Asp Gly Asp Leu Gly Met Gly Ala Ala Lys Gly Leu Gln Ser Leu
          50          55          60
Pro Thr His Asp Pro Ser Pro Leu Gln Arg Tyr Ser Glu Asp Pro Thr
          65          70          75          80
Val Pro Leu Pro Ser Glu Thr Asp Gly Tyr Val Ala Pro Leu Thr Cys
          85          90          95
Ser Pro Gln Pro Glu Tyr Val Asn Gln Pro Asp Val Arg Pro Gln Pro
          100          105          110
Pro Ser Pro Arg Glu Gly Pro Leu Pro Ala Ala Arg Pro Ala Gly Ala
          115          120          125
Thr Leu Glu Arg Ala Lys Thr Leu Ser Pro Gly Lys Asn Gly Val Val
          130          135          140
Lys Asp Val Phe Ala Phe Gly Gly Ala Val Glu Asn Pro Glu Tyr Leu
          145          150          155          160
Thr Pro Gln Gly Gly Ala Ala Pro Gln Pro His Pro Pro Pro Ala Phe
          165          170          175
Ser Pro Ala Phe Asp Asn Leu Tyr Tyr Trp Asp Gln Asp Pro Pro Glu
          180          185          190
Arg Gly Ala Pro Pro Ser Thr Phe Lys Gly Thr Pro Thr Ala Glu Asn
          195          200          205
Pro Glu Tyr Leu Gly Leu Asp Val Pro
          210          215

```

&lt;210&gt; 26

&lt;211&gt; 651

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 26

```

ggcgctgggg gcatgggtcca ccacaggcac cgcagctcat ctaccaggag tggcggtggg 60
gacctgacac tagggctgga gccctctgaa gaggaggccc ccaggtctcc actggcacc 120
tccgaagggg ctggctccga tgtatttgat ggtgacctgg gaatgggggc agccaagggg 180
ctgcaaagcc tccccacaca tgaccccagc cctctacagc ggtacagtga ggaccccaca 240
gtacccctgc cctctgagac tgatggctac gttgcccccc tgacctgcag cccccagcct 300
gaatatgtga accagccaga tgttcggccc cagccccctt cgccccgaga gggccctctg 360
cctgctgccc gacctgctgg tgccactctg gaaagggcca agactctctc cccagggaag 420

```

```

aatgggggtcg tcaaagacgt ttttgccttt ggggggtgccg tggagaaccc cgagtacttg 480
acaccccagg gaggagctgc ccctcagccc caccctcctc ctgccttcag cccagccttc 540
gacaacctct attactggga ccaggaccca ccagagcggg gggctccacc cagcaccttc 600
aaagggaacac ctacggcaga gaaccagag tacctgggtc tggacgtgcc a 651

```

&lt;210&gt; 27

&lt;211&gt; 397

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; NY-ESO-IC tumor antigen

&lt;400&gt; 27

```

Met Gln Ala Glu Gly Arg Gly Thr Gly Gly Ser Thr Gly Asp Ala Asp
 1          5          10          15
Gly Pro Gly Gly Pro Gly Ile Pro Asp Gly Pro Gly Gly Asn Ala Gly
          20          25          30
Gly Pro Gly Glu Ala Gly Ala Thr Gly Gly Arg Gly Pro Arg Gly Ala
          35          40          45
Gly Ala Ala Arg Ala Ser Gly Pro Gly Gly Gly Ala Pro Arg Gly Pro
          50          55          60
His Gly Gly Ala Ala Ser Gly Leu Asn Gly Cys Cys Arg Cys Gly Ala
          65          70          75          80
Arg Gly Pro Glu Ser Arg Leu Leu Glu Phe Tyr Leu Ala Met Pro Phe
          85          90          95
Ala Thr Pro Met Glu Ala Glu Leu Ala Arg Arg Ser Leu Ala Gln Asp
          100          105          110
Ala Pro Pro Leu Pro Val Pro Gly Val Leu Leu Lys Glu Phe Thr Val
          115          120          125
Ser Gly Asn Ile Leu Thr Ile Arg Leu Thr Ala Ala Asp His Arg Gln
          130          135          140
Leu Gln Leu Ser Ile Ser Ser Cys Leu Gln Gln Leu Ser Leu Leu Met
          145          150          155          160
Trp Ile Thr Gln Cys Phe Leu Pro Val Phe Leu Ala Gln Pro Pro Ser
          165          170          175
Gly Gln Arg Arg Gly Ala Gly Gly Met Val His His Arg His Arg Ser
          180          185          190
Ser Ser Thr Arg Ser Gly Gly Gly Asp Leu Thr Leu Gly Leu Glu Pro
          195          200          205
Ser Glu Glu Glu Ala Pro Arg Ser Pro Leu Ala Pro Ser Glu Gly Ala
          210          215          220
Gly Ser Asp Val Phe Asp Gly Asp Leu Gly Met Gly Ala Ala Lys Gly
          225          230          235          240
Leu Gln Ser Leu Pro Thr His Asp Pro Ser Pro Leu Gln Arg Tyr Ser
          245          250          255
Glu Asp Pro Thr Val Pro Leu Pro Ser Glu Thr Asp Gly Tyr Val Ala
          260          265          270
Pro Leu Thr Cys Ser Pro Gln Pro Glu Tyr Val Asn Gln Pro Asp Val
          275          280          285
Arg Pro Gln Pro Pro Ser Pro Arg Glu Gly Pro Leu Pro Ala Ala Arg
          290          295          300
Pro Ala Gly Ala Thr Leu Glu Arg Ala Lys Thr Leu Ser Pro Gly Lys
          305          310          315          320
Asn Gly Val Val Lys Asp Val Phe Ala Phe Gly Gly Ala Val Glu Asn
          325          330          335
Pro Glu Tyr Leu Thr Pro Gln Gly Gly Ala Ala Pro Gln Pro His Pro
          340          345          350
Pro Pro Ala Phe Ser Pro Ala Phe Asp Asn Leu Tyr Tyr Trp Asp Gln
          355          360          365
Asp Pro Pro Glu Arg Gly Ala Pro Pro Ser Thr Phe Lys Gly Thr Pro
          370          375          380

```

Thr Ala Glu Asn Pro Glu Tyr Leu Gly Leu Asp Val Pro  
 385 390 395

<210> 28  
 <211> 1191  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> NY-ESO-IC tumor antigen

<400> 28  
 atgcaggccg aaggccgggg cacagggggt tcgacgggcy atgctgatgg cccaggaggc 60  
 cctggcattc ctgatggccc agggggcaat gctggcggcc caggagaggc ggggtgccacg 120  
 ggcggcagag gtccccgggg cgcaggggca gcaagggcct cggggccggg aggaggcgcc 180  
 ccgcggggtc cgcattggcg cgcggcttca gggctgaatg gatgctgcag atgcggggcc 240  
 agggggccgg agagccgcct gcttgagttc tacctcgcca tgcctttcgc gacacccatg 300  
 gaagcagagc tggcccgcag gagcctggcc caggatgccc caccgcttcc cgtgccaggg 360  
 gtgcttctga aggagttcac tgtgtccggc aacatactga ctatccgact gactgctgca 420  
 gaccaccgcc aactgcagct ctccatcagc tcctgtctcc agcagctttc cctggtgatg 480  
 tggatcacgc agtgctttct gcccggtgtt ttggctcagc ctccctcagg gcagaggcgc 540  
 ggcgctgggg gcatgggtcca ccacaggcac cgcagctcat ctaccaggag tggcggtggg 600  
 gacctgacac tagggctgga gccctctgaa gaggaggccc ccagggtctcc actggcaccc 660  
 tccgaagggg ctgggtccga tgtatttgat ggtgacctgg gaatgggggc agccaagggg 720  
 ctgcaaagcc tccccacaca tgacccagc cctctacagc ggtacagtga ggacccaca 780  
 gtacccctgc cctctgagac tgatggctac gttgcccccc tgacctgcag cccccagcct 840  
 gaatatgtga accagccaga tgttcgcccc cagccccctt cgccccgaga gggccctctg 900  
 cctgctgccc gacctgctgg tgccactctg gaaagggcca agactctctc cccagggaag 960  
 aatggggtcg tcaaagacgt ttttgccctt gggggtgccc tggagaacct cgagtacttg 1020  
 acaccccgag gaggagctgc cctcagccc caccctcctc ctgccttcag cccagccttc 1080  
 gacaacctct attactggga ccaggaccca ccagagcggg gggctccacc cagcaccttc 1140  
 aaaggacac ctacggcaga gaacccagag tacctgggtc tggacgtgcc a 1191

<210> 29  
 <211> 1179  
 <212> PRT  
 <213> Artificial Sequence

<220>  
 <223> SART-3-IC

<400> 29  
 Met Ala Thr Ala Ala Glu Thr Ser Ala Ser Glu Pro Glu Ala Glu Ser  
 1 5 10 15  
 Lys Ala Gly Pro Lys Ala Asp Gly Glu Glu Asp Glu Val Lys Ala Ala  
 20 25 30  
 Arg Thr Arg Arg Lys Val Leu Ser Arg Ala Val Ala Ala Thr Tyr  
 35 40 45  
 Lys Thr Met Gly Pro Ala Trp Asp Gln Gln Glu Glu Gly Val Ser Glu  
 50 55 60  
 Ser Asp Gly Asp Glu Tyr Ala Met Ala Ser Ser Ala Glu Ser Ser Pro  
 65 70 75 80  
 Gly Glu Tyr Glu Trp Glu Tyr Asp Glu Glu Glu Glu Lys Asn Gln Leu  
 85 90 95  
 Glu Ile Glu Arg Leu Glu Glu Gln Leu Ser Ile Asn Val Tyr Asp Tyr  
 100 105 110  
 Asn Cys His Val Asp Leu Ile Arg Leu Leu Arg Leu Glu Gly Glu Leu  
 115 120 125  
 Thr Lys Val Arg Met Ala Arg Gln Lys Met Ser Glu Ile Phe Pro Leu  
 130 135 140  
 Thr Glu Glu Leu Trp Leu Glu Trp Leu His Asp Glu Ile Ser Met Ala  
 145 150 155 160

Gln	Asp	Gly	Leu	Asp	Arg	Glu	His	Val	Tyr	Asp	Leu	Phe	Glu	Lys	Ala	
				165					170					175		
Val	Lys	Asp	Tyr	Ile	Cys	Pro	Asn	Ile	Trp	Leu	Glu	Tyr	Gly	Gln	Tyr	
			180					185					190			
Ser	Val	Gly	Gly	Ile	Gly	Gln	Lys	Gly	Gly	Leu	Glu	Lys	Val	Arg	Ser	
		195					200					205				
Val	Phe	Glu	Arg	Ala	Leu	Ser	Ser	Val	Gly	Leu	His	Met	Thr	Lys	Gly	
	210					215					220					
Leu	Ala	Leu	Trp	Glu	Ala	Tyr	Arg	Glu	Phe	Glu	Ser	Ala	Ile	Val	Glu	
225				230						235					240	
Ala	Ala	Arg	Leu	Glu	Lys	Val	His	Ser	Leu	Phe	Arg	Arg	Gln	Leu	Ala	
			245						250					255		
Ile	Pro	Leu	Tyr	Asp	Met	Glu	Ala	Thr	Phe	Ala	Glu	Tyr	Glu	Glu	Trp	
			260					265					270			
Ser	Glu	Asp	Pro	Ile	Pro	Glu	Ser	Val	Ile	Gln	Asn	Tyr	Asn	Lys	Ala	
		275					280					285				
Leu	Gln	Gln	Leu	Glu	Lys	Tyr	Lys	Pro	Tyr	Glu	Glu	Ala	Leu	Leu	Gln	
	290					295					300					
Ala	Glu	Ala	Pro	Arg	Leu	Ala	Glu	Tyr	Gln	Ala	Tyr	Ile	Asp	Phe	Glu	
305				310						315					320	
Met	Lys	Ile	Gly	Asp	Pro	Ala	Arg	Ile	Gln	Leu	Ile	Phe	Glu	Arg	Ala	
			325						330					335		
Leu	Val	Glu	Asn	Cys	Leu	Val	Pro	Asp	Leu	Trp	Ile	Arg	Tyr	Ser	Gln	
			340					345					350			
Tyr	Leu	Asp	Arg	Gln	Leu	Lys	Val	Lys	Asp	Leu	Val	Leu	Ser	Val	His	
		355					360					365				
Asn	Arg	Ala	Ile	Arg	Asn	Cys	Pro	Trp	Thr	Val	Ala	Leu	Trp	Ser	Arg	
	370					375					380					
Tyr	Leu	Leu	Ala	Met	Glu	Arg	His	Gly	Val	Asp	His	Gln	Val	Ile	Ser	
385				390						395					400	
Val	Thr	Phe	Glu	Lys	Ala	Leu	Asn	Ala	Gly	Phe	Ile	Gln	Ala	Thr	Asp	
			405						410					415		
Tyr	Val	Glu	Ile	Trp	Gln	Ala	Tyr	Leu	Asp	Tyr	Leu	Arg	Arg	Arg	Val	
			420					425					430			
Asp	Phe	Lys	Gln	Asp	Ser	Ser	Lys	Glu	Leu	Glu	Glu	Leu	Arg	Ala	Ala	
		435					440					445				
Phe	Thr	Arg	Ala	Leu	Glu	Tyr	Leu	Lys	Gln	Glu	Val	Glu	Glu	Arg	Phe	
	450					455					460					
Asn	Glu	Ser	Gly	Asp	Pro	Ser	Cys	Val	Ile	Met	Gln	Asn	Trp	Ala	Arg	
465				470						475					480	
Ile	Glu	Ala	Arg	Leu	Cys	Asn	Asn	Met	Gln	Lys	Ala	Arg	Glu	Leu	Trp	
			485						490					495		
Asp	Ser	Ile	Met	Thr	Arg	Gly	Asn	Ala	Lys	Tyr	Ala	Asn	Met	Trp	Leu	
		500					505						510			
Glu	Tyr	Tyr	Asn	Leu	Glu	Arg	Ala	His	Gly	Asp	Thr	Gln	His	Cys	Arg	
		515					520					525				
Lys	Ala	Leu	His	Arg	Ala	Val	Gln	Cys	Thr	Ser	Asp	Tyr	Pro	Glu	His	
	530					535					540					
Val	Cys	Glu	Val	Leu	Leu	Thr	Met	Glu	Arg	Thr	Glu	Gly	Ser	Leu	Glu	
545				550						555					560	
Asp	Trp	Asp	Ile	Ala	Val	Gln	Lys	Thr	Glu	Thr	Arg	Leu	Ala	Arg	Val	
			565						570					575		
Asn	Glu	Gln	Arg	Met	Lys	Ala	Ala	Glu	Lys	Glu	Ala	Ala	Leu	Val	Gln	
			580					585					590			
Gln	Glu	Glu	Glu	Lys	Ala	Glu	Gln	Arg	Lys	Arg	Ala	Arg	Ala	Glu	Lys	
		595					600					605				
Lys	Ala	Leu	Lys	Lys	Lys	Lys	Lys	Ile	Arg	Gly	Pro	Glu	Lys	Arg	Gly	
	610					615					620					
Ala	Asp	Glu	Asp	Asp	Glu	Lys	Glu	Trp	Gly	Asp	Asp	Glu	Glu	Glu	Gln	
625				630						635					640	
Pro	Ser	Lys	Arg	Arg	Arg	Val	Glu	Asn	Ser	Ile	Pro	Ala	Ala	Gly	Glu	
				645					650					655		



Thr	Gln	Asn	Val	Glu	Val	Ala	Ala	Gly	Pro	Ala	Gly	Lys	Cys	Ala	Ala		
			660					665					670				
Val	Asp	Val	Glu	Pro	Pro	Ser	Lys	Gln	Lys	Glu	Lys	Ala	Ala	Ser	Leu		
			675				680						685				
Lys	Arg	Asp	Met	Pro	Lys	Val	Leu	His	Asp	Ser	Ser	Lys	Asp	Ser	Ile		
			690				695					700					
Thr	Val	Phe	Val	Ser	Asn	Leu	Pro	Tyr	Ser	Met	Gln	Glu	Pro	Asp	Thr		
705					710					715					720		
Lys	Leu	Arg	Pro	Leu	Phe	Glu	Ala	Cys	Gly	Glu	Val	Val	Gln	Ile	Arg		
				725					730					735			
Pro	Ile	Phe	Ser	Asn	Arg	Gly	Asp	Phe	Arg	Gly	Tyr	Cys	Tyr	Val	Glu		
			740				745						750				
Phe	Lys	Glu	Glu	Lys	Ser	Ala	Leu	Gln	Ala	Leu	Glu	Met	Asp	Arg	Lys		
			755				760					765					
Ser	Val	Glu	Gly	Arg	Pro	Met	Phe	Val	Ser	Pro	Cys	Val	Asp	Lys	Ser		
			770			775					780						
Lys	Asn	Pro	Asp	Phe	Lys	Val	Phe	Arg	Tyr	Ser	Thr	Ser	Leu	Glu	Lys		
785					790					795					800		
His	Lys	Leu	Phe	Ile	Ser	Gly	Leu	Pro	Phe	Ser	Cys	Thr	Lys	Glu	Glu		
				805					810					815			
Leu	Glu	Glu	Ile	Cys	Lys	Ala	His	Gly	Thr	Val	Lys	Asp	Leu	Arg	Leu		
			820					825					830				
Val	Thr	Asn	Arg	Ala	Gly	Lys	Pro	Lys	Gly	Leu	Ala	Tyr	Val	Glu	Tyr		
			835				840						845				
Glu	Asn	Glu	Ser	Gln	Ala	Ser	Gln	Ala	Val	Met	Lys	Met	Asp	Gly	Met		
			850			855					860						
Thr	Ile	Lys	Glu	Asn	Ile	Ile	Lys	Val	Ala	Ile	Ser	Asn	Pro	Pro	Gln		
865					870					875					880		
Arg	Lys	Val	Pro	Glu	Lys	Pro	Glu	Thr	Arg	Lys	Ala	Pro	Gly	Gly	Pro		
				885					890					895			
Met	Leu	Leu	Pro	Gln	Thr	Tyr	Gly	Ala	Arg	Gly	Lys	Gly	Arg	Thr	Gln		
			900					905					910				
Leu	Ser	Leu	Leu	Pro	Arg	Ala	Leu	Gln	Arg	Pro	Ser	Ala	Ala	Ala	Pro		
			915				920					925					
Gln	Ala	Glu	Asn	Gly	Pro	Ala	Ala	Ala	Pro	Ala	Val	Ala	Ala	Pro	Ala		
			930			935					940						
Ala	Thr	Glu	Ala	Pro	Lys	Met	Ser	Asn	Ala	Asp	Phe	Ala	Lys	Leu	Phe		
945					950					955					960		
Leu	Arg	Gly	Ala	Gly	Gly	Met	Val	His	His	Arg	His	Arg	Ser	Ser	Ser		
				965					970					975			
Thr	Arg	Ser	Gly	Gly	Gly	Asp	Leu	Thr	Leu	Gly	Leu	Glu	Pro	Ser	Glu		
			980					985					990				
Glu	Glu	Ala	Pro	Arg	Ser	Pro	Leu	Ala	Pro	Ser	Glu	Gly	Ala	Gly	Ser		
			995				1000					1005					
Asp	Val	Phe	Asp	Gly	Asp	Leu	Gly	Met	Gly	Ala	Ala	Lys	Gly	Leu	Gln		
			1010			1015					1020						
Ser	Leu	Pro	Thr	His	Asp	Pro	Ser	Pro	Leu	Gln	Arg	Tyr	Ser	Glu	Asp		
1025					1030					1035					1040		
Pro	Thr	Val	Pro	Leu	Pro	Ser	Glu	Thr	Asp	Gly	Tyr	Val	Ala	Pro	Leu		
				1045					1050					1055			
Thr	Cys	Ser	Pro	Gln	Pro	Glu	Tyr	Val	Asn	Gln	Pro	Asp	Val	Arg	Pro		
			1060					1065					1070				
Gln	Pro	Pro	Ser	Pro	Arg	Glu	Gly	Pro	Leu	Pro	Ala	Ala	Arg	Pro	Ala		
			1075				1080					1085					
Gly	Ala	Thr	Leu	Glu	Arg	Ala	Lys	Thr	Leu	Ser	Pro	Gly	Lys	Asn	Gly		
			1090			1095					1100						
Val	Val	Lys	Asp	Val	Phe	Ala	Phe	Gly	Gly	Ala	Val	Glu	Asn	Pro	Glu		
1105					1110					1115					1120		
Tyr	Leu	Thr	Pro	Gln	Gly	Gly	Ala	Ala	Pro	Gln	Pro	His	Pro	Pro	Pro		
				1125					1130					1135			
Ala	Phe	Ser	Pro	Ala	Phe	Asp	Asn	Leu	Tyr	Tyr	Trp	Asp	Gln	Asp	Pro		
			1140					1145					1150				

Pro Glu Arg Gly Ala Pro Pro Ser Thr Phe Lys Gly Thr Pro Thr Ala  
 1155 1160  
 Glu Asn Pro Glu Tyr Leu Gly Leu Asp Val Pro  
 1170 1175

<210> 30  
 <211> 3537  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> SART-3-IC

<400> 30  
 atggcgactg cggccgaaac ctcggcttca gaacccgagg ctgagtccaa ggctgggccc 60  
 aaggctgacg gagaggagga tgaggttaag gcggttagga caaggagaaa ggtgttatcg 120  
 cgggctgtgg ccgctgcgac atacaagacc atggggccag cgtgggatca gcaggaggaa 180  
 ggcgtgagcg agagcgatgg ggatgagtag gccatggctt cctccgcgga gagctcccc 240  
 ggggagtagc agtgggaata tgacgaagag gaggagaaaa accagctgga gattgagaga 300  
 ctggaggagc agttgtctat caacgtctat gactacaact gccatgtgga cttgatcaga 360  
 ctgctcaggg tgggaaggga gcttaccaag gtgaggatgg ccgcccagaa gatgagttaa 420  
 atctttccct tgactgaaga gctctggctg gagtggctgc atgacgagat cagcatggcc 480  
 caggatggcc tggacagaga gcacgtgtat gacctctttg agaaagccgt gaaggattac 540  
 atttgtccta acatttggct agagtatggc cagtactcag ttggtgggat tggtcagaaa 600  
 ggtggccttg agaaagtctg ctccgtgttt gaaagggctc tctcgtctgt tggtttacat 660  
 atgaccaaag gactcgccct ctgggaggct taccgagagt ttgaaagtgc gattgtggaa 720  
 gctgctcggc ttgagaaaagt ccacagtctt ttccggcgac agttggcgat cccactctat 780  
 gatatggagg ccacatttgc agagtatgaa gaatggtcag aagaccaat accagagtca 840  
 gtaattcaga actataacaa agcactacag cagctggaga aatataaacc ctatgaagaa 900  
 gcaactgttg aggcagagcg accaaggctg gcagaatatc aagcatatat cgattttgag 960  
 atgaaaattg gcgatcctgc tcgcattcag ttgatctttg agcgcgccct ggtcgagaac 1020  
 tgccttgttc cagacttatg gatccgttac agtcagtacc tagatcgaca actgaaagta 1080  
 aaggatttgg ttttatctgt acataaccgc gctattagaa actgcccctg gacagttgcc 1140  
 ttatggagtc ggtacctctt ggccatggag agacatggag ttgatcatca agtaatttct 1200  
 gtaaccttcg agaaagcttt gaatgccggc ttcattccagg ccaactgatta tgtggagatt 1260  
 tggcaggcat accttgatta cctgaggaga agggttgatt tcaaacaaga ctccagtaaa 1320  
 gagctggagg agttgagggc cgctttact cgtgccttgg agtatctgaa gcaggaggtg 1380  
 gaagagcggt tcaatgagag ttgtgatcca agctgcgtga ttatgcagaa ctgggctagg 1440  
 attgaggctc cagtgtgcaa taacatgcag aaagctcggg aactctggga tagcatcatg 1500  
 accagaggaa atgccaaagta cgccaacatg tggctagagt attacaacct ggaaagagct 1560  
 catggtgaca ccagcactg ccggaaggct ctgcaccggg ccgtccagtg caccagtgc 1620  
 taccagagc acgtctgcga agtgttactc accatggaga ggacagaagg ttcttttagaa 1680  
 gattgggata tagctgttca gaaaactgaa acccgattag ctcgtgtcaa tgagcagaga 1740  
 atgaaggctg cagagaagga agcagccctt gtgcagcaag aagaagaaaa ggctgaacaa 1800  
 cggaaaagag ctcgggctga gaagaaagcg ttaaaaaaga agaaaaagat cagaggccca 1860  
 gagaagcgcg gagcagatga ggacgatgag aaagagtggg gcgatgatga agaagagcag 1920  
 ccttccaac gcagaagggt cgagaacagc atccctgcag ctggagaaac acaaaatgta 1980  
 gaagtagcag cagggcccgc tgggaaatgt gctgccgtag atgtggagcc cccttcgaag 2040  
 cagaaggaga aggcagcctc cctgaagagg gacatgccc aggtgctgca cgacagcagc 2100  
 aaggacagca tcaccgtctt tgtcagcaac ctgccctaca gcatgcagga gccggacacg 2160  
 aagctcaggc cactcttcga ggctgtggg gaggtggctc agatccgacc catcttcagc 2220  
 aaccgtgggg atttccgagg ttactgctac gtggagttaa aagaagagaa atcagccctt 2280  
 caggcactgg agatggaccg gaaaagtgtg gaagggaggc caatgtttgt ttccccctgt 2340  
 gtggataaga gcaaaaaccc cgatttttaa gtgttcagg acagcacttc cctagagaaa 2400  
 cacaagctgt tcatctcagg cctgcctttc tcctgtacta aagaggaaact agaagaaatc 2460  
 tgaaggctc atggcaccgt gaaggacctc aggtcgttca ccaaccgggc tggcaaacca 2520  
 aagggcctgg cctacgtgga gtatgaaaat gaatcccagg cgtcgcaggc tgtgatgaag 2580  
 atggacggca tgactatcaa agagaacatc atcaaagtgg caatcagcaa ccctcctcag 2640  
 aggaaagtgc cagagaagcc agagaccagg aaggcaccag gtggccccc atgttttgcg 2700  
 cagacatacg gagcgagggg gaagggaagg acgcagctgt ctctactgcc tctgtccctg 2760  
 cagcgcccaa gtgctgcagc tcctcaggct gagaacggcc ctgcgcggc tcctgcagtt 2820  
 gccgcccag cagccaccga ggcacccaag atgtccaatg ccgattttgc caagctgttt 2880

ctgagaggcg	ctgggggcat	ggtccaccac	aggcaccgca	gctcatctac	caggagtggc	2940
ggtggggacc	tgacactagg	gctggagccc	tctgaagagg	aggccccag	gtctccactg	3000
gcaccctccg	aaggggctgg	ctccgatgta	tttgatgggtg	acctgggaat	gggggcagcc	3060
aaggggctgc	aaagcctccc	cacacatgac	cccagccctc	tacagcggta	cagtgaggac	3120
cccacagtac	ccctgccctc	tgagactgat	ggctacgttg	ccccctgac	ctgcagcccc	3180
cagcctgaat	atgtgaacca	gccagatggt	cggccccagc	ccccttcgcc	ccgagagggc	3240
cctctgcctg	ctgcccagcc	tgtgggtgcc	actctggaaa	gggccaagac	tctctcccca	3300
gggaagaatg	gggtcgtcaa	agacgttttt	gcctttgggg	gtgccgtgga	gaaccccag	3360
tacttgacac	cccagggagg	agctgcccct	cagccccacc	ctcctcctgc	cttcagccca	3420
gccttcgaca	acctctatta	ctgggaccag	gacccaccag	agcggggggc	tccaccacgc	3480
accttcaaag	ggacacctac	ggcagagaac	ccagagtacc	tgggtctgga	cgtgccca	3537

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
11 October 2001 (11.10.2001)

PCT

(10) International Publication Number  
**WO 01/74855 A3**

(51) International Patent Classification<sup>7</sup>: C12N 15/12,  
15/27, 15/55, 15/62, 9/16, 5/06, C07K 14/535, 14/71,  
19/00, A61K 39/00

(21) International Application Number: PCT/US01/10515

(22) International Filing Date: 30 March 2001 (30.03.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
60/193,504 30 March 2000 (30.03.2000) US

(71) Applicant: DENDREON CORPORATION [US/US];  
3005 1st Avenue, Seattle, WA 98121 (US).

(72) Inventors: LAUS, Reiner; 4733 154th Place S.E., Belle-  
vue, WA (US). VIDOVIC, Damir; 14309 S.E. 49th Street,  
Bellevue, WA 98006 (US). GRADDIS, Thomas; 7014  
29th Avenue, N.E., Seattle, WA 98115 (US).

(74) Agents: THROWER, Larry, W. et al.; Iota Pi Law Group,  
P.O. Office Box 60850, Palo Alto, CA 94306-0850 (US).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,  
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,  
CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM,  
HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK,  
LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX,  
MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL,  
TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM,  
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian  
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European  
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,  
IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF,  
CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

**Published:**

— with international search report

(88) Date of publication of the international search report:  
7 March 2002

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

(54) Title: COMPOSITIONS AND METHODS FOR DENDRITIC CELL-BASED IMMUNOTHERAPY

(57) Abstract: Disclosed are immunostimulatory fusion proteins and methods for generating protective DC-induced, T cell-mediated immune responses *in vitro* and *in vivo*. The immunostimulatory fusion proteins comprise a polypeptide antigen component and an immunostimulatory component derived from the intracellular domain of the HER-2 protein. Also disclosed are immunostimulatory compositions comprising dendritic cells pulsed with such an immunostimulatory fusion protein and methods for immunotherapy using the compositions.

WO 01/74855 A3



# INTERNATIONAL SEARCH REPORT

International Application No  
PCT/US 01/10515

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C12N15/12 C12N15/27 C12N15/55 C12N15/62 C12N9/16  
C12N5/06 C07K14/535 C07K14/71 C07K19/00 A61K39/00

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C12N C07K A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

WPI Data, PAJ, CAB Data, SEQUENCE SEARCH, BIOSIS, EPO-Internal

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 97 24438 A (LAUS REINER ;WU HONGYU (US); RUEGG CURTIS L (US); ACTIVATED CELL T) 10 July 1997 (1997-07-10) the whole document	1-6,9-18
P,X	WO 00 44899 A (GHEYSEN DIRK ;SMITHKLINE BEECHAM (GB); CORIXA CORP (US); CHEEVER M) 3 August 2000 (2000-08-03) claims 51,56,57,79,81-92 -/-	1-4,9, 10,12-18

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

° Special categories of cited documents :

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

- \*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- \*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- \*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- \*&\* document member of the same patent family

Date of the actual completion of the international search

10 October 2001

Date of mailing of the international search report

16/10/2001

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Hornig, H

# INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 01/10515

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>DISIS M L ET AL: "Peptide-based, but not whole protein, vaccines elicit immunity to HER-2/neu, oncogenic self-protein" JOURNAL OF IMMUNOLOGY, THE WILLIAMS AND WILKINS CO. BALTIMORE, US, vol. 156, no. 9, 1 May 1996 (1996-05-01), pages 3151-3158, XP002139506 ISSN: 0022-1767 the whole document</p> <p>---</p>	
A	<p>JAMESON S C ET AL: "CLONE-SPECIFIC T CELL RECEPTOR ANTAGONISTS OF MAJOR HISTOCOMPATIBILITY COMPLEX CLASS I-RESTRICTED CYTOTOXIC T CELLS" JOURNAL OF EXPERIMENTAL MEDICINE, TOKYO, JP, vol. 177, no. 6, 1 June 1993 (1993-06-01), pages 1541-1550, XP000604978 ISSN: 0022-1007 cited in the application the whole document</p> <p>---</p>	
A	<p>WO 94 21287 A (US HEALTH) 29 September 1994 (1994-09-29) the whole document</p> <p>---</p>	
A	<p>WO 98 46769 A (SHAPERO MICHAEL H ;DENDREON CORP (US); LAUS REINER (US); RUEGG CUR) 22 October 1998 (1998-10-22) the whole document</p> <p>---</p>	
A	<p>WO 99 09166 A (SHAPERO MICHAEL H ;DENDREON CORP (US); LAUS REINER (US); TSAVALER) 25 February 1999 (1999-02-25) the whole document</p> <p>---</p>	
P,A	<p>WO 00 35949 A (DENDREON CORP) 22 June 2000 (2000-06-22) the whole document</p> <p>-----</p>	

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 01/10515

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 9724438	A	10-07-1997	US 6080409 A	27-06-2000
			AU 716783 B2	09-03-2000
			AU 1338097 A	28-07-1997
			CA 2241373 A1	10-07-1997
			EP 0870022 A1	14-10-1998
			JP 2000502567 T	07-03-2000
			WO 9724438 A1	10-07-1997
			US 5976546 A	02-11-1999
			US 6210662 B1	03-04-2001
WO 0044899	A	03-08-2000	AU 2742600 A	18-08-2000
			WO 0044899 A1	03-08-2000
WO 9421287	A	29-09-1994	AU 4002497 A	08-01-1998
			AU 6363094 A	11-10-1994
			CA 2158281 A1	29-09-1994
			EP 0692973 A1	24-01-1996
			WO 9421287 A1	29-09-1994
			US 5997869 A	07-12-1999
WO 9846769	A	22-10-1998	AU 6897998 A	11-11-1998
			EP 0973916 A1	26-01-2000
			WO 9846769 A1	22-10-1998
WO 9909166	A	25-02-1999	US 6194152 B1	27-02-2001
			AU 9021898 A	08-03-1999
			EP 1005549 A2	07-06-2000
			WO 9909166 A2	25-02-1999
WO 0035949	A	22-06-2000	AU 2053800 A	03-07-2000
			EP 1141007 A1	10-10-2001
			WO 0035949 A1	22-06-2000